(dp0
(S'ZEB1'
p1
S'FOXA1'
p2
S'increases'
p3
tp4
(lp5
s(S'FOXJ1'
p6
S'GATA6'
p7
S'increases'
p8
tp9
(lp10
s(S'TFAP4'
p11
S'FOXD3'
p12
S'increases'
p13
tp14
(lp15
s(S'TBP'
p16
S'MEIS1'
p17
S'increases'
p18
tp19
(lp20
s(S'GCM1'
p21
S'GATA6'
p22
S'increases'
p23
tp24
(lp25
s(S'T-DHT'
p26
S'SRC'
p27
S'adds_modification'
p28
tp29
(lp30
s(S'MAZ'
p31
S'GABPB2'
p32
S'increases'
p33
tp34
(lp35
s(S'HMGA1'
p36
S'EN1'
p37
S'increases'
p38
tp39
(lp40
s(S'CYP26A1'
p41
S'NRAS'
p42
S'increases'
p43
tp44
(lp45
s(S'CUX1'
p46
S'MEIS1'
p47
S'increases'
p48
tp49
(lp50
s(S'REPIN1'
p51
S'BACH1'
p52
S'increases'
p53
tp54
(lp55
s(S'TFDP1'
p56
S'HOXA9'
p57
S'increases'
p58
tp59
(lp60
s(S'NFE2L1'
p61
S'CYP26A1'
p62
S'increases'
p63
tp64
(lp65
s(S'MAZ'
p66
S'GATA1'
p67
S'increases'
p68
tp69
(lp70
s(S'TCF12'
p71
S'GABPB2'
p72
S'increases'
p73
tp74
(lp75
s(S'ETS2'
p76
S'FOXO3'
p77
S'increases'
p78
tp79
(lp80
s(S'hsa-let-7c-5p'
p81
S'NRAS'
p82
S'decreases'
p83
tp84
(lp85
s(S'SPI1'
p86
S'CYP26A1'
p87
S'increases'
p88
tp89
(lp90
s(S'RAC1/GTP'
p91
S'MKK4'
p92
S'adds_modification'
p93
tp94
(lp95
s(S'Quercetin'
p96
S'KRAS MRNA'
p97
S'decreases'
p98
tp99
(lp100
s(S'INSULIN RECEPTOR/INSULIN/SHC'
p101
S'GRB2'
p102
S'binds'
p103
tp104
(lp105
s(S'TAp63a (tetramer)'
p106
S'PKC DELTA'
p107
S'increases'
p108
tp109
(lp110
s(S'FOXO1'
p111
S'POU2F1'
p112
S'increases'
p113
tp114
(lp115
s(S'FOXL1'
p116
S'EN1'
p117
S'increases'
p118
tp119
(lp120
s(S'TBP'
p121
S'CYP26A1'
p122
S'increases'
p123
tp124
(lp125
s(S'Heptachlor'
p126
S'HRAS MRNA'
p127
S'decreases'
p128
tp129
(lp130
s(S'PCBP1'
p131
S'CYP26A1'
p132
S'increases'
p133
tp134
(lp135
s(S'ZBTB18'
p136
S'CYP26A1'
p137
S'increases'
p138
tp139
(lp140
s(S'GATA2'
p141
S'CYP26A1'
p142
S'increases'
p143
tp144
(lp145
s(S'Cadmium'
p146
S'KRAS MRNA'
p147
S'increases'
p148
tp149
(lp150
s(S'HNF1A'
p151
S'POU2F1'
p152
S'increases'
p153
tp154
(lp155
s(S'ABT-100'
p156
S'HRAS PROTEIN'
p157
S'inhibits_modification'
p158
tp159
(lp160
s(S'ELF1'
p161
S'CYP26A1'
p162
S'increases'
p163
tp164
(lp165
s(S'LEF1'
p166
S'KRAS'
p167
S'increases'
p168
tp169
(lp170
s(S'NKX2-1'
p171
S'FOXD3'
p172
S'increases'
p173
tp174
(lp175
s(S'PI-3-4-5-P3'
p176
S'BTK-ITK'
p177
S'translocates'
p178
tp179
(lp180
s(S'POU6F1'
p181
S'HOXA9'
p182
S'increases'
p183
tp184
(lp185
s(S'Myb'
p186
S'MYB'
p187
S'increases'
p188
tp189
(lp190
S'The c-Myb (MYB) protein was found to be associated with over 10,000 promoters as the evidence of being a master transcription factor in MCF-7 cell model ['
p191
as(S'PAX5'
p192
S'CYP26A1'
p193
S'increases'
p194
tp195
(lp196
s(S'FOXO4'
p197
S'FOXD3'
p198
S'increases'
p199
tp200
(lp201
s(S'CYP26A1'
p202
S'FOXO4'
p203
S'increases'
p204
tp205
(lp206
s(S'cell adhesion'
p207
S'HRAS/GDP'
p208
S'increases_activity'
p209
tp210
(lp211
s(S'IRF7'
p212
S'CYP26A1'
p213
S'increases'
p214
tp215
(lp216
s(S'7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide'
p217
S'KRAS PROTEIN'
p218
S'increases'
p219
tp220
(lp221
s(S'PITX2'
p222
S'POU2F1'
p223
S'increases'
p224
tp225
(lp226
s(S'E2F1'
p227
S'CYP26A1'
p228
S'increases'
p229
tp230
(lp231
s(S'ATF1'
p232
S'CYP26A1'
p233
S'increases'
p234
tp235
(lp236
s(S'PI3K'
p237
S'PKC DELTA'
p238
S'adds_modification'
p239
tp240
(lp241
s(S'SOX5'
p242
S'HOXA9'
p243
S'increases'
p244
tp245
(lp246
s(S'FOXO4'
p247
S'POU2F1'
p248
S'increases'
p249
tp250
(lp251
s(S'FOXO4'
p252
S'GATA6'
p253
S'increases'
p254
tp255
(lp256
s(S'LEF1'
p257
S'FOXF2'
p258
S'increases'
p259
tp260
(lp261
s(S'Insulin Receptor/Insuli/IRS1/GRB2/SHC/Sos'
p262
S'HRAS/GDP'
p263
S'increases_activity'
p264
tp265
(lp266
s(S'TLX2'
p267
S'RUNX1'
p268
S'increases'
p269
tp270
(lp271
s(S'ALX4'
p272
S'JUN'
p273
S'increases'
p274
tp275
(lp276
s(S'RHOA/GTP'
p277
S'RHOGDI'
p278
S'binds'
p279
tp280
(lp281
s(S'GCM1'
p282
S'CYP26A1'
p283
S'increases'
p284
tp285
(lp286
s(S'RB1'
p287
S'ONECUT1'
p288
S'increases'
p289
tp290
(lp291
s(S'NHLH1'
p292
S'CYP26A1'
p293
S'increases'
p294
tp295
(lp296
s(S'NR3C1'
p297
S'BACH1'
p298
S'increases'
p299
tp300
(lp301
s(S'HNF4A'
p302
S'CYP26A1'
p303
S'increases'
p304
tp305
(lp306
s(S'YY1'
p307
S'FOXO3'
p308
S'increases'
p309
tp310
(lp311
s(S'GRB2:SOS1'
p312
S'P-EGFR MUTANTS DIMER'
p313
S'binds'
p314
tp315
(lp316
s(S'P-Y349,350-SHC1:P-ERBB4'
p317
S'GRB2:SOS1'
p318
S'binds'
p319
tp320
(lp321
s(S'FOXN1'
p322
S'ONECUT1'
p323
S'increases'
p324
tp325
(lp326
s(S'TFAP4'
p327
S'MYC'
p328
S'increases'
p329
tp330
(lp331
s(S'MYC'
p332
S'EN1'
p333
S'increases'
p334
tp335
(lp336
s(S'Antigen/IgE/Fc epsilon R1/LYN/SYK'
p337
S'SHC/GRB2/SOS1'
p338
S'increases_activity'
p339
tp340
(lp341
s(S'14-3-3 BETA, ZETA'
p342
S'GARNL4'
p343
S'binds'
p344
tp345
(lp346
s(S'SMAD1'
p347
S'EN1'
p348
S'increases'
p349
tp350
(lp351
s(S'Raf-1'
p352
S'MEK1-2'
p353
S'adds_modification'
p354
tp355
(lp356
s(S'POU2F1'
p357
S'FOXO3'
p358
S'increases'
p359
tp360
(lp361
s(S'NGF (dimer)/TRKA'
p362
S'RASGRF1'
p363
S'adds_modification'
p364
tp365
(lp366
s(S'TCF4'
p367
S'CYP26A1'
p368
S'increases'
p369
tp370
(lp371
s(S'STAT5B'
p372
S'TLX2'
p373
S'increases'
p374
tp375
(lp376
s(S'CYP26A1'
p377
S'SRF'
p378
S'increases'
p379
tp380
(lp381
s(S'STAT1'
p382
S'NRAS'
p383
S'increases'
p384
tp385
(lp386
s(S'TFDP1'
p387
S'GATA1'
p388
S'increases'
p389
tp390
(lp391
s(S'PI3K'
p392
S'ALPHA6/BETA4 INTEGRIN/LAMININ'
p393
S'binds'
p394
tp395
(lp396
s(S'FOXF2'
p397
S'NRAS'
p398
S'increases'
p399
tp400
(lp401
s(S'CUX1'
p402
S'POU2F1'
p403
S'increases'
p404
tp405
(lp406
s(S'ETS2'
p407
S'STAT4'
p408
S'increases'
p409
tp410
(lp411
s(S'EN1'
p412
S'CYP26A1'
p413
S'increases'
p414
tp415
(lp416
s(S'COMPLEX (RAS/GTP)'
p417
S'RAF'
p418
S'binds'
p419
tp420
(lp421
s(S'LEF1'
p422
S'EN1'
p423
S'increases'
p424
tp425
(lp426
s(S'FOXL1'
p427
S'NRAS'
p428
S'increases'
p429
tp430
(lp431
s(S'ELF2'
p432
S'CYP26A1'
p433
S'increases'
p434
tp435
(lp436
s(S'Src Family Kinases-active'
p437
S'EGF/EGFR'
p438
S'adds_modification'
p439
tp440
(lp441
s(S'RUNX1'
p442
S'POU2F1'
p443
S'increases'
p444
tp445
(lp446
s(S'RHOA/GTP'
p447
S'CITRON-N'
p448
S'increases_activity'
p449
tp450
(lp451
s(S'PAX4'
p452
S'SRF'
p453
S'increases'
p454
tp455
(lp456
s(S'Vitamin E'
p457
S'HRAS MRNA'
p458
S'increases'
p459
tp460
(lp461
s(S'CDX2'
p462
S'FOXD3'
p463
S'increases'
p464
tp465
(lp466
s(S'Plant Extracts'
p467
S'KEAP1 PROTEIN'
p468
S'decreases'
p469
tp470
(lp471
s(S'PAX4'
p472
S'CBFA2T3'
p473
S'increases'
p474
tp475
(lp476
s(S'FOXD1'
p477
S'CYP26A1'
p478
S'increases'
p479
tp480
(lp481
s(S'Antigen/IgE/Fc epsilon R1/LYN/SYK'
p482
S'VAV1'
p483
S'adds_modification'
p484
tp485
(lp486
s(S'PCBP1'
p487
S'MEIS1'
p488
S'increases'
p489
tp490
(lp491
s(S'FOXI1'
p492
S'FOXD3'
p493
S'increases'
p494
tp495
(lp496
s(S'GATA4'
p497
S'MEIS1'
p498
S'increases'
p499
tp500
(lp501
s(S'STAT5B'
p502
S'CEBPG'
p503
S'increases'
p504
tp505
(lp506
s(S'TFDP2'
p507
S'MAZ'
p508
S'increases'
p509
tp510
(lp511
s(S'PI3K'
p512
S'SHP2'
p513
S'binds'
p514
tp515
(lp516
s(S'SPI1'
p517
S'ONECUT1'
p518
S'increases'
p519
tp520
(lp521
s(S'STAT6'
p522
S'EN1'
p523
S'increases'
p524
tp525
(lp526
s(S'TLX2'
p527
S'CYP26A1'
p528
S'increases'
p529
tp530
(lp531
s(S'RAF1'
p532
S'MEK1-2'
p533
S'increases_activity'
p534
tp535
(lp536
s(S'STAT5A'
p537
S'IRF1'
p538
S'increases'
p539
tp540
(lp541
s(S'2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine'
p542
S'HRAS MRNA'
p543
S'increases'
p544
tp545
(lp546
s(S'MAZ'
p547
S'POU2F1'
p548
S'increases'
p549
tp550
(lp551
s(S'MAZ'
p552
S'SRF'
p553
S'increases'
p554
tp555
(lp556
s(S'GATA1'
p557
S'JUN'
p558
S'increases'
p559
tp560
(lp561
s(S'FOXA1'
p562
S'NRAS'
p563
S'increases'
p564
tp565
(lp566
s(S'STAT1'
p567
S'EN1'
p568
S'increases'
p569
tp570
(lp571
s(S'GTF2A2'
p572
S'MAX'
p573
S'increases'
p574
tp575
(lp576
s(S'LMO2'
p577
S'EN1'
p578
S'increases'
p579
tp580
(lp581
S'H217 and F238, at the interface between SCL and LMO2, are conserved in hematopoietic bHLH proteins (LYL1, TAL2), but not in neuronal and muscle proteins (NeuroD1, HEN1, HEN2, and MyoD, '
p582
as(S'MYOD1'
p583
S'LEF1'
p584
S'increases'
p585
tp586
(lp587
s(S'ATF3'
p588
S'JUN'
p589
S'increases'
p590
tp591
(lp592
s(S'GRB2:SOS1'
p593
S'ACTIVATED FGFR:P-SHC1'
p594
S'binds'
p595
tp596
(lp597
s(S'MAFG'
p598
S'BACH1'
p599
S'increases'
p600
tp601
(lp602
s(S'POU3F2'
p603
S'POU2F1'
p604
S'increases'
p605
tp606
(lp607
s(S'K 7174'
p608
S'KRAS MRNA'
p609
S'increases'
p610
tp611
(lp612
s(S'POU1F1'
p613
S'RUNX1'
p614
S'increases'
p615
tp616
(lp617
s(S'HRAS protein'
p618
S'CCND1 MRNA'
p619
S'increases'
p620
tp621
(lp622
s(S'YY1'
p623
S'EN1'
p624
S'increases'
p625
tp626
(lp627
s(S'resveratrol'
p628
S'HRAS MRNA'
p629
S'increases'
p630
tp631
(lp632
s(S'NKX2-1'
p633
S'HOXA9'
p634
S'increases'
p635
tp636
(lp637
s(S'HSF1'
p638
S'CYP26A1'
p639
S'increases'
p640
tp641
(lp642
s(S'MYC'
p643
S'HOXA9'
p644
S'increases'
p645
tp646
(lp647
s(S'Raf'
p648
S'MEK'
p649
S'adds_modification'
p650
tp651
(lp652
S'In the MM, by simply altering the rate equation for Raf-catalyzed phosphorylation of MEK in a manner consistent with competitive inhibition, and likewise for the receptor inhibitor, the MM predicts a modest 58% decrease in ERK* ('
p653
aS'Dysregulated signaling through the RAS/RAF/mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway due to mutations in K-Ras and B-Raf are common events in CRC.'
p654
aS'Numerous agents targeting mTOR, PI-3K, growth factor receptors, and related tyrosine kinases, Ras, Raf, and B-Raf, S6K, MEK1/2 have been tested to treat cancer.'
p655
aS'The Raf1 kinase inhibitor (GW5074) and different MEK inhibitors (U0126 and AZD6244) were used to treat HCC cells to identify their effects on HCC cell growth and ABC proteins expression '
p656
aS'Both Raf1 inhibitor (GW5074) and MEK inhibitors (U0126 and AZD6244) suppressed HCC cell growth in a dose dependent manner.'
p657
aS'The objective of this investigation was to elucidate the interaction between two key kinases within the MAPK pathway (Raf1 and MEK) and ABC proteins expression in HCC.'
p658
aS'Highly selective inhibitors which inhibited the Raf1 kinase (GW5074) and the MEK activity (U0126 and AZD6244) were applied to identify their effects on the MRP1 and MRP3 protein expression.'
p659
aS'The Raf1 inhibitor GW5074 and MEK inhibitor U0126 were purchased from Calbiochem (Darmstadt, Germany).'
p660
aS'The antibodies for western blot were purchased from: Actin (A1978) (Sigma Aldrich, Steinheim, Germany); p-ERK (#4377), p-MEK (#9121), MEK (#4694), p-Raf1 (#9427), and Raf1 (#9422) (Cell Signaling, Frankfurt, Germany); MRP3 (sc-20767), ERK (sc-135900), and the secondary antibodies goat anti rabbit (sc-2004) as well as goat anti mouse (sc-2005) (Santa Cruz, Heidelberg, Germany); MRP1 (ab32574) (Abcam, Cambridge, UK).'
p661
aS'ABC protein: ATP binding cassette proteins; EGFR: Epidermal growth factor receptor; ERK: Mitogen-activated protein kinase; MAPK: Mitogen activated protein kinase; MEK: Mitogen-activated protein kinase kinase; MRP1: Multidrug resistance-associated protein 1; MRP3: Multidrug resistance-associated protein 3; PDGFR: Platelet-derived growth factor receptor; PGP: P-glycoprotein; Raf: Proto-oncogene serine/threonine-protein kinase; siRNA: Small interfering RNA; VEGFR: Vascular endothelial growth factor receptor.'
p662
aS'Conversely, knockdown of Mirk/Dyrk1B by siRNA led to up-regulated activation of c-Raf-MEK-ERK1/2 pathway and subsequent changes in cell cycle proteins (cyclin D1, p27kip1), accompanied by increased growth rate and cells from G0/G1 into S of cell cycle which could be blocked by U0126 in a dose-dependent manner, indicating Mirk/Dyrk1B may sequester MAPK/ERK pathway, and vice versa.'
p663
aS'The Ras/Raf/mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway (Ras-Raf-MEK-ERK pathway) is an intracellular key signaling pathway that transmits mitogenic stimuli from the extracellular environment to the nucleus of the cell by multiple phosphorylation steps ['
p664
aS'All human cells contain B-Raf, C-Raf, MEK, and EGF, usually in wild-type form, although it is increasingly being appreciated that mutant forms of all of these enzymes are far more widespread than initially thought.'
p665
aS'In addition, we showed that this compound suppressed cell proliferation in both cell lines by inhibiting the PI3K/Akt/mTOR pathway as well as the Raf/MEK/ERK pathway.'
p666
aS'On the other hand, this drug did not inhibit the phosphorylation and expression of EGFR, MEK, PI3K and PDK1, and upstream receptors of Raf/MEK/ERK and PI3K/Akt/mTOR pathways.'
p667
aS'The Raf/MEK/ERK signal transduction pathway is present in all eukaryotic cells.'
p668
aS'This pivotal pathway relays extracellular signals to the nucleus via a cascade of specific phosphorylation events involving Raf, MEK, and ERK to regulate fundamental cellular processes, including proliferation, differentiation, and cell survival ['
p669
aS'Effective inhibitors specific for many of the key components of the Raf/MEK/ERK or PI3K/Akt/mTOR pathway have been developed.'
p670
aS'Our findings have important implications for metastatic RCC therapy because they provide a rationale for dual inhibition of the Raf/MEK/ERK and PI3K/Akt/mTOR pathways.'
p671
aS'Previous reports indicated the efficacy of combining Raf/MEK/ERK inhibitors with PI3K/Akt/mTOR inhibitors.'
p672
aS'Through serine/threonine phosphorylation, Raf activates a family of dual specificity kinases known as MAPK kinases (MAP2K) or MAPK/ERK kinases (MEKs).'
p673
aS'Presumably, the epigenetic changes might comprise pathways involved in chromatin remodelling and/or the Ras/Raf/MEK/ERK pathway.'
p674
aS'However, other signals impinge on mTORC1, including the Ras/Raf/MEK/ERK1/2/p90'
p675
aS'Raf activates MEK which in turn phosphorylates and activates ERK1/2 ['
p676
aS'Most B-Raf mutations involve the V600E amino acid substitution, resulting in constitutive activation of the MEK-ERK signaling pathway.'
p677
aS'In the present study a recently conceived 4-gene marker panel covering the Wnt and Ras-Raf-MEK-MAPK signaling pathways was used to analyze 20 colorectal serrated lesions and 41 colorectal adenoma samples and to determine the percentage of each of the above-mentioned potentially precancerous lesions carrying at least one of the four above-mentioned genes in a mutated form. '
p678
aS'In serrated lesions the Ras-Raf-MEK-MAPK pathway was significantly more often altered than the Wnt pathway (60% '
p679
aS'The Ras-Raf-MEK-MAPK signaling cascade was solely affected in 92.3 and 56% of the serrated lesion and adenoma cases with mutations, respectively, whereas the Wnt signaling cascade was solely mutated in 15.4 and 68% of the serrated lesion and adenoma cases with mutations, respectively.'
p680
aS'Moreover, in a recent study by our group, in which CRC samples underwent a mutational analysis with the same oligonucleotide primer panel used in the present report, it was shown that 45% of mutation-positive CRC only exhibited alterations in the Wnt signaling cascade and 38% of mutation-positive CRC only exhibited alterations in the Ras-Raf-MEK-MAPK signaling cascade ['
p681
aS'By making use of a recently conceived combination of oligonucleotide primers it could be shown that: (1) In 65% of the analyzed serrated lesions and in 61% of the traditional adenomas of the colon and rectum, at least one of the four genes studied was altered; (2) in 92.3% of the serrated lesions with mutations and in 76% of the adenoma samples with mutations either the Ras-Raf-MEK-MAPK or the Wnt signaling cascade was altered; (3) in 35% of the serrated lesions and in 39% of the adenomas neither the Wnt pathway nor the Ras-Raf-MEK-MAPK pathway were affected.'
p682
aS'Frequency of genetic alterations affecting the Wnt or the Ras-Raf-MEK-MAPK pathway in the colorectal lesions analyzed.'
p683
aS'The frequency of genetic alterations affecting the Ras-Raf-MEK-MAPK signaling pathway is significantly higher than that affecting the Wnt pathway ('
p684
aS'Anatomical location of the colorectal lesions with an altered Wnt or Ras-Raf- MEK-MAPK pathway.'
p685
aS'The frequency of genetic alterations affecting the Wnt signaling pathway is significantly higher than that affecting the Ras-Raf-MEK-MAPK signaling pathway in adenomas arising in the distal colon ('
p686
aS'The frequency of genetic alterations affecting the Ras-Raf-MEK-MAPK signaling pathway is significantly higher than that affecting the Wnt signaling pathway in serrated lesions arising in the proximal colon ('
p687
aS'Zoledronic acid enhances fluvastatin and paclitaxel activity against T24 in a synergistic manner and this is mediated largely by inhibition of both the Ras/Raf/MEK/ERK and PI3K/AKT signaling pathways via isoprenylation inhibition.'
p688
aS'The effects of the fluvastatin and zoledronic acid on signal transduction pathways of Ras/Raf/MEK/ERK and PI3K /AKT were investigated under the same conditions as above.'
p689
aS'Abbreviations are the following: CD10: 100 kDa transmembrane metallo-endopeptidase; CD14: cluster of differentiation 14; TLR1: Toll-like receptor 1; TLR2: Toll-like receptor 2; TLR3: Toll-like receptor 3; NGF-beta: Nerve growth factor beta; Her2: Human Epidermal Growth Factor Receptor-2; ERbeta: Estrogen receptor beta; FGF-2: Fibroblast growth factor 2; VEGF: vascular endothelial growth factor; IKKbeta: inhibitor of nuclear factor kappa-B kinase subunit beta; DAXX: death domain-associated protein 6; PKC delta: protein kinase C delta; RhoA: Ras homolog gene family member A; PKCalpha: protein kinase C alpha; Akt: protein kinase B; P38: P38 mitogen-activated protein kinases; MK2: Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2); Phk: Phosphorylase kinase (PhK); PTEN: phosphatase and TENsin homolog; PRKD1: Serine/threonine-protein kinase D1; PPM1A: protein phosphatase 1A (formerly 2C), magnesium-dependent, alpha isoform; TRAF6: tumor necrosis factor receptor-associated factor 6; Raf, MEK, ERK: Mitogen activated protein (MAP) kinase pathways; Bax: Bcl-2 associated X protein; PEA-15: astrocytic phosphoprotein PEA-15; XIAP: X-linked inhibitor of apoptosis; p66Shc: 66 kDa isoform of ShcA (Src homology 2 domain containing transforming protein 2); G6PD: glucose 6-phosphate dehydrogenase; HDM2: Human double minute 2 homolog; IF: intermediate filaments; MAPs: microtubule-associated proteins; GFAP: Glial fibrillary acidic protein; GRIFIN: galectin-related interfiber protein; HDAC6: histone deacetylase 6; STAT2 and 3: signal transducer and activator of transcription 2 and 3; HSF-1: heat shock factor 1; GATA-1: globin transcription factor 1; Snail: zinc finger protein that binds and inhibits E-cadherin promoter to induce epithelial mesenchymal transformation; eIF4E: eukaryotic translation initiation factor 4E; eIF4G: eukaryotic translation initiation factor 4G; AUF1: AU-rich element (ARE)-binding protein; p90 ribosomal S6 kinase; Smad-Smurf2: Smad ubiquitination regulatory factor 2; p27kip1: cyclin-dependent kinase inhibitor p27kip1; Fbx4: Fbox only protein 4.'
p690
aS'Activation of the Ras/Raf/MEK/ERK pathway induces RET downregulation, growth inhibition, and differentiation in MTC cells by inducing expression and secretion of LIF, which activates STAT3 in an autocrine/paracrine mode.'
p691
aS'GRKs phosphorylate PAK, MEKK/Raf, MEK, MAPK, SAP/JNK, p38, Arrestins, beta2-adrenergic receptor, and other proteins.'
p692
aS'The Ras-Raf-MEK signaling pathway is fundamental to cellular metabolism and growth in humans; inherited mutations involving this pathway cause disorders of early growth and development ('
p693
aS'KSR2_921 was expressed at a lower level and had a reduced ability to bind B-Raf and facilitate MEK and ERK phosphorylation.'
p694
aS'Using confocal microscopy, we investigated the intracellular localization of WT and mutant KSR2 expressed in Cos7 cells and its colocalization with endogenous B-Raf, MEK, or ERK.'
p695
aS'To determine whether KSR2 mutations affect Ras-Raf-MEK-ERK signaling, HEK293 cells were transfected with Flag-tagged WT and mutant forms of KSR2 and stimulated with EGF.'
p696
aS'(A) Confocal microscopy of EGF-stimulated Cos7 cells showing the colocalization of transiently expressed KSR2 WT and the frameshift mutation, L822Pfsx26 (green), with endogenous B-Raf, MEK, and ERK (red) in the cytoplasm and plasma membrane (inset).'
p697
aS'Subcellular Localization of KSR2 Mutants and Colocalization with B-Raf, MEK, and ERK, Related to '
p698
aS'Cells were coimmunostained with anti-Flag (green) and either: anti-B-Raf, anti-MEK or anti-ERK (red) antibodies and analyzed by confocal microscopy.'
p699
aS'Other Ras-MAPK components such as Raf, MEK and ERK are also being investigated and are proving more successful drug targets ['
p700
aS'Compared with normal bladder tissues, phosphorylation levels of B-Raf (Ser455), C-Raf (Ser338), MEK (1/2) and ERK significantly increased in bladder carcinoma tissues.'
p701
aS'The NCFC syndromes comprise neurofibromatosis (NF) and the Noonan (NS), Costello (CS), LEOPARD (LS) and cardio-facious-cutaneous (CFC) syndromes, which are correlated with autosomal-dominant germ-line mutations within either the core components (Ras, B-Raf, Raf-1, MEK) or modulators of the Ras/ERK pathway (NF1, SHP2, SOS and Spred).'
p702
aS'Following activation, Raf phosphorylates and activates mitogen-activated protein kinase (MAP) kinase (MEK) which in turn phosphorylates and activates the MAP kinases extracellular signal-regulated protein kinases ERK1 and ERK2 ['
p703
aS'The activation of the MEK/ERK signaling pathway by Raf has been correlated with inhibition of programmed cell death.'
p704
aS'Treatment with the MEK inhibitor PD98059 blocked the anti-apoptotic activity of B-Raf, indicating that the activation of the Raf-MEK-ERK signaling pathway is necessary for the anti-apoptotic role of B-Raf in Rat-1 fibroblasts ['
p705
aS'In addition to the well-established target MEK, Raf may use other effectors to inhibit programmed cell death.'
p706
aS'It has been shown that Raf-1 promotes cell survival in a MEK/ERK-independent manner via antagonizing apoptosis signal-regulating kinase-1 (ASK-1) ['
p707
aS'The Ser/Thr-kinase B-Raf represents an important signaling element of the Ras/Raf/MEK/ERK pathway ['
p708
aS'Raf is the MAPKKK in the first MAPK pathway identified, the Ras-Raf-MEK-ERK pathway.'
p709
aS'A recent example is the scaffold KSR2, member of the extended Raf family and well known for its role in coordinating Raf-MEK-ERK complexes ['
p710
aS'They are regulated by phosphorylation via the classical mitogen-activated protein kinase (MAPK) pathway involving the GTPase Ras, which activates the serine-threonine kinases Raf, MEK and ERK.'
p711
aS'The transduction of a cellular signal as it propagates through the MAPK cascades, exemplified by the Raf/MEK/ERK module, is predominantly controlled by phosphorylation events where typically, each kinase in the cascade is activated by an upstream kinase and inactivated by relevant phosphatases.'
p712
aS'The canonical ERK pathway consists of three kinase tiers: Raf, MEK (MAPK and ERK kinase) and ERK.'
p713
aS'ERK/MAPK scaffolds, in the narrow sense, assemble two or all three tiers of the canonical ERK pathway (Raf, MEK and ERK), thus - when expressed at optimal stoichiometry - facilitating and accelerating ERK activation, but at the same time restricting signal amplification.'
p714
aS'KSR1, which binds to Raf, MEK and ERK, belongs to this category.'
p715
aS'Scaffold proteins in the broader sense associate with one or more members of the MAPK pathway within a larger complex or protein platform, such as paxillin, which interacts with Raf, MEK and ERK within the focal adhesion complex ['
p716
aS'The possibilities include (1) direct interaction of caveolin-1 and IQGAP1, (2) sequential or (3) simultaneous interaction with the Raf-MEK-ERK cassette, possibly through dimerization of Raf, MEK and/or ERK ['
p717
aS'Our data show that the phorbol ester stimulated pathway PKC-Ras-Raf-MEK-ERK is broken down into two modules, of which one, PKC-Ras-(C-)Raf, is assembled at the caveolae with the help of caveolin-1, and the other one, (B-)Raf-MEK-ERK, is tethered to the actin cytoskeleton with the help of IQGAP1.'
p718
aS'Insulin-like growth factor I (IGF-I) is a hormone that promotes proliferation, differentiation, and survival in a number of cells types mediated principally through PI3K/Akt, and Ras/Raf/MEK/ERK pathways ('
p719
aS'The binding of NGF to TrkA activates the PI3K-Akt (phosphatidylinositol 3-kinase-Akt) and Raf-MEK-ERK (Raf-MAPK/extracellular signal-regulated kinase kinase-extracellular signal-regulated kinase) signalling pathways, which promote the growth and survival of sympathetic neurons.'
p720
aS'NGF deprivation decreases the activity of the PI3K-Akt and Raf-MEK-ERK survival pathways, but increases the activity of the MLK-JNK-c-Jun (mixed lineage kinase-c-Jun N-terminal kinase-Jun proto-oncogene) pathway, which is required for the increased expression of BH3-only proteins and for mitochondrial cytochrome '
p721
aS'The binding of NGF to its receptor TrkA can also activate the Raf-MEK-ERK signalling pathway.'
p722
aS'The signaling cascades downstream of RTKs and NRTKs include mainly the Ras/Raf/MEK/ERK, JAK/STAT and the PI3K/AKT pathways.'
p723
aS'In particular, the Ras/Raf/MEK/ERK signaling cascade has a pivotal role in the molecular circuitry of CRPC, and the majority of the RTKs upregulated in prostate cancer have been shown to activate Ras.'
p724
aS'The Raf/MEK/ERK signaling cascades that leads to phosphorylation/inactivation of Bad and upregulation of the anti-apoptotic Bcl-2 family members is critical for the survival of 22Rv1 cells and sorafenib, by targeting this signaling cascade is highly efficacious in killing these cells.'
p725
aS'We determined whether and to which extent sorafenib might mediate its pro-apoptotic action by inhibiting the Raf/MEK/ERK pathway.'
p726
aS'One of the best-characterized targets of sorafenib is the Raf/MEK/ERK pathway.'
p727
aS'With regard to the lack of ERK phosphorylation in PC3 cells, it has been previously reported that metastatic cell lines express low levels of the proteins involved in the Raf/MEK/ERK axis.'
p728
aS'In prostate cancer, the tumor stroma activates RTKs in the prostate cancer cells via the secretion of cytokines (e.g., PDGF, VEGF), hence stimulating the oncogenic signaling cascades Ras/Raf/MEK/ERK and PI3K/AKT.'
p729
aS'To that end, lovastatin was shown to induce apoptosis in AML cells by downregulating the pro-survival Raf-MEK-ERK pathway.'
p730
aS'It has been demonstrated that Ras, a GTP-binding protein, is a common upstream activator of the Raf/MEK pathway.'
p731
aS'Raf-1 dependent phosphotransferase activity is measured in a kinase reaction using recombinant MEK1 unactive as a Raf-1 substrate over PC12 lysates where Raf-1 was immunoprecipitated using anti-Raf-1 antibody (Santa Cruz, Biotechnology).'
p732
aS'Therefore, the above results together suggest that inhibition of the PI3K/AKT and MEK/ERK pathways by atorvastatin in KRAS mutant NSCLC cells correlates with disruption of the Kras/Raf and Kras/PI3K complexes irrespective of the PIK3CA and PTEN statuses.'
p733
aS'A recent report describes that ERK2, a downstream kinase of Ras-Raf-MEK-ERK pathway, can directly phosphorylate components of WAVE2 complex, WAVE2 and Abi1, essential for interaction of WAVE complex with Arp2/3 and actin to mediate actin polymerization and lamellipodia formation.'
p734
aS'In the cells, Jak-Stat, p38MAPK, PI3K-AKT-mTOR, and Ras-Raf-MEK-ERK pathways are interdependent, interconnected signaling pathways that are responsible for regulating, integrating, and balancing various signals from exogenous or endogenous stimulators, including growth factors, cytokines, and stress stimuli ('
p735
aS'As they are almost exclusively activated downstream of extracellular signal-regulated kinases 1 and 2 (ERK1/2), therapeutic intervention by RSK inhibition is less likely to produce such severe side effects as those observed following inhibition of the upstream master regulators Raf, MEK and ERK1/2.'
p736
aS'Mutational activation of RAS proteins is associated with the occurrence of almost 30% of all human tumors, but due to off-target and severe side effects clinical trials based on small molecule inhibitors targeting participating downstream kinases including Raf, MEK and ERK1/2 have so far not been very successful.'
p737
aS'Furthermore, AKT phosphorylates C-Raf Ser259 that leads to inhibition of the MEK/ERK pathway.'
p738
aS'c-Raf kinase activity assay is based on the biochemical reaction using inactive recombinant MEK1 as a c-Raf substrate.'
p739
aS'Rasfonin clearly inhibited c-Raf, MEK and ERK phosphorylation, but had no significant effect on total MEK and ERK levels ('
p740
aS'ADCY5 knockout mice showed increased longevity as a result of activating Raf/MEK/ERK signaling and cAMP levels.'
p741
aS'P27 maintains PHLPP expression, which inhibits Ras/Raf/MEK/ERK/ p90RSK/S6 cascade.'
p742
aS'Recent evidence indicates that Raf Kinase Inhibitory Protein regulates the mitotic spindle assembly checkpoint by controlling Aurora B Kinase activity, and the mechanism involves Raf/MEK/ERK signaling.'
p743
aS'Activated Raf-1 was localized on early mitotic kinetochores, activation of the MAP kinase cascade mimicked effects of RKIP depletion, and inhibition of ERK1,2 signaling by either drugs, dominant-negative MEK, or siRNA for Raf-1 rescued defects caused by RKIP loss.'
p744
aS'RKIP, Raf Kinase Inhibitory Protein; MAP kinase, mitogen activated protein kinase; ERK, extracellular signal regulated kinase; MEK, MAP/ERK kinase; PKC, protein kinase C'
p745
aS'Cell proliferation is regulated by multiple pathways such as the Raf-MEK-ERK, NF-kB or phosphatidylinositol- 3 kinase (PI3K)-AKT pathways\n['
p746
aS'Whereas the Raf/MEK/ERK signaling pathway is well studied in relation to cell proliferation, apoptosis, differentiation, and immune responses ('
p747
aS'The canonical MAPK cascade is widely associated with cell proliferation and consists of Ras/Raf/MEK/(MAPK)Erk.'
p748
aS'PAK phosphorylates two mediators of the MAP kinase pathway, MEK1 and Raf1, at Ser298 and at Ser338, respectively.'
p749
aS'The total Raf1 and ERK1/2 protein level did not change, but those of K-RAS, p-Raf1, MEK1, p-MEK1, and p-ERK1/2 decreased.'
p750
aS'A previous study showed that the total Raf1, ERK1/2, or MEK1 protein level was unchanged when RAS/MAPK signaling pathways were activated.'
p751
aS'Each dimer can subsequently trigger various intracellular signaling pathways, including those of PI3K/Akt, Ras/Raf/MEK/ERK, and STATs, which all play important roles in cellular oncogenic processes such as proliferation, survival, motility, and angiogenesis. '
p752
aS'These effects are dependent on Akt down-regulation, vitamin D3 disassociation with Raf1, and subsequent activation of Raf/MEK/ERK2 MAPK signaling.'
p753
aS'The Ras-Raf-MEK-MAPK pathway has its own distinct downstream effects, but also converges with the PI3K-AKT pathway.'
p754
aS'A good example is that combined treatment with proto-oncogene B-Raf (BRAF) inhibitor dabrafenib and mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor trametinib delays the development of treatment resistance in patients with BRAF-positive metastatic malignant melanoma'
p755
aS'Besides, sorafenib combined with cytotoxic drug shows an impossible synergism as that sorafenib inhibits the Ras/Raf/MEK/ERK pathway, which will prevent activation of the multidrug resistance pathway that mainly induce the failure of chemotherapy in HCC'
p756
aS'The signal initiated by RTKs is transduced and amplified through downstream molecule cascades, such as Ras-MAPK, Ras-Raf-MEK-ERK-Elk, and the pro-survival AKT/phosphoinositide 3-hydroxykinase pathway [for an outstanding review, see Patra '
p757
aS'Activation of the Raf Sarcoma (RAS) family of GTPases by growth factors or by RAS mutation then drives activation of the RAF kinase family (ARAF, BRAF, CRAF) with subsequent phosphorylation and activation of MEK kinases (MEK 1 and 2) and extracellular signal- regulated kinases (ERK 1 and 2).'
p758
aS'However, the increased insulin concentrations increase signalling via the kinases of the MAPK pathway {p21Ras, Raf, MEK [MAPK/ERK (extracellular-signal-regulated kinase) kinase] and ERK} to increase cell proliferation and survival.'
p759
aS'Both Raf/mitogen activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) and phosphoinositide 3-kinase(PI3K)/Akt/mammalian target of rapamycin (mTOR) pathways are over-expressed and/or over-activated in pituitary tumors ('
p760
aS'Loss of menin expression is associated with over-expression of the Raf/MEK/ERK and P13K/AKT/mTOR pathways in pancreatic tumors ('
p761
aS'BRAF is a member of the Raf family of serine threonine kinases (ARAF, BRAF, CRAF) which are part of the Ras/ Raf/MEK/ERK mitogen-activated protein kinase (MAPK) signalling pathway.'
p762
aS'Unconjugated B-Raf antibody was from Santa Cruz Biotechnology (sc-5284), pMEK1/2 antibody from Cell Signaling Technology (9121), anti-FLAG M2 from Sigma.'
p763
aS'For the pharmacological evaluation we generated double stable cells constitutively expressing either cSTKpep-3, wild-type MEK1(WT) or kinase-inactive MEK1(KD) substrates in combination with Tet-inducible B-Raf(V600E).'
p764
aS'Moreover, the observed potencies of a panel of selective in-house B-Raf inhibitors correlated very well in cSTKpep-3 and MEK1(WT) TR-FRET-assays (R'
p765
aS'The Raf-MEK-ERK pathway is commonly activated in human cancers, largely attributable to the extracellular signal-regulated kinases (ERKs) being a common downstream target of growth factor receptors, Ras, and Raf.'
p766
aS'In addition, MEK1/2 kinases are activated by Raf (MAPK kinase kinase) ['
p767
aS'The growth factor mediated activation of the RAS/Raf/MEK/ERK/RSK1 pathway is another mechanism whereby\nthere can be crosstalk regulation of the AKT/mTOR signaling pathway.'
p768
aS'Raf-MEK-ERK1/2 forms a regulatory complex with ENaC and inhibits its function.'
p769
aS'Interruption of ERK signalling may occur by (1) hyperphosphorylation of Raf and MEK 1 and 2, (2) dephosphorylation of aminoacidic residues of ERK and (3) sequestration of ERK in the nucleus.'
p770
aS'In regard to the levels of phosphorylation of Raf and MEK, it is possible that ERK, apart from phosphorylating downstream substrates, could also phosphorylate upstream targets, such as those two kinases ['
p771
aS'Studies have focused in 3 proteins: Ras, Raf and MEK.'
p772
aS'Previously we have reported that acute exposure to ammonium activated ouabain/Na,K-ATPase signalling pathway, which includes Src, EGF receptor, Raf, Ras, MEK and ERK'
p773
aS'The released HB-EGF activates (phosphorylates) the EGF receptor (inhibited by AG1478), leading to activation of the MAP kinase cascade, Ras (inhibited by bumetanide), Raf and MEK (inhibited by U0126), with activation of MEK causing ERK1/2 phosphorylation.'
p774
aS'Active immune strategies aimed at interfering with the Ras-Raf-MEK pathway in NSCLC are also incipient exploring the use of a Ras peptide based vaccine ['
p775
aS'The Ras-Raf-MEK-ERK MAPK pathway is a particularly well studied MAPK pathway unique to metazoans and consists of a three-tiered kinase cascade from Raf-to-ERK.'
p776
as(S'TFDP1'
p777
S'MAZ'
p778
S'increases'
p779
tp780
(lp781
s(S'SPRED1'
p782
S'HRAS'
p783
S'binds'
p784
tp785
(lp786
s(S'MYCN'
p787
S'CYP26A1'
p788
S'increases'
p789
tp790
(lp791
s(S'AHR'
p792
S'FOXD3'
p793
S'increases'
p794
tp795
(lp796
s(S'SF1'
p797
S'CYP26A1'
p798
S'increases'
p799
tp800
(lp801
s(S'MEIS1'
p802
S'ETS1'
p803
S'increases'
p804
tp805
(lp806
s(S'Copper Sulfate'
p807
S'HRAS MRNA'
p808
S'decreases'
p809
tp810
(lp811
s(S'MAZ'
p812
S'MYC'
p813
S'increases'
p814
tp815
(lp816
s(S'E4F1'
p817
S'HOXA9'
p818
S'increases'
p819
tp820
(lp821
s(S'GATA1'
p822
S'GATA6'
p823
S'increases'
p824
tp825
(lp826
S'The evolutionary conserved GATA family of tissue- and organ-specific vertebrate transcription factors (GATA-binding proteins 1 to 6; GATA1 to GATA6) consists of two zinc finger domains.'
p827
as(S'RUNX2'
p828
S'POU2F1'
p829
S'increases'
p830
tp831
(lp832
s(S'CYP26A1'
p833
S'GATA6'
p834
S'increases'
p835
tp836
(lp837
s(S'PAX4'
p838
S'GATA1'
p839
S'increases'
p840
tp841
(lp842
s(S'ELF2'
p843
S'STAT5A'
p844
S'increases'
p845
tp846
(lp847
s(S'CART1'
p848
S'NRAS'
p849
S'increases'
p850
tp851
(lp852
s(S'IGF-1R heterotetramer/IGF1/GRB2/Sos/Shc'
p853
S'HRAS/GDP'
p854
S'increases_activity'
p855
tp856
(lp857
s(S'RB1'
p858
S'CYP26A1'
p859
S'increases'
p860
tp861
(lp862
s(S'CEBPG'
p863
S'HOXA9'
p864
S'increases'
p865
tp866
(lp867
s(S'GRB2/SOS1/SHC'
p868
S'IGF-1R HETEROTETRAMER/IGF1'
p869
S'binds'
p870
tp871
(lp872
s(S'PRRX2'
p873
S'CYP26A1'
p874
S'increases'
p875
tp876
(lp877
s(S'TEAD1'
p878
S'CYP26A1'
p879
S'increases'
p880
tp881
(lp882
s(S'STAT5A'
p883
S'FOXA1'
p884
S'increases'
p885
tp886
(lp887
s(S'ATF2'
p888
S'FOXD3'
p889
S'increases'
p890
tp891
(lp892
s(S'REPIN1'
p893
S'FOXO4'
p894
S'increases'
p895
tp896
(lp897
s(S'FOXF2'
p898
S'ETS1'
p899
S'increases'
p900
tp901
(lp902
s(S'ETV7'
p903
S'MEIS1'
p904
S'increases'
p905
tp906
(lp907
s(S'RUNX2'
p908
S'RUNX1'
p909
S'increases'
p910
tp911
(lp912
S'The mammalian RUNX family of nuclear hetero-dimeric transcription factors includes three members, Runt-related transcription factor 1 (RUNX1), RUNX2 and RUNX3, which have pivotal roles in the regulation of normal development and tumorigenesis.'
p913
aS'The RUNX (Runt-related transcription factor) family consists of three members, RUNX1, RUNX2 and RUNX3.'
p914
aS'RUNX1 and RUNX2 were essential for hematopoiesis and osteogenesis, respectively.'
p915
as(S'OR5I1'
p916
S'GATA1'
p917
S'increases'
p918
tp919
(lp920
s(S'MSX1'
p921
S'EN1'
p922
S'increases'
p923
tp924
(lp925
s(S'GTF3A'
p926
S'IRF1'
p927
S'increases'
p928
tp929
(lp930
s(S'POU2F1'
p931
S'SRF'
p932
S'increases'
p933
tp934
(lp935
s(S'PLC-GAMMA'
p936
S'COMPLEX (GADS/SLP-76)'
p937
S'binds'
p938
tp939
(lp940
s(S'STAT4'
p941
S'STAT5A'
p942
S'increases'
p943
tp944
(lp945
s(S'JUN'
p946
S'BACH1'
p947
S'increases'
p948
tp949
(lp950
s(S'POU1F1'
p951
S'HOXA9'
p952
S'increases'
p953
tp954
(lp955
s(S'docetaxel'
p956
S'HRAS PROTEIN'
p957
S'increases'
p958
tp959
(lp960
s(S'MAX'
p961
S'LEF1'
p962
S'increases'
p963
tp964
(lp965
s(S'FOXA1'
p966
S'CYP26A1'
p967
S'increases'
p968
tp969
(lp970
s(S'GATA4'
p971
S'FOXD3'
p972
S'increases'
p973
tp974
(lp975
s(S'ZBTB18'
p976
S'RUNX1'
p977
S'increases'
p978
tp979
(lp980
s(S'ATF3'
p981
S'RUNX1'
p982
S'increases'
p983
tp984
(lp985
s(S'NKX2-1'
p986
S'CYP26A1'
p987
S'increases'
p988
tp989
(lp990
s(S'NR3C1'
p991
S'FOXA1'
p992
S'increases'
p993
tp994
(lp995
s(S'RAS family/GTP'
p996
S'RIN1'
p997
S'increases_activity'
p998
tp999
(lp1000
s(S'COMPLEX (RAS/GTP/ RAF)'
p1001
S'MEK'
p1002
S'binds'
p1003
tp1004
(lp1005
s(S'CDC5L'
p1006
S'NRAS'
p1007
S'increases'
p1008
tp1009
(lp1010
s(S'Vitamin E'
p1011
S'NRAS MRNA'
p1012
S'decreases'
p1013
tp1014
(lp1015
s(S'NF1'
p1016
S'LEF1'
p1017
S'increases'
p1018
tp1019
(lp1020
s(S'ETS1'
p1021
S'EN1'
p1022
S'increases'
p1023
tp1024
(lp1025
s(S'CRAF'
p1026
S'YWHAB'
p1027
S'binds'
p1028
tp1029
(lp1030
s(S'CEBPD'
p1031
S'JUN'
p1032
S'increases'
p1033
tp1034
(lp1035
s(S'MAX'
p1036
S'RUNX2'
p1037
S'increases'
p1038
tp1039
(lp1040
s(S'CEBPA'
p1041
S'MECOM'
p1042
S'increases'
p1043
tp1044
(lp1045
s(S'PAX2'
p1046
S'GATA1'
p1047
S'increases'
p1048
tp1049
(lp1050
s(S'CYP26A1'
p1051
S'TLX2'
p1052
S'increases'
p1053
tp1054
(lp1055
s(S'GFI1'
p1056
S'ETS1'
p1057
S'increases'
p1058
tp1059
(lp1060
s(S'14-3-3:P-S259,Y340,Y341,S621-RAF1:RAS:GTP'
p1061
S'MEK'
p1062
S'binds'
p1063
tp1064
(lp1065
s(S'P-S,T-MEK2'
p1066
S'ERK2'
p1067
S'binds'
p1068
tp1069
(lp1070
s(S'HRAS/GTP'
p1071
S'RIN2'
p1072
S'increases_activity'
p1073
tp1074
(lp1075
s(S'Ras-GTP'
p1076
S'P42/P44MAPKS'
p1077
S'adds_modification'
p1078
tp1079
(lp1080
s(S'SRF'
p1081
S'CYP26A1'
p1082
S'increases'
p1083
tp1084
(lp1085
s(S'FOXL1'
p1086
S'RUNX2'
p1087
S'increases'
p1088
tp1089
(lp1090
s(S'EGR4'
p1091
S'LEF1'
p1092
S'increases'
p1093
tp1094
(lp1095
s(S'P-IRS1,2'
p1096
S'GRB2:SOS1'
p1097
S'binds'
p1098
tp1099
(lp1100
s(S'VEGFR2 (dimer)/VEGFA (dimer)/alphav/beta3 Integrin/Vitronectin'
p1101
S'SRC'
p1102
S'adds_modification'
p1103
tp1104
(lp1105
s(S'BACH2'
p1106
S'BACH1'
p1107
S'increases'
p1108
tp1109
(lp1110
S'Nrf1 (NF-E2 related factor-1) and Nrf2 (NF-E2 related factor-2) are two oxidative stress sensitive transcription factors that belong to the CNC/bZIP family of transcription factors consisting of NF-E2, Nrf1, Nrf2, Nrf3, BACH1, and BACH2 ['
p1111
as(S'ONECUT1'
p1112
S'RUNX1'
p1113
S'increases'
p1114
tp1115
(lp1116
s(S'FOXJ2'
p1117
S'RUNX2'
p1118
S'increases'
p1119
tp1120
(lp1121
s(S'PI-3-4-5-P3'
p1122
S'AKT1'
p1123
S'translocates'
p1124
tp1125
(lp1126
s(S'TFAP4'
p1127
S'BACH1'
p1128
S'increases'
p1129
tp1130
(lp1131
s(S'MEKK1/4'
p1132
S'MKK3/6'
p1133
S'adds_modification'
p1134
tp1135
(lp1136
s(S'VSX1'
p1137
S'MECOM'
p1138
S'increases'
p1139
tp1140
(lp1141
s(S'IRF1'
p1142
S'GATA6'
p1143
S'increases'
p1144
tp1145
(lp1146
s(S'MAX'
p1147
S'HOXA9'
p1148
S'increases'
p1149
tp1150
(lp1151
s(S'RB1'
p1152
S'MAZ'
p1153
S'increases'
p1154
tp1155
(lp1156
s(S'GATA1'
p1157
S'EN1'
p1158
S'increases'
p1159
tp1160
(lp1161
s(S'HIF1A'
p1162
S'SRF'
p1163
S'increases'
p1164
tp1165
(lp1166
s(S'IRF8'
p1167
S'CYP26A1'
p1168
S'increases'
p1169
tp1170
(lp1171
s(S'MTF1'
p1172
S'CYP26A1'
p1173
S'increases'
p1174
tp1175
(lp1176
s(S'PI-3-4-5-P3'
p1177
S'GAB1'
p1178
S'translocates'
p1179
tp1180
(lp1181
s(S'PI-3-4-5-P3'
p1182
S'AKT1'
p1183
S'adds_modification'
p1184
tp1185
(lp1186
s(S'RXRA'
p1187
S'HOXA9'
p1188
S'increases'
p1189
tp1190
(lp1191
s(S'AKT1'
p1192
S'RAF1'
p1193
S'binds'
p1194
tp1195
(lp1196
s(S'HSF2'
p1197
S'JUN'
p1198
S'increases'
p1199
tp1200
(lp1201
s(S'PAX2'
p1202
S'CYP26A1'
p1203
S'increases'
p1204
tp1205
(lp1206
s(S'ETV7'
p1207
S'CYP26A1'
p1208
S'increases'
p1209
tp1210
(lp1211
s(S'FOXO3'
p1212
S'NRAS'
p1213
S'increases'
p1214
tp1215
(lp1216
s(S'TP53'
p1217
S'REPIN1'
p1218
S'increases'
p1219
tp1220
(lp1221
s(S'STAT6'
p1222
S'CYP26A1'
p1223
S'increases'
p1224
tp1225
(lp1226
s(S'JUN'
p1227
S'NRAS'
p1228
S'increases'
p1229
tp1230
(lp1231
s(S'MYCN'
p1232
S'NRAS'
p1233
S'increases'
p1234
tp1235
(lp1236
s(S'STAT3'
p1237
S'YY1'
p1238
S'increases'
p1239
tp1240
(lp1241
s(S'Methyl Methanesulfonate'
p1242
S'HRAS MRNA'
p1243
S'increases'
p1244
tp1245
(lp1246
s(S'RHOA/GTP'
p1247
S'PKN'
p1248
S'increases_activity'
p1249
tp1250
(lp1251
s(S'NHLH1'
p1252
S'FOXJ2'
p1253
S'increases'
p1254
tp1255
(lp1256
s(S'RAS family/GTP'
p1257
S'BRAF'
p1258
S'adds_modification'
p1259
tp1260
(lp1261
s(S'RELA'
p1262
S'FOXJ2'
p1263
S'increases'
p1264
tp1265
(lp1266
s(S'TCF3'
p1267
S'RUNX1'
p1268
S'increases'
p1269
tp1270
(lp1271
S'The pruned dataset contains 413 samples belonging to seven different leukemia types: class 1 = hyperdiploid (115 samples), class 2 = TCF3-PBX1 (40 samples), class 3 = ETV6_RUNX1 (99 samples), class 4 = MLL (30 samples), class 5 = PH (23 samples), class 6 = hypodiploid (23 samples), and class 7 = T-ALL (83 samples).'
p1272
as(S'FOXF2'
p1273
S'FOXO4'
p1274
S'increases'
p1275
tp1276
(lp1277
s(S'ATF4'
p1278
S'FOXD3'
p1279
S'increases'
p1280
tp1281
(lp1282
s(S'HAND1'
p1283
S'MECOM'
p1284
S'increases'
p1285
tp1286
(lp1287
s(S'RHOA/GTP'
p1288
S'P27KIP1'
p1289
S'adds_modification'
p1290
tp1291
(lp1292
s(S'SRF'
p1293
S'NRAS'
p1294
S'increases'
p1295
tp1296
(lp1297
s(S'ESRRA'
p1298
S'POU3F2'
p1299
S'increases'
p1300
tp1301
(lp1302
s(S'BRAF'
p1303
S'MEK1'
p1304
S'adds_modification'
p1305
tp1306
(lp1307
S'For western blotting the following antibodies were used: rabbit anti-ppMEK1/2 and mouse anti-myc 9B11 (Cell Signaling Technology); mouse anti-NRAS (C-20), rabbit anti-ERK2 (C-14), rabbit anti-ARAF (C-20), mouse anti-BRAF (F-7) (Santa Cruz Biotechnology); mouse anti-Tubulin, and mouse anti-ppERK1/2 (Sigma); mouse anti-CRAF (for western blotting) (BD Transduction Laboratories).'
p1308
aS'(A and B) Structure of the MEK1-KSR2-BRAF ternary complex ('
p1309
aS'Children with germ-line mutations in KRAS, BRAF, MEK1 and MEK2 develop Cardio-facio-cutaneous syndrome (CFC), characterized by abnormal heart, craniofacial, and skin development.'
p1310
aS'Trametinib, an allosteric inhibitor of MEK1 and MEK2, has recently been shown to improve OS when compared to cytotoxic chemotherapy in BRAF mutated melanoma, though response rates are lower than those observed with the single agent vemurafenib.'
p1311
as(S'Cadmium Chloride'
p1312
S'KRAS PROTEIN'
p1313
S'increases'
p1314
tp1315
(lp1316
s(S'PRRX2'
p1317
S'MEIS1'
p1318
S'increases'
p1319
tp1320
(lp1321
s(S'MYC'
p1322
S'NRAS'
p1323
S'increases'
p1324
tp1325
(lp1326
s(S'MAZ'
p1327
S'KRAS'
p1328
S'increases'
p1329
tp1330
(lp1331
s(S'Rho Family GTPase-active'
p1332
S'PI3K'
p1333
S'increases_activity'
p1334
tp1335
(lp1336
s(S'STAT2'
p1337
S'CYP26A1'
p1338
S'increases'
p1339
tp1340
(lp1341
s(S'hsa-let-7a-5p'
p1342
S'KRAS'
p1343
S'decreases'
p1344
tp1345
(lp1346
s(S'POU3F2'
p1347
S'NRAS'
p1348
S'increases'
p1349
tp1350
(lp1351
s(S'SRF'
p1352
S'FOXO4'
p1353
S'increases'
p1354
tp1355
(lp1356
s(S'S1P1/Sphingosine-1-phosphate/PDGF-BB/PDGFRB (dimer)'
p1357
S'SRC FAMILY KINASES'
p1358
S'increases_activity'
p1359
tp1360
(lp1361
s(S'MYC/Max'
p1362
S'ERBB2'
p1363
S'decreases'
p1364
tp1365
(lp1366
s(S'SREBF1'
p1367
S'CBFA2T3'
p1368
S'increases'
p1369
tp1370
(lp1371
s(S'PI3K'
p1372
S'GELSOLIN/PI-3-4-5-P3'
p1373
S'binds'
p1374
tp1375
(lp1376
s(S'NHLH1'
p1377
S'EN1'
p1378
S'increases'
p1379
tp1380
(lp1381
s(S'LMO2'
p1382
S'GATA6'
p1383
S'increases'
p1384
tp1385
(lp1386
s(S'POU1F1'
p1387
S'FOXD3'
p1388
S'increases'
p1389
tp1390
(lp1391
s(S'hsa-miR-148b-3p'
p1392
S'NRAS'
p1393
S'decreases'
p1394
tp1395
(lp1396
s(S'Quercetin'
p1397
S'KRAS PROTEIN'
p1398
S'decreases'
p1399
tp1400
(lp1401
s(S'PAK2'
p1402
S'MEKK1'
p1403
S'adds_modification'
p1404
tp1405
(lp1406
s(S'LMO2'
p1407
S'MAZ'
p1408
S'increases'
p1409
tp1410
(lp1411
s(S'FOXO1'
p1412
S'POU3F2'
p1413
S'increases'
p1414
tp1415
(lp1416
s(S'NKX2-1'
p1417
S'MAZ'
p1418
S'increases'
p1419
tp1420
(lp1421
s(S'GRB2/SOS1'
p1422
S'PDGF-BB/PDGFRB (DIMER)/P52 SHC'
p1423
S'binds'
p1424
tp1425
(lp1426
s(S'PI3K'
p1427
S'CRK/P130 CAS/PAXILLIN'
p1428
S'increases_activity'
p1429
tp1430
(lp1431
s(S'ATF1'
p1432
S'FOXD3'
p1433
S'increases'
p1434
tp1435
(lp1436
s(S'GATA1'
p1437
S'SRF'
p1438
S'increases'
p1439
tp1440
(lp1441
s(S'TFAP2C'
p1442
S'CYP26A1'
p1443
S'increases'
p1444
tp1445
(lp1446
s(S'AHR'
p1447
S'MEIS1'
p1448
S'increases'
p1449
tp1450
(lp1451
s(S'ETS2'
p1452
S'CYP26A1'
p1453
S'increases'
p1454
tp1455
(lp1456
s(S'Estradiol'
p1457
S'NRAS MRNA'
p1458
S'increases'
p1459
tp1460
(lp1461
s(S'E2F1'
p1462
S'HOXA9'
p1463
S'increases'
p1464
tp1465
(lp1466
s(S'PDGF-BB/PDGFRB (DIMER)'
p1467
S'RASGAP'
p1468
S'binds'
p1469
tp1470
(lp1471
s(S'E2F1'
p1472
S'GABPB2'
p1473
S'increases'
p1474
tp1475
(lp1476
s(S'FOXJ1'
p1477
S'POU3F2'
p1478
S'increases'
p1479
tp1480
(lp1481
s(S'VSX1'
p1482
S'CYP26A1'
p1483
S'increases'
p1484
tp1485
(lp1486
s(S'SPI1'
p1487
S'CDC5L'
p1488
S'increases'
p1489
tp1490
(lp1491
s(S'Gi family'
p1492
S'HRAS/GDP'
p1493
S'increases_activity'
p1494
tp1495
(lp1496
s(S'TCF3'
p1497
S'CYP26A1'
p1498
S'increases'
p1499
tp1500
(lp1501
s(S'IGF-1R HETEROTETRAMER/IGF1/IRS1'
p1502
S'GRB2/SOS1'
p1503
S'binds'
p1504
tp1505
(lp1506
s(S'RAS family/GTP'
p1507
S'RALGDS'
p1508
S'translocates'
p1509
tp1510
(lp1511
s(S'PI3K'
p1512
S'RAC1/GDP'
p1513
S'increases_activity'
p1514
tp1515
(lp1516
s(S'Ca2+'
p1517
S'PKC'
p1518
S'increases_activity'
p1519
tp1520
(lp1521
S'WHO: World Health Organisation; ART: Assisted reproductive technology; HFEA: Human Fertilisation and Embryology Authority; IVF: In-vitro fertilisation; ICSI: Intracytoplasmic sperm injection; CG: Cortical granule; PN: Pro-nuclear; Ca2+: Calcium; IP3: Inositol trisphosphate; ER: Endoplasmic reticulum; PLC: Phospholipase C; PIP2: Phosphotidylinositol 4,5-bisphosphate; DAG: Diacylglycerol; PKC: Protein kinase C; PAWP: Post-acrosomal sheath WW domain-binding protein; NLS: Nuclear localisation signal; OAD: Oocyte activation deficiency; AOA: Artificial oocyte activation; MOAT: Mouse oocyte activation test; PIV: Particle image velocimetry.'
p1522
as(S'ZIC1'
p1523
S'CYP26A1'
p1524
S'increases'
p1525
tp1526
(lp1527
s(S'IRF7'
p1528
S'TLX2'
p1529
S'increases'
p1530
tp1531
(lp1532
s(S'SHC/SHIP'
p1533
S'HRAS/GDP'
p1534
S'decreases_activity'
p1535
tp1536
(lp1537
s(S'hsa-let-7a-5p'
p1538
S'HRAS'
p1539
S'decreases'
p1540
tp1541
(lp1542
s(S'GATA4'
p1543
S'MAZ'
p1544
S'increases'
p1545
tp1546
(lp1547
s(S'EN1'
p1548
S'NRAS'
p1549
S'increases'
p1550
tp1551
(lp1552
s(S'PI3K'
p1553
S'BAM32'
p1554
S'adds_modification'
p1555
tp1556
(lp1557
s(S'GABPB1'
p1558
S'CYP26A1'
p1559
S'increases'
p1560
tp1561
(lp1562
s(S'Trifluoroethanol'
p1563
S'HRAS'
p1564
S'increases_activity'
p1565
tp1566
(lp1567
s(S'SOX5'
p1568
S'CYP26A1'
p1569
S'increases'
p1570
tp1571
(lp1572
s(S'GRB2/SOS1'
p1573
S'HGF(DIMER)/MET(DIMER)/P52 SHC'
p1574
S'binds'
p1575
tp1576
(lp1577
s(S'TCF12'
p1578
S'EN1'
p1579
S'increases'
p1580
tp1581
(lp1582
s(S'SOX9'
p1583
S'MEIS1'
p1584
S'increases'
p1585
tp1586
(lp1587
s(S'RB1'
p1588
S'MYC'
p1589
S'increases'
p1590
tp1591
(lp1592
s(S'RXRA'
p1593
S'FOXA1'
p1594
S'increases'
p1595
tp1596
(lp1597
s(S'decitabine'
p1598
S'HRAS MRNA'
p1599
S'decreases'
p1600
tp1601
(lp1602
s(S'VSX1'
p1603
S'EN1'
p1604
S'increases'
p1605
tp1606
(lp1607
s(S'FOXL1'
p1608
S'CYP26A1'
p1609
S'increases'
p1610
tp1611
(lp1612
s(S'PAX2'
p1613
S'RUNX1'
p1614
S'increases'
p1615
tp1616
(lp1617
s(S'MEKK1/4'
p1618
S'MKK4/7'
p1619
S'adds_modification'
p1620
tp1621
(lp1622
s(S'HOXA9'
p1623
S'CYP26A1'
p1624
S'increases'
p1625
tp1626
(lp1627
s(S'TRKC'
p1628
S'NT3 (DIMER)'
p1629
S'binds'
p1630
tp1631
(lp1632
s(S'PTF1A'
p1633
S'REPIN1'
p1634
S'increases'
p1635
tp1636
(lp1637
s(S'TGIF'
p1638
S'CYP26A1'
p1639
S'increases'
p1640
tp1641
(lp1642
s(S'MYOD1'
p1643
S'MYC'
p1644
S'increases'
p1645
tp1646
(lp1647
s(S'PKCT'
p1648
S'KRAS ISO2'
p1649
S'adds_modification'
p1650
tp1651
(lp1652
s(S'RAS family/GTP'
p1653
S'BRAF'
p1654
S'increases_activity'
p1655
tp1656
(lp1657
s(S'SPZ1'
p1658
S'CYP26A1'
p1659
S'increases'
p1660
tp1661
(lp1662
s(S'HRAS/GTP'
p1663
S'GALECTIN-1'
p1664
S'binds'
p1665
tp1666
(lp1667
s(S'DBP'
p1668
S'FOXD3'
p1669
S'increases'
p1670
tp1671
(lp1672
s(S'E2F1'
p1673
S'POU2F1'
p1674
S'increases'
p1675
tp1676
(lp1677
s(S'MEIS1'
p1678
S'CYP26A1'
p1679
S'increases'
p1680
tp1681
(lp1682
s(S'YY1'
p1683
S'NRAS'
p1684
S'increases'
p1685
tp1686
(lp1687
s(S'RAS:RAF'
p1688
S'YWHAB'
p1689
S'binds'
p1690
tp1691
(lp1692
s(S'NFE2L2'
p1693
S'CYP26A1'
p1694
S'increases'
p1695
tp1696
(lp1697
s(S'FARNESYL'
p1698
S'KRAS'
p1699
S'increases_activity'
p1700
tp1701
(lp1702
s(S'MTF1'
p1703
S'MECOM'
p1704
S'increases'
p1705
tp1706
(lp1707
s(S'TLX2'
p1708
S'FOXD3'
p1709
S'increases'
p1710
tp1711
(lp1712
s(S'Insulin Receptor/Insulin/SHC/GRB2/Sos1'
p1713
S'HRAS/GDP'
p1714
S'increases_activity'
p1715
tp1716
(lp1717
s(S'MYC'
p1718
S'ELK1'
p1719
S'increases'
p1720
tp1721
(lp1722
s(S'ONECUT1'
p1723
S'POU2F1'
p1724
S'increases'
p1725
tp1726
(lp1727
s(S'Paraquat'
p1728
S'HRAS MRNA'
p1729
S'translocates'
p1730
tp1731
(lp1732
s(S'GRB2/SOS1'
p1733
S'PDGF-BB/PDGFRB (DIMER)/SHP2'
p1734
S'binds'
p1735
tp1736
(lp1737
s(S'ONECUT1'
p1738
S'CYP26A1'
p1739
S'increases'
p1740
tp1741
(lp1742
s(S'MYC'
p1743
S'FOXO3'
p1744
S'increases'
p1745
tp1746
(lp1747
s(S'PAX3'
p1748
S'ELK1'
p1749
S'increases'
p1750
tp1751
(lp1752
s(S'DOK-R'
p1753
S'RASGAP'
p1754
S'binds'
p1755
tp1756
(lp1757
s(S'HOXA4'
p1758
S'HOXA9'
p1759
S'increases'
p1760
tp1761
(lp1762
s(S'MAX'
p1763
S'POU3F2'
p1764
S'increases'
p1765
tp1766
(lp1767
s(S'Estradiol'
p1768
S'KRAS MRNA'
p1769
S'decreases'
p1770
tp1771
(lp1772
s(S'KRAS ISOFORM 4B/GTP'
p1773
S'CAM/CA2+'
p1774
S'binds'
p1775
tp1776
(lp1777
s(S'MAZ'
p1778
S'FOXO4'
p1779
S'increases'
p1780
tp1781
(lp1782
s(S'hsa-miR-181a-5p'
p1783
S'KRAS'
p1784
S'decreases'
p1785
tp1786
(lp1787
s(S'GATA1'
p1788
S'CYP26A1'
p1789
S'increases'
p1790
tp1791
(lp1792
s(S'PGR'
p1793
S'ETS1'
p1794
S'increases'
p1795
tp1796
(lp1797
s(S'GATA1'
p1798
S'POU2F1'
p1799
S'increases'
p1800
tp1801
(lp1802
s(S'BRAF'
p1803
S'MEK1-2'
p1804
S'increases_activity'
p1805
tp1806
(lp1807
s(S'LEF1'
p1808
S'GABPB2'
p1809
S'increases'
p1810
tp1811
(lp1812
s(S'CYP26A1'
p1813
S'MYC'
p1814
S'increases'
p1815
tp1816
(lp1817
s(S'STAT1'
p1818
S'IRF1'
p1819
S'increases'
p1820
tp1821
(lp1822
S'For example, similarly to the observation that unphosphorylated STAT1 could mediate LMP2 transcription in collaboration with IRF1 ['
p1823
as(S'SMAD1'
p1824
S'RUNX2'
p1825
S'increases'
p1826
tp1827
(lp1828
s(S'ZEB1'
p1829
S'TLX2'
p1830
S'increases'
p1831
tp1832
(lp1833
s(S'STAT5B'
p1834
S'IRF1'
p1835
S'increases'
p1836
tp1837
(lp1838
s(S'POU6F1'
p1839
S'CYP26A1'
p1840
S'increases'
p1841
tp1842
(lp1843
s(S'Vincristine'
p1844
S'HRAS MRNA'
p1845
S'increases'
p1846
tp1847
(lp1848
s(S'DAG'
p1849
S'RASGRP1'
p1850
S'adds_modification'
p1851
tp1852
(lp1853
S'ACP5, acid phosphatase 5, tartrate resistant; AIF1, allograft inflammatory factor 1; ASB2, ankyrin repeat and SOCS box containing 2; ASCL2, achaete-scute complex homolog 2 (Drosophila); BMP1, bone morphogenetic protein 1; CCR5, chemokine (C-C motif) receptor 5; Cd55, CD55 antigen; CDH5, cadherin 5, type 2 (vascular endothelium); CDK5R1, cyclin-dependent kinase 5, regulatory subunit 1 (p35); CITED1, Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 1; ETV5, ets variant 5; F11R, F11 receptor; F13A1, coagulation factor XIII, A1 polypeptide; FCGR3A, Fc fragment of IgG, low affinity IIIa, receptor (CD16a); FGL2, fibrinogen-like 2; FUT7, fucosyltransferase 7 (alpha (1,3) fucosyltransferase); GPR56, G protein-coupled receptor 56; HOXA1, homeobox A1; HSD11B1, hydroxysteroid (11-beta) dehydrogenase 1; ID1, inhibitor of DNA binding 1, dominant negative helix-loop-helix protein; ID3, inhibitor of DNA binding 3, dominant negative helix-loop-helix protein; IL1B, interleukin 1, beta; ITGA9, integrin, alpha 9; ITGAL, integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide); KALRN, kalirin, RhoGEF kinase; KLF2, Kruppel-like factor 2 (lung); LIFR, leukemia inhibitory factor receptor alpha; LMO1, LIM domain only 1 (rhombotin 1); LTB, lymphotoxin beta (TNF superfamily, member 3); MKL2, MKL/myocardin-like 2; NCOR1, nuclear receptor corepressor 1; NDRG1, N-myc downstream regulated 1; PECAM1, platelet/endothelial cell adhesion molecule 1; RASGRP1, RAS guanyl releasing protein 1 (calcium and DAG-regulated); Siglec5, sialic acid binding Ig-like lectin 5; SMAD6, SMAD family member 6; TCF7L2, transcription factor 7-like 2 (T-cell specific, HMG-box); TOP1, topoisomerase (DNA) I; TSPAN32, tetraspanin 32.'
p1854
as(S'PI3K'
p1855
S'PDK1'
p1856
S'increases_activity'
p1857
tp1858
(lp1859
S'While strategies aimed at attenuating the PI3K signal have been mainly focused on inhibiting the PI3K catalytic subunits, there is currently growing evidence suggesting that PDK1 itself may be a viable target.'
p1860
aS'PDK1 is integral to the PI3K/AKT pathway, as it phosphorylates the activating segment of AKT, a potent proto-oncogene involved in a variety of cellular functions such as proliferation and survival.'
p1861
aS'Emerging evidence indicates that PDK1 plays a critical role in the context of PI3K activation.'
p1862
aS'Key issues that remain to be addressed before proceeding down the long road that leads to clinical testing include the advantage of PDK1 targeting over specific PI3K inhibition, and which particular clinical settings will benefit from specific PDK1 inhibition.'
p1863
aS'Accumulating evidence suggests that PDK1 plays a specific and distinct role from the canonical PI3K/Akt pathway, and that PDK1 may specifically activate signal propagation in tumor progression, as well as in cell migration and invasion.'
p1864
aS'Expressions of MEK, PDK1, PI3K, and EGFR in the two RCC lines were evaluated using Western blotting ('
p1865
ag667
aS'Rather, Bisebromoamide would inhibit the activation of ERK and Akt, not MEK, PI3K, and PDK1.'
p1866
aS'The binding of PI3Ks and RTKs results in activation of Akt through PiP3 and PDK1, which affects multiple cellular processes including cell survival, proliferation, and motility ['
p1867
aS'Activated PI3K activates PDK1 which phosphorylates Akt, which transduces signals for cell survival, proliferation, motility, and angiogenesis as shown in '
p1868
aS'PI3K: phosphoinositide 3-kinases; PDK1: phosphoinositide-dependent kinase-1; mTOR: mammalian target of rapamycin; TSC: tuberous sclerosis complex; AMPK: AMP-dependent protein kinase; ERK: extracellular signal-regulated kinase; PKC: protein kinase C.'
p1869
aS'IR could lead to several biochemical alterations, including inflammation and oxidant stress, which leads to the dysfunction of EPCs via the following two pathways: PI3K-PDK1-Akt and RAS-MAPK-p38 pathway ['
p1870
aS'The PI3K-dependent Akt serine/threonine phosphorylation by PDK1 and mTORC2 has long been thought to be the primary mechanism accounting for Akt activation.'
p1871
aS'Results showed that this bidirectional regulation of the activity of raft-associated Akt by aPPD was not due to changes in the activity of PI3K or PDK1 in the rafts ('
p1872
aS'Having discovered that selenite treatment inhibited Src/PI3K/PDK1/AKT signaling and activated FoxO proteins, we conducted a series of experiments to investigate the relationship between AKT and FoxO3a in selenite-induced apoptosis in CRC cells.'
p1873
aS'Selenite treatment inhibited Src/PI3K/PDK1/AKT pathway and accumulation of FoxO3a in the nucleus possibly through induced ROS in CRC cells.'
p1874
aS'Targeting the PI3K-mTOR pathway causes MYC activation through PDK1-dependent MYC phosphorylation and '
p1875
aS'Molecules that maintain the survival of primordial follicles include PI3K, PDK1, mTORC1, S6K1, and rpS6.'
p1876
aS'RPTK, receptor protein tyrosine kinase; PTEN, phosphatase and tensin homolog; PIP2, phosphatidylinositol (4,5)-bisphosphate; PIP3, phosphatidylinositol (3,4,5)-triphosphate; PI3K, phosphatidylinositol 3-kinase; PDK1, 3-phosphoinositide-dependent protein kinase-1; Akt, protein kinase B; FOXO3a, forkhead box O3a; mTORC1,C2, mammalian target of rapamycin complex 1,2; TSC1/2, tuberin/tuberous sclerosis complex 1,2; S6K1, p70 ribosomal protein S6 kinase 1; rpS6, S6K1-ribosomal protein S6; p27, cyclin-dependent kinase inhibitor p27'
p1877
aS'Simplified pathway diagram showing EGFR signaling through the RAS/MEK/ERK and PI3K/PDK1/AKT pathways, illustrating the points of mutation/amplification in EGFR TKI resistance, along with other mechanisms.'
p1878
aS'SCF-receptor activation results in recruitment of PI3K to the receptor, which generates phosphorylates membrane lipids (PIP3) that form an anchor for the PH-domain containing kinases PDK1 and PKB.'
p1879
aS'PDK1-mediated activation of AKT, the key effector of class I PI3K signaling, results in modulation of distinct signaling cascades regulating cell proliferation (GSK3, FOXO), survival (BAD, MDM2) and protein synthesis/cell growth (TSC, RHEB, mTOR).'
p1880
aS'Andersen and colleagues have employed immunoaffinity precipitation followed by mass spectrometry of protein extracts from cells that were treated with inhibitors of PDK1, AKT or PI3K/mTOR ['
p1881
aS'Insulin has been shown to activate IR and stimulate PI3K/PDK1/AKT and GRB2/SOS/RAS kinase cascades, which are known to regulate mitochondrial function, as reviewed elsewhere ['
p1882
as(S'ETS2'
p1883
S'PAX4'
p1884
S'increases'
p1885
tp1886
(lp1887
s(S'NR3C1'
p1888
S'ONECUT1'
p1889
S'increases'
p1890
tp1891
(lp1892
s(S'CUX1'
p1893
S'CYP26A1'
p1894
S'increases'
p1895
tp1896
(lp1897
s(S'ZEB1'
p1898
S'GATA1'
p1899
S'increases'
p1900
tp1901
(lp1902
s(S'NRF1'
p1903
S'POU2F1'
p1904
S'increases'
p1905
tp1906
(lp1907
s(S'FOXJ2'
p1908
S'MECOM'
p1909
S'increases'
p1910
tp1911
(lp1912
s(S'MAZ'
p1913
S'MYCN'
p1914
S'increases'
p1915
tp1916
(lp1917
s(S'Hydrogen Peroxide'
p1918
S'HRAS MRNA'
p1919
S'increases'
p1920
tp1921
(lp1922
s(S'RASA1'
p1923
S'P-EPHBS:EFNBS'
p1924
S'binds'
p1925
tp1926
(lp1927
s(S'SPI1'
p1928
S'CEBPG'
p1929
S'increases'
p1930
tp1931
(lp1932
s(S'EGR1'
p1933
S'LEF1'
p1934
S'increases'
p1935
tp1936
(lp1937
s(S'RET51/GFRALPHA1/GDNF'
p1938
S'P62DOK'
p1939
S'binds'
p1940
tp1941
(lp1942
s(S'TFDP2'
p1943
S'CYP26A1'
p1944
S'increases'
p1945
tp1946
(lp1947
s(S'matrine'
p1948
S'NRAS MRNA'
p1949
S'increases'
p1950
tp1951
(lp1952
s(S'Isotretinoin'
p1953
S'KRAS MRNA'
p1954
S'decreases'
p1955
tp1956
(lp1957
s(S'PITX2'
p1958
S'FOXF2'
p1959
S'increases'
p1960
tp1961
(lp1962
s(S'MYOD1'
p1963
S'POU2F1'
p1964
S'increases'
p1965
tp1966
(lp1967
s(S'sodium arsenite'
p1968
S'KRAS PROTEIN'
p1969
S'increases'
p1970
tp1971
(lp1972
s(S'TCF4'
p1973
S'CBFA2T3'
p1974
S'increases'
p1975
tp1976
(lp1977
s(S'CYP26A1'
p1978
S'FOXA1'
p1979
S'increases'
p1980
tp1981
(lp1982
s(S'TP53'
p1983
S'CYP26A1'
p1984
S'increases'
p1985
tp1986
(lp1987
s(S'ATF3'
p1988
S'FOXD3'
p1989
S'increases'
p1990
tp1991
(lp1992
s(S'POU2F1'
p1993
S'NRAS'
p1994
S'increases'
p1995
tp1996
(lp1997
s(S'NRF1'
p1998
S'GABPB2'
p1999
S'increases'
p2000
tp2001
(lp2002
s(S'PAX4'
p2003
S'TLX2'
p2004
S'increases'
p2005
tp2006
(lp2007
s(S'PITX2'
p2008
S'FOXA1'
p2009
S'increases'
p2010
tp2011
(lp2012
s(S'GTF3A'
p2013
S'POU2F1'
p2014
S'increases'
p2015
tp2016
(lp2017
s(S'HLF'
p2018
S'FOXO3'
p2019
S'increases'
p2020
tp2021
(lp2022
s(S'PAX4'
p2023
S'FOXO4'
p2024
S'increases'
p2025
tp2026
(lp2027
s(S'CEBPA'
p2028
S'FOXD3'
p2029
S'increases'
p2030
tp2031
(lp2032
s(S'NFE2'
p2033
S'CYP26A1'
p2034
S'increases'
p2035
tp2036
(lp2037
s(S'MYB'
p2038
S'GABPB2'
p2039
S'increases'
p2040
tp2041
(lp2042
s(S'MYC'
p2043
S'CEBPA'
p2044
S'increases'
p2045
tp2046
(lp2047
s(S'ELK1'
p2048
S'EN1'
p2049
S'increases'
p2050
tp2051
(lp2052
s(S'E2F1'
p2053
S'CDC5L'
p2054
S'increases'
p2055
tp2056
(lp2057
s(S'YWHAZ (DIMER)'
p2058
S'RAF1'
p2059
S'binds'
p2060
tp2061
(lp2062
s(S'ATF6'
p2063
S'CYP26A1'
p2064
S'increases'
p2065
tp2066
(lp2067
s(S'sodium arsenite'
p2068
S'HRAS MRNA'
p2069
S'increases'
p2070
tp2071
(lp2072
s(S'EGR3'
p2073
S'CYP26A1'
p2074
S'increases'
p2075
tp2076
(lp2077
s(S'lead acetate'
p2078
S'HRAS PROTEIN'
p2079
S'increases_activity'
p2080
tp2081
(lp2082
s(S'REPIN1'
p2083
S'MYC'
p2084
S'increases'
p2085
tp2086
(lp2087
s(S'CEBPA'
p2088
S'NRAS'
p2089
S'increases'
p2090
tp2091
(lp2092
s(S'Quercetin'
p2093
S'NRAS MRNA'
p2094
S'decreases'
p2095
tp2096
(lp2097
s(S'14-3-3 E'
p2098
S'TERT'
p2099
S'binds'
p2100
tp2101
(lp2102
s(S'Antigen/IgE/Fc epsilon R1/LYN/SYK'
p2103
S'BTK'
p2104
S'adds_modification'
p2105
tp2106
(lp2107
s(S'HSF2'
p2108
S'CBFA2T3'
p2109
S'increases'
p2110
tp2111
(lp2112
s(S'Fluorouracil'
p2113
S'HRAS MRNA'
p2114
S'increases'
p2115
tp2116
(lp2117
s(S'STAT4'
p2118
S'MECOM'
p2119
S'increases'
p2120
tp2121
(lp2122
s(S'ETS2'
p2123
S'ETS1'
p2124
S'increases'
p2125
tp2126
(lp2127
S'We compared the reliability and validity of two four-level emergency triage systems: the ETS1, used in our emergency department (ED); and the ETS2, a triage algorithm derived from the Emergency Severity Index ['
p2128
aS'Ten trained triage nurses were randomly assigned either to training in ETS2, or to refresh the ETS1.'
p2129
aS'A complete disagreement in UC was found in 3% and 5% cases of ETS1 and ETS2; a complete agreement in 52% and 56% cases of ETS1 and ETS2.'
p2130
aS'Hospital admission by ETS1 and ETS2 was similar for UC2 (39% vs 37%), UC3 (5% vs 8%), and UC4 (3% vs 0%); 100% of patients with UC1 in ETS1 and 60% in ETS2 were admitted to the ICU.'
p2131
as(S'CEBPG'
p2132
S'CYP26A1'
p2133
S'increases'
p2134
tp2135
(lp2136
s(S'Complex (PDGF receptor A/PDGF receptor B)'
p2137
S'NCK'
p2138
S'adds_modification'
p2139
tp2140
(lp2141
s(S'Fog1'
p2142
S'MYB'
p2143
S'decreases'
p2144
tp2145
(lp2146
s(S'CREB1'
p2147
S'FOXD3'
p2148
S'increases'
p2149
tp2150
(lp2151
s(S'Numb'
p2152
S'NICS'
p2153
S'translocates'
p2154
tp2155
(lp2156
s(S'STAT6'
p2157
S'STAT5A'
p2158
S'increases'
p2159
tp2160
(lp2161
s(S'RAF1/14-3-3'
p2162
S'BRAF/14-3-3'
p2163
S'binds'
p2164
tp2165
(lp2166
s(S'B-cell antigen/BCR complex/LYN/SYK/BLNK'
p2167
S'SHC/GRB2/SOS1'
p2168
S'increases_activity'
p2169
tp2170
(lp2171
s(S'IRF2'
p2172
S'CYP26A1'
p2173
S'increases'
p2174
tp2175
(lp2176
s(S'GATA6'
p2177
S'CYP26A1'
p2178
S'increases'
p2179
tp2180
(lp2181
s(S'HMGA1'
p2182
S'CYP26A1'
p2183
S'increases'
p2184
tp2185
(lp2186
s(S'MTF1'
p2187
S'FOXO4'
p2188
S'increases'
p2189
tp2190
(lp2191
s(S'STAT1'
p2192
S'GABPB2'
p2193
S'increases'
p2194
tp2195
(lp2196
s(S'manumycin'
p2197
S'HRAS PROTEIN'
p2198
S'decreases'
p2199
tp2200
(lp2201
s(S'STAT5A'
p2202
S'ETS1'
p2203
S'increases'
p2204
tp2205
(lp2206
s(S'SPI1'
p2207
S'CBFA2T3'
p2208
S'increases'
p2209
tp2210
(lp2211
s(S'GMCSF/GMR ALPHA/CSF2RB/JAK2 (DODECAMER)/SHC'
p2212
S'GRB2/SOS1'
p2213
S'binds'
p2214
tp2215
(lp2216
s(S'7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide'
p2217
S'NRAS PROTEIN'
p2218
S'increases'
p2219
tp2220
(lp2221
s(S'CDC5L'
p2222
S'CYP26A1'
p2223
S'increases'
p2224
tp2225
(lp2226
s(S'PAX4'
p2227
S'POU3F2'
p2228
S'increases'
p2229
tp2230
(lp2231
s(S'SPRED2'
p2232
S'HRAS'
p2233
S'binds'
p2234
tp2235
(lp2236
s(S'PITX2'
p2237
S'FOXO4'
p2238
S'increases'
p2239
tp2240
(lp2241
s(S'FOXD3'
p2242
S'CYP26A1'
p2243
S'increases'
p2244
tp2245
(lp2246
s(S'NFIL3'
p2247
S'FOXO3'
p2248
S'increases'
p2249
tp2250
(lp2251
s(S'MTF1'
p2252
S'POU2F1'
p2253
S'increases'
p2254
tp2255
(lp2256
s(S'TFCP2'
p2257
S'BACH1'
p2258
S'increases'
p2259
tp2260
(lp2261
s(S'NF1'
p2262
S'MECOM'
p2263
S'increases'
p2264
tp2265
(lp2266
s(S'FOXO3'
p2267
S'FOXD3'
p2268
S'increases'
p2269
tp2270
(lp2271
s(S'STAT5A'
p2272
S'TLX2'
p2273
S'increases'
p2274
tp2275
(lp2276
s(S'RIN1'
p2277
S'HRAS/GTP'
p2278
S'adds_modification'
p2279
tp2280
(lp2281
s(S'STAT5A'
p2282
S'CEBPG'
p2283
S'increases'
p2284
tp2285
(lp2286
s(S'DAG'
p2287
S'PKC'
p2288
S'increases_activity'
p2289
tp2290
(lp2291
S'In a previous study we identified the pro-apoptotic genes PAWR (PKC apoptosis WT1 regulator; also named PAR-4, prostate apoptosis response-4) and PHLDA1 (pleckstrin homology-like domain, family A, member 1; also named TDAG51) as differentially expressed in breast tumors.'
p2292
aS'Protein kinase C (PKC) was originally discovered by Yasutomi Nishizuka in 1977 as a histone protein kinase activated by calcium and diacylglycerol (DAG), phospholipids and/or phorbol esters ['
p2293
aS'DAG is rapidly metabolized and thus activates PKC only transiently, while TPA persists much longer and results in prolonged activation of PKC ['
p2294
aS'The PKC activator DAG is also induces ROS in the skin, suggesting PKC may be necessary for TPA induction of oxidative stress ['
p2295
aS'High ambient glucose concentrations activate PKC by increasing the formation of diacylglycerol (DAG), the major endogenous cellular co-factor for PKC activation, from glycolytic intermediates such as dihydroxy-acetone phosphate and glyceraldehyde-3-phosphate.'
p2296
aS'The elevation of DAG and subsequent activation of PKC in the vasculature can be maintained chronically ['
p2297
aS'Oxidative stress may also be involved in the activation of DAG-PKC in vascular tissue ['
p2298
aS'Activation of the diacylglycerol (DAG)-protein kinase C (PKC) pathway has been implicated in the pathogenesis of a number of diabetic complications.'
p2299
aS'Diacylglycerol kinase (DGK) converts DAG to phosphatidic acid and acts as an endogenous regulator of PKC activity.'
p2300
aS'One of the best known functional roles of DGK is to regulate PKC activity through DAG metabolism ['
p2301
ag1522
aS'Protein kinase D (PKD) constitutes a novel family of diacylglycerol (DAG)-responsive serine/threonine protein kinases with different structural, enzymological and regulatory properties from the protein kinase C (PKC) family members ['
p2302
aS'PKC binds DAG and PS via its N-terminal C1 domain.'
p2303
aS'The members of the canonical TRP receptor subfamily, TRPC3, TRPC6, and TRPC7, are activated by the permeant diacyl glycerol (DAG) analogue, 1-oleoyl-2-acetyl-sn-glycerol (OAG) and this activation is reversed by the PKC activator 12-myristate 13-acetate (PMA) ['
p2304
aS'2-AG (2-arachidonoylglycerol), AA (arachidonic acid), AEA (anandamide), CB1 (cannabinoid receptor type I), CB2 (cannabinoid receptor type I), DAG (diacylglycerol), FAAH (fatty acid amide hydrolase), GPCR (G protein-coupled receptor), HpETEs (hydroperoxyeicosatetraenoic acids), LO (lipoxygenase), NADA (N-arachidonoyl dopamine), NAPE (N-acylphosphatidylethanolamine), NAPE-PLD (NAPE-specific phospholipase D), PIP2 (phosphatidylinositol 4,5-bisphosphate), PKC (protein kinase C), PLA2 (phospholipase A2), PLC (phospholipase C).'
p2305
aS'DAG: diacylglicerol; fMLP: N-formyl-L-methionyl-L-leucyl-L-phenylalanine; GRK: G-coupled receptor kinase; HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; HMC-1: human mast cell line-1; LAMP-3: lysosome associated membrane protein-3; MFI: Mean of fluorescence intensity; PI3K: phosphoinositide-3 kinase; PKC: protein kinase C; PLC: phospholypase C; PMA: phorbol-12-myristate-13-acetate; p38MAPK: p38-mitogen activated protein kinase; PtdIns3,4,5-P'
p2306
aS'Experimental studies have shown that protein kinase C (PKC) activity and levels of diacylglycerol (DAG), an activator of PKC, are increased following exposure of vascular tissues to elevated glucose ('
p2307
aS'At the same time, DAG activates novel Protein Kinase Cs (nPKCs) the main upstream activators of PKD.'
p2308
aS'DAG, diacylglycerol; ERK, extracellular signal regulated kinase; GRB, growth factor receptor binding protein; MAPK, mitogen-activated protein kinase; MEK, mitogen-activated protein kinase kinase; PAMP, pathogen-associated molecular pattern; PI3K, phosphatidylinositol 3-kinase; PKC, protein kinase C; PLC, phospholipase C; SOS, son of sevenless; TLR, Toll-like receptor; TREM, triggering receptor expressed on myeloid cells; TREM-1L, TREM-1 ligand.'
p2309
aS'ACTH = adrenocorticotropic hormone; DAG = diacylglycerol; DDAVP = 1-deamino-8-D-arginine vasopressin; GPCR = G-protein-coupled receptor; GRK = G protein-coupled receptor kinase; OTR = oxytocin receptor; PKC = protein kinase C; P'
p2310
aS'AC, adenylyl cyclase; AR, adrenoceptor; DAG, diacylglycerol; IP3, inositol-tris-phosphate; MLC, myosin light chain; PKA, protein kinase A; PKC, protein kinase C; PLC, phospholipase C; PLD, phospholipase D; SR, sarcoplasmic reticulum.'
p2311
as(S'HNF4A'
p2312
S'FOXA1'
p2313
S'increases'
p2314
tp2315
(lp2316
S'We determined the genome-wide binding in livers of five mouse species and rat for CEBPA, HNF4A, and FOXA1 by performing chromatin immunoprecipitation (ChIP) experiments coupled to high-throughput sequencing in biological duplicates ('
p2317
aS'We first assessed how rapidly TF binding differences accumulate among these five mouse genomes by determining the proportion of HNF4A, CEBPA, and FOXA1 TFBRs that reciprocally overlap between species in a qualitative manner; that is, how often TF binding in one species was evaluated as not identified in the homologous position in a second mouse species when comparing present-absent binding calls.'
p2318
aS'Because few differences in TF binding between mouse species could be connected to specific SNVs in the motif, we explored whether the extent of combinatorial binding among CEBPA, FOXA1, and HNF4A could help to explain these differences.'
p2319
aS'We then categorized the remaining regions with overlapping binding of HNF4A, CEBPA, and/or FOXA1 as clusters of TF cobinding.'
p2320
aS'To elucidate the first steps of TF binding evolution and the underlying mechanisms in mammals, we characterized the binding profiles of three tissue-specific TFs, CEBPA, HNF4A, and FOXA1, in livers from six inbred rodents.'
p2321
aS'(A) Livers from a genetically engineered CEBPA KO mice were obtained, and ChIP experiments were performed against HNF4A and FOXA1 to evaluate the impact of CEBPA deletion on cobound TFs located in clusters ([HNF4A (H, blue), FOXA1 (F, green), and CEBPA (C, red)] and CTCF [a noninteracting partner, as a control]).'
p2322
aS'(B) The effect of knocking out CEBPA and HNF4A was evaluated for the following cluster classes: 2TF clusters containing HNF4A and FOXA1 (HF), CEBPA and FOXA1 (CF), and CEBPA and HNF4A (CH) and finally, all three TFs (CHF).'
p2323
aS'(A) ChIP followed by high-throughput sequencing (ChIP-seq) of CEBPA, HNF4A and FOXA1 in C57BL/6J, A/J, CAST/EiJ, SPRET/EiJ, and Caroli/EiJ mice showing their phylogenetic relationship and H&E stained livers for each species.'
p2324
aS'(C) Summary table of genomic background (Input) and ChIP-seq data sets for CEBPA, HNF4A and FOXA1 duplicate in C57BL/6J, A/J, CAST/EiJ, SPRET/EiJ, and Caroli/EiJ, and rat included in the subsequent analysis.'
p2325
aS'(F) The correspondence of TFBR intensities between individuals is shown quantitatively by correlating two Inter-pools, each containing two biological replicates of SPRET/EiJ (for CEBPA, HNF4A) or C57BL/6J (for FOXA1), showing high correlation coefficients when we consider all TF binding regions (R'
p2326
aS'(D) For CEBPA, FOXA1, and HNF4A, TF binding sites that had a SNV in the directly bound motif were collected.'
p2327
aS'(E) The difference in TF binding intensity is correlated with the change in information content of the TF binding motif of CEBPA, HNF4A and FOXA1.'
p2328
aS'Within singletons, the proportion of free-standing CEBPA, HNF4A, and FOXA1 is shown by color as an inset (right side of each white bar).'
p2329
aS'Within the 2TF clusters (multicolored, right outset is the total numbers of TFBR), the 2TF clusters containing FOXA1 and HNF4A (F+H, blue) are more often found than the combinations of the other two TFs (F+C, yellow; C+H, purple).'
p2330
aS'(B) The distribution of binding intensities for each TF category in C57BL/6J are shown, color-coded (blue is HNF4A, green is FOXA1, red is CEBPA).'
p2331
aS'We tested if these regions are more likely to be lost in CEBPA KO mouse liver, when compared to control regions where cluster disappearance is associated with changes in the HNF4A motif (1,882) or the FOXA1 (1,390) motif.'
p2332
aS'We tested if these regions are more likely to be lost in HNF4A KO mouse liver, when compared to control regions where cluster disappearance can be linked to changes in the CEBPA (1,173) motif or the FOXA1 (1,390) motif.'
p2333
as(S'LEF1'
p2334
S'MAZ'
p2335
S'increases'
p2336
tp2337
(lp2338
s(S'hsa-miR-124-3p'
p2339
S'NRAS'
p2340
S'decreases'
p2341
tp2342
(lp2343
s(S'RAF1'
p2344
S'14-3-3 E'
p2345
S'binds'
p2346
tp2347
(lp2348
s(S'GATA1'
p2349
S'MYB'
p2350
S'decreases'
p2351
tp2352
(lp2353
s(S'LMO2'
p2354
S'GATA1'
p2355
S'increases'
p2356
tp2357
(lp2358
S'Notably, none of the examined tissue-specific GATA1 co-factors (FOG1, SCL/TAL1, Ldb1 and LMO2) were found on mitotic chromosomes, regardless of whether GATA1 was retained at these sites.'
p2359
aS'In erythroid cells, LMO2 associates with corepressors mSIN3A and ETO2 only when in a complex with SCL:E47; therefore, not through GATA1.'
p2360
aS'The hinge movement is differentially required for the LMO2 interactions with SCL:E47 and GATA1 or for its SCL-independent interaction with P300/PCAF and LSD1.'
p2361
aS'Building a Network of Interactions between SCL:E47:LMO2:LDB1 and GATA1, Corepressors, Coactivators, and Chromatin-Remodeling Proteins'
p2362
as(S'HRAS/GTP'
p2363
S'RAF1'
p2364
S'increases_activity'
p2365
tp2366
(lp2367
s(S'MYCN'
p2368
S'RUNX2'
p2369
S'increases'
p2370
tp2371
(lp2372
s(S'STAT5B'
p2373
S'CYP26A1'
p2374
S'increases'
p2375
tp2376
(lp2377
s(S'ZIC2'
p2378
S'MYCN'
p2379
S'increases'
p2380
tp2381
(lp2382
s(S'FOXL1'
p2383
S'FOXD3'
p2384
S'increases'
p2385
tp2386
(lp2387
s(S'ZBTB18'
p2388
S'CBFA2T3'
p2389
S'increases'
p2390
tp2391
(lp2392
s(S'HSF1'
p2393
S'IRF1'
p2394
S'increases'
p2395
tp2396
(lp2397
s(S'SPZ1'
p2398
S'MAZ'
p2399
S'increases'
p2400
tp2401
(lp2402
s(S'SRY'
p2403
S'CYP26A1'
p2404
S'increases'
p2405
tp2406
(lp2407
s(S'FOXO4'
p2408
S'HOXA9'
p2409
S'increases'
p2410
tp2411
(lp2412
s(S'IGF-1R heterotetramer/IGF1/IRS1/GRB2/Sos'
p2413
S'HRAS/GDP'
p2414
S'increases_activity'
p2415
tp2416
(lp2417
s(S'hsa-miR-615-3p'
p2418
S'HRAS'
p2419
S'decreases'
p2420
tp2421
(lp2422
s(S'ESRRA'
p2423
S'FOXD3'
p2424
S'increases'
p2425
tp2426
(lp2427
s(S'ELK1'
p2428
S'CYP26A1'
p2429
S'increases'
p2430
tp2431
(lp2432
s(S'Hexane-1,6-Diol'
p2433
S'HRAS'
p2434
S'increases_activity'
p2435
tp2436
(lp2437
s(S'MAZ'
p2438
S'NRAS'
p2439
S'increases'
p2440
tp2441
(lp2442
s(S'MIF'
p2443
S'CYP26A1'
p2444
S'increases'
p2445
tp2446
(lp2447
s(S'AHR'
p2448
S'POU2F1'
p2449
S'increases'
p2450
tp2451
(lp2452
s(S'SMAD3'
p2453
S'CYP26A1'
p2454
S'increases'
p2455
tp2456
(lp2457
s(S'PI-3-4-5-P3'
p2458
S'GELSOLIN'
p2459
S'binds'
p2460
tp2461
(lp2462
s(S'ADP'
p2463
S'P-S724-IRE1 DIMER'
p2464
S'binds'
p2465
tp2466
(lp2467
s(S'testosterone enanthate'
p2468
S'KRAS MRNA'
p2469
S'increases'
p2470
tp2471
(lp2472
s(S'CYP26A1'
p2473
S'ONECUT1'
p2474
S'increases'
p2475
tp2476
(lp2477
s(S'Valproic Acid'
p2478
S'NRAS MRNA'
p2479
S'decreases'
p2480
tp2481
(lp2482
s(S'GTF2A2'
p2483
S'CYP26A1'
p2484
S'increases'
p2485
tp2486
(lp2487
s(S'CEBPA'
p2488
S'FOXO3'
p2489
S'increases'
p2490
tp2491
(lp2492
s(S'GATA3'
p2493
S'POU2F1'
p2494
S'increases'
p2495
tp2496
(lp2497
s(S'PI3K'
p2498
S'RAC1B/GDP'
p2499
S'increases_activity'
p2500
tp2501
(lp2502
s(S'CDC25C'
p2503
S'YWHAB'
p2504
S'binds'
p2505
tp2506
(lp2507
s(S'RAC1/GTP'
p2508
S'PAK1/BETAPIX/PKL/NCK1-2'
p2509
S'increases_activity'
p2510
tp2511
(lp2512
s(S'SMAD1'
p2513
S'CYP26A1'
p2514
S'increases'
p2515
tp2516
(lp2517
s(S'PI3K'
p2518
S'FAK'
p2519
S'adds_modification'
p2520
tp2521
(lp2522
S'Integrins appear to activate a focal adhesion kinase (FAK)/ phosphoinositide 3-kinase (PI3K)/AKT pathway ['
p2523
aS'The clustering of activated integrins triggers signaling cascades involving FAK, Src, PI3K, RhoA, Rho kinase (ROCK), and myosin regulatory light chain (MLCK) phosphorylation, culminating in actinomyosin-mediated cell contractility, which transmits forces that alter the ECM.'
p2524
aS'Recent data in murine macrophages demonstrated a CD11b/CD18-dependent expression of pro-inflammatory cytokines via activation of FAK/PI3K/Akt/NF-kappaB signaling pathways ['
p2525
aS'CTGF was previously reported to block FAK/PI3K/AKT or miR-504/FOXP1 signaling suppressing cell motility and invasion in oral squamous cell carcinoma.'
p2526
aS'To determine if targeting the signaling cascades in the regulation of the actin cytoskeleton pathway would overcome resistance to HDACi, inhibitors to the MAPK, FAK and PI3K pathways were evaluated in combination with LBH589 against HMCL, OCI-MY1, RPMI-8266, OPM2 and U266.'
p2527
aS'It should also be noted that within the two HDACi-resistant HMCL, although both cell lines were sensitive to HDACi and MEKi combination, OPM2 was more sensitive to HDACi and FAKi and PI3K combinations.'
p2528
aS'The formation of podosomes on fluid surfaces is mediated by local activation of phosphoinositide 3-kinase (PI3K) and the production of phosphatidylinositol-(3,4,5)-triphosphate (PIP3) in a FAK/PYK2-dependent manner.'
p2529
aS'FAK activates the important PI3K/Akt survival pathway.'
p2530
aS'Metastatic tumour cells evade anoikis by intrinsically activated survival pathways via for example PI3K or Akt signalling, independent of extrinsic Integrin and FAK signalling ['
p2531
as(S'NRF1'
p2532
S'MAX'
p2533
S'increases'
p2534
tp2535
(lp2536
s(S'FOXI1'
p2537
S'RUNX2'
p2538
S'increases'
p2539
tp2540
(lp2541
s(S'7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide'
p2542
S'HRAS MRNA'
p2543
S'increases'
p2544
tp2545
(lp2546
s(S'ETS1'
p2547
S'CBFA2T3'
p2548
S'increases'
p2549
tp2550
(lp2551
s(S'hsa-miR-98-5p'
p2552
S'NRAS'
p2553
S'decreases'
p2554
tp2555
(lp2556
s(S'PHOSPHORYLATED BRF1 (SER92, SER203):MRNA COMPLEX'
p2557
S'YWHAB'
p2558
S'binds'
p2559
tp2560
(lp2561
s(S'LMO2'
p2562
S'CYP26A1'
p2563
S'increases'
p2564
tp2565
(lp2566
s(S'SOS1'
p2567
S'GRB2:PFAK BOUND TO NCAM1:PFYN'
p2568
S'binds'
p2569
tp2570
(lp2571
s(S'GTF3A'
p2572
S'GATA6'
p2573
S'increases'
p2574
tp2575
(lp2576
s(S'ZIC2'
p2577
S'CYP26A1'
p2578
S'increases'
p2579
tp2580
(lp2581
s(S'PAX2'
p2582
S'POU3F2'
p2583
S'increases'
p2584
tp2585
(lp2586
s(S'CEBPD'
p2587
S'FOXO3'
p2588
S'increases'
p2589
tp2590
(lp2591
s(S'NF1'
p2592
S'CYP26A1'
p2593
S'increases'
p2594
tp2595
(lp2596
s(S'BRAF'
p2597
S'MEK2'
p2598
S'adds_modification'
p2599
tp2600
(lp2601
g1310
ag1311
as(S'TFAP4'
p2602
S'RUNX1'
p2603
S'increases'
p2604
tp2605
(lp2606
s(S'FAK'
p2607
S'SOS'
p2608
S'binds'
p2609
tp2610
(lp2611
S'This takes place either through activation of Ras, recruiting the adaptor protein Grb2 and the Ras guanine nucleotide exchange factor SOS to phospho-FAK at the plasma membrane, or through Src-dependent phosphorylation of p130Cas.'
p2612
as(S'EGR1'
p2613
S'RUNX1'
p2614
S'increases'
p2615
tp2616
(lp2617
s(S'TCF4'
p2618
S'FOXO4'
p2619
S'increases'
p2620
tp2621
(lp2622
s(S'MAZ'
p2623
S'CBFA2T3'
p2624
S'increases'
p2625
tp2626
(lp2627
s(S'MEIS1'
p2628
S'HRAS'
p2629
S'increases'
p2630
tp2631
(lp2632
s(S'RELA'
p2633
S'CYP26A1'
p2634
S'increases'
p2635
tp2636
(lp2637
s(S'hsa-miR-877-3p'
p2638
S'NRAS'
p2639
S'decreases'
p2640
tp2641
(lp2642
s(S'MYC'
p2643
S'LEF1'
p2644
S'increases'
p2645
tp2646
(lp2647
S'Application of the framework to study the differences between gastrointestinal stromal tumor (GIST) and leiomyosarcoma (LMS) resulted in the identification of nine transcription factors (SRF, NKX2-5, CCDC6, LEF1, VDR, ZNF250, TRIM63, MAF, and MYC).'
p2648
as(S'FOXO4'
p2649
S'RUNX1'
p2650
S'increases'
p2651
tp2652
(lp2653
s(S'LEF1'
p2654
S'RUNX1'
p2655
S'increases'
p2656
tp2657
(lp2658
s(S'TFDP2'
p2659
S'GATA1'
p2660
S'increases'
p2661
tp2662
(lp2663
s(S'AHR'
p2664
S'CYP26A1'
p2665
S'increases'
p2666
tp2667
(lp2668
s(S'4-Nitroquinoline-1-oxide'
p2669
S'PTGS2 MRNA'
p2670
S'increases'
p2671
tp2672
(lp2673
s(S'TGIF'
p2674
S'FOXO3'
p2675
S'increases'
p2676
tp2677
(lp2678
s(S'FOXF2'
p2679
S'CEBPA'
p2680
S'increases'
p2681
tp2682
(lp2683
s(S'NFE2L1'
p2684
S'POU2F1'
p2685
S'increases'
p2686
tp2687
(lp2688
s(S'LHX3'
p2689
S'CYP26A1'
p2690
S'increases'
p2691
tp2692
(lp2693
s(S'HMGA1'
p2694
S'MEIS1'
p2695
S'increases'
p2696
tp2697
(lp2698
s(S'POU2F1'
p2699
S'CYP26A1'
p2700
S'increases'
p2701
tp2702
(lp2703
s(S'PRRX2'
p2704
S'HOXA9'
p2705
S'increases'
p2706
tp2707
(lp2708
s(S'ETS2'
p2709
S'CEBPG'
p2710
S'increases'
p2711
tp2712
(lp2713
s(S'hsa-miR-193b-3p'
p2714
S'KRAS'
p2715
S'decreases'
p2716
tp2717
(lp2718
s(S'RREB1'
p2719
S'RUNX1'
p2720
S'increases'
p2721
tp2722
(lp2723
s(S'IL2/IL2R BETA/GAMMA/JAK1/FYN/JAK3'
p2724
S'PI3K'
p2725
S'binds'
p2726
tp2727
(lp2728
s(S'ELK1'
p2729
S'MEIS1'
p2730
S'increases'
p2731
tp2732
(lp2733
s(S'CYP26A1'
p2734
S'HOXA9'
p2735
S'increases'
p2736
tp2737
(lp2738
s(S'SPZ1'
p2739
S'HOXA9'
p2740
S'increases'
p2741
tp2742
(lp2743
s(S'ERK1'
p2744
S'P-S218,222-MEK1'
p2745
S'binds'
p2746
tp2747
(lp2748
s(S'NHLH1'
p2749
S'MYC'
p2750
S'increases'
p2751
tp2752
(lp2753
s(S'Daunorubicin'
p2754
S'NRAS MRNA'
p2755
S'increases'
p2756
tp2757
(lp2758
s(S'HNF1A'
p2759
S'FOXA1'
p2760
S'increases'
p2761
tp2762
(lp2763
s(S'MYC'
p2764
S'ONECUT1'
p2765
S'increases'
p2766
tp2767
(lp2768
s(S'Vanadates'
p2769
S'HRAS PROTEIN'
p2770
S'increases'
p2771
tp2772
(lp2773
s(S'Purine nucleotide'
p2774
S'H+'
p2775
S'translocates'
p2776
tp2777
(lp2778
s(S'NFE2'
p2779
S'BACH1'
p2780
S'increases'
p2781
tp2782
(lp2783
s(S'EGR4'
p2784
S'CYP26A1'
p2785
S'increases'
p2786
tp2787
(lp2788
s(S'NRF1'
p2789
S'ONECUT1'
p2790
S'increases'
p2791
tp2792
(lp2793
s(S'GFI1'
p2794
S'HOXA9'
p2795
S'increases'
p2796
tp2797
(lp2798
s(S'NR1H4'
p2799
S'FOXD3'
p2800
S'increases'
p2801
tp2802
(lp2803
s(S'STAT6'
p2804
S'FOXA1'
p2805
S'increases'
p2806
tp2807
(lp2808
s(S'INSULIN RECEPTOR/INSULI/IRS1/GRB2/SHC'
p2809
S'SOS1'
p2810
S'binds'
p2811
tp2812
(lp2813
s(S'Tetrachlorodibenzodioxin'
p2814
S'KRAS MRNA'
p2815
S'increases'
p2816
tp2817
(lp2818
s(S'TCF3'
p2819
S'MYC'
p2820
S'increases'
p2821
tp2822
(lp2823
s(S'BACH1'
p2824
S'EN1'
p2825
S'increases'
p2826
tp2827
(lp2828
s(S'RFX1'
p2829
S'CYP26A1'
p2830
S'increases'
p2831
tp2832
(lp2833
s(S'ZEB1'
p2834
S'FOXD3'
p2835
S'increases'
p2836
tp2837
(lp2838
s(S'IRF7'
p2839
S'EN1'
p2840
S'increases'
p2841
tp2842
(lp2843
s(S'GAB2/GRB2/SOS1'
p2844
S'IL2/IL2R ALPHA/BETA/GAMMA/JAK1/LCK/JAK3/SHC'
p2845
S'binds'
p2846
tp2847
(lp2848
s(S'GATA3'
p2849
S'FOXA1'
p2850
S'increases'
p2851
tp2852
(lp2853
S'Because no significant difference in FOXA1 and GATA3 mRNA expression was observed in the ER-positive group, we decided to explore a more specific breast cancer subtype.'
p2854
aS'FOXA1 and GATA3 proteins are expressed in ER-positive luminal breast cancers (Sorlie et al. '
p2855
aS'In breast carcinoma cell lines, the complex created by FOXA1, GATA3, and ER regulates estrogen ('
p2856
as(S'TFAP4'
p2857
S'CYP26A1'
p2858
S'increases'
p2859
tp2860
(lp2861
s(S'FOXF2'
p2862
S'MECOM'
p2863
S'increases'
p2864
tp2865
(lp2866
s(S'NF1'
p2867
S'POU2F1'
p2868
S'increases'
p2869
tp2870
(lp2871
s(S'IRF1'
p2872
S'FOXA1'
p2873
S'increases'
p2874
tp2875
(lp2876
s(S'Rho Family GTPase-active'
p2877
S'PIP5K1A'
p2878
S'increases_activity'
p2879
tp2880
(lp2881
s(S'POU6F1'
p2882
S'EN1'
p2883
S'increases'
p2884
tp2885
(lp2886
s(S'TCF4'
p2887
S'LEF1'
p2888
S'increases'
p2889
tp2890
(lp2891
S'(D) miR-135b expression following silencing of TCF4 and LEF1 transcription in '
p2892
aS'Furthermore, LEF1 as well as TCF1 and TCF4 repressed Runx2 activity on the osteocalcin promoter ['
p2893
aS'Samples with nuclear LEF1 as well as high TCF4 (++++) expression were associated with a shorter survival ('
p2894
aS'Recent in vivo experiments in a xenograft brain lung metastasis model postulated a functional role for lymphoid enhancer factor 1/T cell factor 4 (LEF1/TCF4) in a subgroup of adenocarcinomas ['
p2895
aS'Genes were assigned to the LEF1/TCF4 or AXIN2 gene list according to their mean negative and positive correlations ('
p2896
aS'Two groups of patients were defined by clustering the gene expression profiles of the LEF1/TCF4 gene signature with significantly different survival ('
p2897
aS'Pathway analyses of the two LEF1/TCF4 clusters in primary lung adenocarcinomas'
p2898
aS'An essential function of the transcription factors LEF1/TCF4 in cerebral metastases of lung adenocarcinomas has been described in mouse models ['
p2899
aS'First of all, our data strongly support a role of LEF1/TCF4 in at least one subgroup of cerebrally metastasized adenocarcinoma patients.'
p2900
aS'This subgroup is characterized by a poor prognosis, in particular regarding both nuclear LEF1 and high TCF4 positive (4+) patients.'
p2901
aS'Additionally, we revealed the prognostic relevance of a LEF1/TCF4 signature in primary lung adenocarcinomas in a microarray dataset of primary lung adenocarcinomas.'
p2902
aS'However, this does not exclude any direct activation or modification of LEF1/TCF4 by WNT signaling.'
p2903
aS'In conclusion, this retrospective study underlines the previous results obtained in a mouse model concerning a role of LEF1/TCF4 in brain metastasis of lung adenocarcinoma.'
p2904
aS'However, further studies are needed to highlight the significance of our findings and to specify which signaling pathways are involved in the LEF1/TCF4 function.'
p2905
as(S'MAZ'
p2906
S'FOXO3'
p2907
S'increases'
p2908
tp2909
(lp2910
s(S'POU3F2'
p2911
S'MECOM'
p2912
S'increases'
p2913
tp2914
(lp2915
s(S'GTF3A'
p2916
S'CYP26A1'
p2917
S'increases'
p2918
tp2919
(lp2920
s(S'PI-3-4-5-P3'
p2921
S'AKT2'
p2922
S'adds_modification'
p2923
tp2924
(lp2925
s(S'VSX1'
p2926
S'POU2F1'
p2927
S'increases'
p2928
tp2929
(lp2930
s(S'PHOSPHORYLATED TTP:MRNA COMPLEX'
p2931
S'YWHAB'
p2932
S'binds'
p2933
tp2934
(lp2935
s(S'MEIS1'
p2936
S'MYC'
p2937
S'increases'
p2938
tp2939
(lp2940
s(S'Complex (PDGF receptor A/PDGF receptor B)'
p2941
S'RASGAP'
p2942
S'adds_modification'
p2943
tp2944
(lp2945
s(S'RORA'
p2946
S'CYP26A1'
p2947
S'increases'
p2948
tp2949
(lp2950
s(S'ATF4'
p2951
S'CDC5L'
p2952
S'increases'
p2953
tp2954
(lp2955
s(S'SHC/RasGAP'
p2956
S'RAS FAMILY/GTP'
p2957
S'increases_activity'
p2958
tp2959
(lp2960
s(S'NKX2-1'
p2961
S'MYC'
p2962
S'increases'
p2963
tp2964
(lp2965
s(S'NF1'
p2966
S'SRF'
p2967
S'increases'
p2968
tp2969
(lp2970
s(S'STAT4'
p2971
S'NRAS'
p2972
S'increases'
p2973
tp2974
(lp2975
s(S'POU6F1'
p2976
S'MEIS1'
p2977
S'increases'
p2978
tp2979
(lp2980
s(S'P-KIT COMPLEX'
p2981
S'GRB2:SOS1'
p2982
S'binds'
p2983
tp2984
(lp2985
s(S'MYCN'
p2986
S'MAX'
p2987
S'increases'
p2988
tp2989
(lp2990
s(S'STAT5A'
p2991
S'CYP26A1'
p2992
S'increases'
p2993
tp2994
(lp2995
s(S'GATA3'
p2996
S'EN1'
p2997
S'increases'
p2998
tp2999
(lp3000
s(S'E4F1'
p3001
S'FOXD3'
p3002
S'increases'
p3003
tp3004
(lp3005
s(S'MYB'
p3006
S'ONECUT1'
p3007
S'increases'
p3008
tp3009
(lp3010
s(S'Cadmium Chloride'
p3011
S'NRAS PROTEIN'
p3012
S'increases'
p3013
tp3014
(lp3015
s(S'Deoxycholic Acid'
p3016
S'HRAS PROTEIN'
p3017
S'increases_activity'
p3018
tp3019
(lp3020
s(S'HLF'
p3021
S'CYP26A1'
p3022
S'increases'
p3023
tp3024
(lp3025
s(S'GMCSF/GMR ALPHA/CSF2RB/JAK2 (DIMER)'
p3026
S'YWHAZ'
p3027
S'binds'
p3028
tp3029
(lp3030
s(S'HNF1A'
p3031
S'FOXF2'
p3032
S'increases'
p3033
tp3034
(lp3035
s(S'FOXF2'
p3036
S'GATA6'
p3037
S'increases'
p3038
tp3039
(lp3040
s(S'Arsenic'
p3041
S'GSS PROTEIN'
p3042
S'increases'
p3043
tp3044
(lp3045
s(S'COMPLEX (SOS/GRB2)'
p3046
S'FGFR1-4'
p3047
S'binds'
p3048
tp3049
(lp3050
s(S'MYOD1'
p3051
S'NRAS'
p3052
S'increases'
p3053
tp3054
(lp3055
s(S'MECOM'
p3056
S'CYP26A1'
p3057
S'increases'
p3058
tp3059
(lp3060
s(S'PBX1'
p3061
S'CYP26A1'
p3062
S'increases'
p3063
tp3064
(lp3065
s(S'MAZ'
p3066
S'MEIS1'
p3067
S'increases'
p3068
tp3069
(lp3070
s(S'PAX4'
p3071
S'ELK1'
p3072
S'increases'
p3073
tp3074
(lp3075
s(S'ESRRA'
p3076
S'MECOM'
p3077
S'increases'
p3078
tp3079
(lp3080
s(S'CEBPD'
p3081
S'TLX2'
p3082
S'increases'
p3083
tp3084
(lp3085
s(S'CRX'
p3086
S'FOXA1'
p3087
S'increases'
p3088
tp3089
(lp3090
s(S'GABPB1'
p3091
S'NRAS'
p3092
S'increases'
p3093
tp3094
(lp3095
s(S'CRX'
p3096
S'MEIS1'
p3097
S'increases'
p3098
tp3099
(lp3100
s(S'pirinixic acid/PPARA protein'
p3101
S'KRAS MRNA'
p3102
S'increases'
p3103
tp3104
(lp3105
s(S'BACH2'
p3106
S'FOXA1'
p3107
S'increases'
p3108
tp3109
(lp3110
s(S'JUN'
p3111
S'MECOM'
p3112
S'increases'
p3113
tp3114
(lp3115
s(S'7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide'
p3116
S'KRAS MRNA'
p3117
S'decreases'
p3118
tp3119
(lp3120
s(S'SRY'
p3121
S'FOXO4'
p3122
S'increases'
p3123
tp3124
(lp3125
s(S'PI3K'
p3126
S'AKT1'
p3127
S'adds_modification'
p3128
tp3129
(lp3130
S'When ChEMBL is selected as the interaction database, the MI Overlay displays small molecules from ChEMBL as interactors of AKT1 E17K variant protein of the PI3K/AKT Signaling in Cancer pathway.'
p3131
as(S'GATA3'
p3132
S'CYP26A1'
p3133
S'increases'
p3134
tp3135
(lp3136
s(S'RAS:GTP'
p3137
S'P-EPHBS:EFNBS:RASA1'
p3138
S'binds'
p3139
tp3140
(lp3141
s(S'STAT5A'
p3142
S'MECOM'
p3143
S'increases'
p3144
tp3145
(lp3146
s(S'RAS family/GTP'
p3147
S'RAF1'
p3148
S'increases_activity'
p3149
tp3150
(lp3151
s(S'RHOA/GTP'
p3152
S'PLD1-2'
p3153
S'increases_activity'
p3154
tp3155
(lp3156
s(S'FOXJ2'
p3157
S'CYP26A1'
p3158
S'increases'
p3159
tp3160
(lp3161
s(S'LEF1'
p3162
S'MECOM'
p3163
S'increases'
p3164
tp3165
(lp3166
s(S'GABPB2'
p3167
S'CDC5L'
p3168
S'increases'
p3169
tp3170
(lp3171
s(S'ESRRA'
p3172
S'CYP26A1'
p3173
S'increases'
p3174
tp3175
(lp3176
s(S'PI-3-4-5-P3'
p3177
S'WAVE2/NAP1/SRA1/ABI1/HSPC300'
p3178
S'translocates'
p3179
tp3180
(lp3181
s(S'CUX1'
p3182
S'MECOM'
p3183
S'increases'
p3184
tp3185
(lp3186
s(S'MAX'
p3187
S'CYP26A1'
p3188
S'increases'
p3189
tp3190
(lp3191
s(S'RXRB'
p3192
S'FOXD3'
p3193
S'increases'
p3194
tp3195
(lp3196
s(S'IRF1'
p3197
S'NRAS'
p3198
S'increases'
p3199
tp3200
(lp3201
s(S'MECOM'
p3202
S'MAX'
p3203
S'increases'
p3204
tp3205
(lp3206
s(S'PAX6'
p3207
S'CYP26A1'
p3208
S'increases'
p3209
tp3210
(lp3211
s(S'GRB2/SOS1'
p3212
S'EGFR/EGFR/EGF/EGF/P46 SHC'
p3213
S'binds'
p3214
tp3215
(lp3216
s(S'POU6F1'
p3217
S'POU2F1'
p3218
S'increases'
p3219
tp3220
(lp3221
s(S'RUNX1'
p3222
S'MYOD1'
p3223
S'increases'
p3224
tp3225
(lp3226
s(S'COMPLEX (GRB2/SOS)'
p3227
S'EGFR'
p3228
S'binds'
p3229
tp3230
(lp3231
s(S'MAZ'
p3232
S'MECOM'
p3233
S'increases'
p3234
tp3235
(lp3236
s(S'REPIN1'
p3237
S'EN1'
p3238
S'increases'
p3239
tp3240
(lp3241
s(S'RAS family/GTP'
p3242
S'RAF1'
p3243
S'adds_modification'
p3244
tp3245
(lp3246
s(S'E4F1'
p3247
S'CYP26A1'
p3248
S'increases'
p3249
tp3250
(lp3251
s(S'Rac'
p3252
S'MEKK1-5'
p3253
S'adds_modification'
p3254
tp3255
(lp3256
s(S'HAND1'
p3257
S'CYP26A1'
p3258
S'increases'
p3259
tp3260
(lp3261
s(S'Quercetin'
p3262
S'NRAS PROTEIN'
p3263
S'decreases'
p3264
tp3265
(lp3266
s(S'HRAS:GTP'
p3267
S'CRAF'
p3268
S'binds'
p3269
tp3270
(lp3271
s(S'REPIN1'
p3272
S'FOXA1'
p3273
S'increases'
p3274
tp3275
(lp3276
s(S'hsa-miR-155-5p'
p3277
S'KRAS'
p3278
S'decreases'
p3279
tp3280
(lp3281
s(S'PAX4'
p3282
S'EN1'
p3283
S'increases'
p3284
tp3285
(lp3286
s(S'FOXN1'
p3287
S'JUN'
p3288
S'increases'
p3289
tp3290
(lp3291
s(S'TFCP2'
p3292
S'GATA1'
p3293
S'increases'
p3294
tp3295
(lp3296
s(S'SHC'
p3297
S'GRAP2'
p3298
S'binds'
p3299
tp3300
(lp3301
s(S'CEBPG'
p3302
S'NRAS'
p3303
S'increases'
p3304
tp3305
(lp3306
s(S'FOXN1'
p3307
S'FOXO4'
p3308
S'increases'
p3309
tp3310
(lp3311
s(S'IL2/IL2R ALPHA/BETA/GAMMA/JAK1/LCK/JAK3/IRS1-2'
p3312
S'PI3K'
p3313
S'binds'
p3314
tp3315
(lp3316
s(S'POU1F1'
p3317
S'EN1'
p3318
S'increases'
p3319
tp3320
(lp3321
s(S'FOXJ1'
p3322
S'POU2F1'
p3323
S'increases'
p3324
tp3325
(lp3326
s(S'YY1'
p3327
S'POU2F1'
p3328
S'increases'
p3329
tp3330
(lp3331
s(S'7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide'
p3332
S'NRAS MRNA'
p3333
S'increases'
p3334
tp3335
(lp3336
s(S'EGF/EGFR'
p3337
S'HRAS/GDP'
p3338
S'increases_activity'
p3339
tp3340
(lp3341
s(S'TFAP4'
p3342
S'GABPB2'
p3343
S'increases'
p3344
tp3345
(lp3346
s(S'TFAP2A'
p3347
S'POU3F2'
p3348
S'increases'
p3349
tp3350
(lp3351
s(S'TCF12'
p3352
S'CBFA2T3'
p3353
S'increases'
p3354
tp3355
(lp3356
s(S'STAT3'
p3357
S'IRF1'
p3358
S'increases'
p3359
tp3360
(lp3361
s(S'MYOD1'
p3362
S'GATA1'
p3363
S'increases'
p3364
tp3365
(lp3366
s(S'REPIN1'
p3367
S'HRAS'
p3368
S'increases'
p3369
tp3370
(lp3371
s(S'PAX4'
p3372
S'MAX'
p3373
S'increases'
p3374
tp3375
(lp3376
s(S'PAX2'
p3377
S'FOXA1'
p3378
S'increases'
p3379
tp3380
(lp3381
S'HER2 signaling has also connection with the ER-cooperating factors FOXA1, PAX2, and AIB-1.'
p3382
as(S'Lipopolysaccharides'
p3383
S'HRAS PROTEIN'
p3384
S'increases_activity'
p3385
tp3386
(lp3387
s(S'7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide'
p3388
S'KRAS MRNA'
p3389
S'increases'
p3390
tp3391
(lp3392
s(S'REPIN1'
p3393
S'GATA1'
p3394
S'increases'
p3395
tp3396
(lp3397
s(S'Formaldehyde'
p3398
S'HRAS MRNA'
p3399
S'increases'
p3400
tp3401
(lp3402
s(S'ESRRA'
p3403
S'STAT5A'
p3404
S'increases'
p3405
tp3406
(lp3407
s(S'farnesylthiosalicylic acid'
p3408
S'HRAS PROTEIN'
p3409
S'decreases'
p3410
tp3411
(lp3412
s(S'JUN'
p3413
S'RUNX1'
p3414
S'increases'
p3415
tp3416
(lp3417
S'RUNX1 siRNA experiments that reduce expression of SPI-1, MEF2D, JUND, and JUNB ('
p3418
as(S'FOXD3'
p3419
S'RUNX1'
p3420
S'increases'
p3421
tp3422
(lp3423
s(S'SOX9'
p3424
S'CYP26A1'
p3425
S'increases'
p3426
tp3427
(lp3428
s(S'hexabromocyclododecane'
p3429
S'HRAS MRNA'
p3430
S'increases'
p3431
tp3432
(lp3433
s(S'RUNX2'
p3434
S'KRAS'
p3435
S'increases'
p3436
tp3437
(lp3438
s(S'PGR'
p3439
S'CYP26A1'
p3440
S'increases'
p3441
tp3442
(lp3443
s(S'CYP26A1'
p3444
S'MAZ'
p3445
S'increases'
p3446
tp3447
(lp3448
s(S'RAC1/GTP'
p3449
S'AKT1'
p3450
S'adds_modification'
p3451
tp3452
(lp3453
s(S'FOXO3'
p3454
S'CYP26A1'
p3455
S'increases'
p3456
tp3457
(lp3458
s(S'MAX'
p3459
S'SRF'
p3460
S'increases'
p3461
tp3462
(lp3463
s(S'RUNX2'
p3464
S'NRAS'
p3465
S'increases'
p3466
tp3467
(lp3468
s(S'HSF2'
p3469
S'CYP26A1'
p3470
S'increases'
p3471
tp3472
(lp3473
s(S'IL2/IL2R ALPHA/BETA/GAMMA/JAK1/LCK/JAK3/SHC/GRB2/SOS1/GAB2/SHP2'
p3474
S'PI3K'
p3475
S'binds'
p3476
tp3477
(lp3478
s(S'SPI1'
p3479
S'STAT5A'
p3480
S'increases'
p3481
tp3482
(lp3483
s(S'ZHX2'
p3484
S'MYC'
p3485
S'increases'
p3486
tp3487
(lp3488
s(S'RAF1-BRAF'
p3489
S'MEK1-2'
p3490
S'increases_activity'
p3491
tp3492
(lp3493
s(S'SHC'
p3494
S'GRB2'
p3495
S'binds'
p3496
tp3497
(lp3498
S'Using the previously curated human EGFR pathway, which included a number of annotations for EGFR and downstream signaling by SHC1, GRB2, PLCG1 and CBL, as a template from which to extend the EGFR pathway, we imported this dataset into the Reactome Curator Tool ['
p3499
as(S'RB1'
p3500
S'GATA1'
p3501
S'increases'
p3502
tp3503
(lp3504
s(S'TCF3'
p3505
S'FOXJ2'
p3506
S'increases'
p3507
tp3508
(lp3509
s(S'FOXJ2'
p3510
S'NRAS'
p3511
S'increases'
p3512
tp3513
(lp3514
s(S'REPIN1'
p3515
S'LEF1'
p3516
S'increases'
p3517
tp3518
(lp3519
s(S'Aflatoxin B1'
p3520
S'HRAS MRNA'
p3521
S'increases'
p3522
tp3523
(lp3524
s(S'PAX4'
p3525
S'MEIS1'
p3526
S'increases'
p3527
tp3528
(lp3529
s(S'FOXF2'
p3530
S'FOXD3'
p3531
S'increases'
p3532
tp3533
(lp3534
s(S'CBFA2T3'
p3535
S'RUNX1'
p3536
S'increases'
p3537
tp3538
(lp3539
s(S'FOXC1'
p3540
S'HOXA9'
p3541
S'increases'
p3542
tp3543
(lp3544
s(S'DBP'
p3545
S'CYP26A1'
p3546
S'increases'
p3547
tp3548
(lp3549
s(S'TGIF'
p3550
S'EN1'
p3551
S'increases'
p3552
tp3553
(lp3554
s(S'PI-3-4-5-P3'
p3555
S'P62DOK'
p3556
S'adds_modification'
p3557
tp3558
(lp3559
s(S'JUN'
p3560
S'TLX2'
p3561
S'increases'
p3562
tp3563
(lp3564
s(S'Benzo(a)pyrene'
p3565
S'HRAS MRNA'
p3566
S'increases'
p3567
tp3568
(lp3569
s(S'STAT4'
p3570
S'CYP26A1'
p3571
S'increases'
p3572
tp3573
(lp3574
s(S'EGFR/EGFR/EGF/EGF'
p3575
S'SRC'
p3576
S'adds_modification'
p3577
tp3578
(lp3579
s(S'FOXQ1'
p3580
S'FOXD3'
p3581
S'increases'
p3582
tp3583
(lp3584
s(S'FOXJ1'
p3585
S'NRAS'
p3586
S'increases'
p3587
tp3588
(lp3589
s(S'TCF3'
p3590
S'POU2F1'
p3591
S'increases'
p3592
tp3593
(lp3594
s(S'MYB'
p3595
S'CYP26A1'
p3596
S'increases'
p3597
tp3598
(lp3599
s(S'GATA4'
p3600
S'CYP26A1'
p3601
S'increases'
p3602
tp3603
(lp3604
s(S'ELK1'
p3605
S'STAT4'
p3606
S'increases'
p3607
tp3608
(lp3609
s(S'CYP26A1'
p3610
S'LEF1'
p3611
S'increases'
p3612
tp3613
(lp3614
s(S"Guanosine-5'-Diphosphate"
p3615
S'HRAS'
p3616
S'increases_activity'
p3617
tp3618
(lp3619
s(S'ETV4'
p3620
S'CYP26A1'
p3621
S'increases'
p3622
tp3623
(lp3624
s(S'EPHRIN B/EPHB2'
p3625
S'RASGAP'
p3626
S'binds'
p3627
tp3628
(lp3629
s(S'ESR1'
p3630
S'FOXF2'
p3631
S'increases'
p3632
tp3633
(lp3634
s(S'CDC5L'
p3635
S'FOXA1'
p3636
S'increases'
p3637
tp3638
(lp3639
s(S'MAZ'
p3640
S'HOXA9'
p3641
S'increases'
p3642
tp3643
(lp3644
s(S'HIF1A'
p3645
S'MAX'
p3646
S'increases'
p3647
tp3648
(lp3649
s(S'FOXN1'
p3650
S'HOXA9'
p3651
S'increases'
p3652
tp3653
(lp3654
s(S'LEF1'
p3655
S'BACH1'
p3656
S'increases'
p3657
tp3658
(lp3659
s(S'PDX1'
p3660
S'FOXO3'
p3661
S'increases'
p3662
tp3663
(lp3664
s(S'CBFA2T3'
p3665
S'CYP26A1'
p3666
S'increases'
p3667
tp3668
(lp3669
s(S'Rabex5'
p3670
S'HRAS/GTP'
p3671
S'adds_modification'
p3672
tp3673
(lp3674
s(S'CBFA2T3'
p3675
S'RUNX2'
p3676
S'increases'
p3677
tp3678
(lp3679
s(S'PI-3-4-5-P3'
p3680
S'ARAP3'
p3681
S'translocates'
p3682
tp3683
(lp3684
s(S'CART1'
p3685
S'CYP26A1'
p3686
S'increases'
p3687
tp3688
(lp3689
s(S'Arsenic'
p3690
S'NRAS MRNA'
p3691
S'increases'
p3692
tp3693
(lp3694
s(S'NRF1'
p3695
S'CDC5L'
p3696
S'increases'
p3697
tp3698
(lp3699
s(S'Quercetin'
p3700
S'HRAS PROTEIN'
p3701
S'decreases'
p3702
tp3703
(lp3704
s(S"N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE"
p3705
S'HRAS'
p3706
S'increases_activity'
p3707
tp3708
(lp3709
s(S'TFDP1'
p3710
S'FOXD3'
p3711
S'increases'
p3712
tp3713
(lp3714
s(S'AR'
p3715
S'TLX2'
p3716
S'increases'
p3717
tp3718
(lp3719
s(S'hsa-miR-181c-5p'
p3720
S'KRAS'
p3721
S'decreases'
p3722
tp3723
(lp3724
s(S'SMAD3'
p3725
S'CBFA2T3'
p3726
S'increases'
p3727
tp3728
(lp3729
s(S'HOXA9'
p3730
S'NRAS'
p3731
S'increases'
p3732
tp3733
(lp3734
s(S'PITX2'
p3735
S'CYP26A1'
p3736
S'increases'
p3737
tp3738
(lp3739
s(S'ATF3'
p3740
S'CYP26A1'
p3741
S'increases'
p3742
tp3743
(lp3744
s(S'E2F1'
p3745
S'MAZ'
p3746
S'increases'
p3747
tp3748
(lp3749
s(S'Ethyl Methanesulfonate'
p3750
S'HRAS MRNA'
p3751
S'increases'
p3752
tp3753
(lp3754
s(S'LMO2'
p3755
S'FOXA1'
p3756
S'increases'
p3757
tp3758
(lp3759
s(S'FOXC1'
p3760
S'POU2F1'
p3761
S'increases'
p3762
tp3763
(lp3764
s(S'DDIT3'
p3765
S'CYP26A1'
p3766
S'increases'
p3767
tp3768
(lp3769
s(S'PAX8'
p3770
S'CYP26A1'
p3771
S'increases'
p3772
tp3773
(lp3774
s(S'LHX3'
p3775
S'EN1'
p3776
S'increases'
p3777
tp3778
(lp3779
s(S'KAT2B'
p3780
S'CYP26A1'
p3781
S'increases'
p3782
tp3783
(lp3784
s(S'P100'
p3785
S'MYB'
p3786
S'binds'
p3787
tp3788
(lp3789
s(S'SOX9'
p3790
S'FOXA1'
p3791
S'increases'
p3792
tp3793
(lp3794
s(S'HIF1A'
p3795
S'EN1'
p3796
S'increases'
p3797
tp3798
(lp3799
s(S'REPIN1'
p3800
S'RUNX1'
p3801
S'increases'
p3802
tp3803
(lp3804
s(S'MYOD1'
p3805
S'BACH1'
p3806
S'increases'
p3807
tp3808
(lp3809
s(S'EBF2'
p3810
S'REPIN1'
p3811
S'increases'
p3812
tp3813
(lp3814
s(S'bisphenol A'
p3815
S'HRAS MRNA'
p3816
S'increases'
p3817
tp3818
(lp3819
s(S'E2F1'
p3820
S'EN1'
p3821
S'increases'
p3822
tp3823
(lp3824
s(S'MYC/Max/MIZ-1'
p3825
S'GALECTIN-1'
p3826
S'decreases'
p3827
tp3828
(lp3829
s(S'PI-3-4-5-P3'
p3830
S'WAVE2/NAP1/SRA1/ABI1/HSPC300'
p3831
S'adds_modification'
p3832
tp3833
(lp3834
s(S'FOXF2'
p3835
S'FOXO3'
p3836
S'increases'
p3837
tp3838
(lp3839
s(S'REPIN1'
p3840
S'STAT5A'
p3841
S'increases'
p3842
tp3843
(lp3844
s(S'RUNX1'
p3845
S'NRAS'
p3846
S'increases'
p3847
tp3848
(lp3849
s(S'benzo(a)pyrene 7,8-dihydrodiol'
p3850
S'HRAS MRNA'
p3851
S'increases'
p3852
tp3853
(lp3854
s(S'RAC1/GTP'
p3855
S'PAK1 (DIMER)'
p3856
S'adds_modification'
p3857
tp3858
(lp3859
s(S'PAX4'
p3860
S'POU2F1'
p3861
S'increases'
p3862
tp3863
(lp3864
s(S'MYOD1'
p3865
S'CBFA2T3'
p3866
S'increases'
p3867
tp3868
(lp3869
s(S'STAT5A'
p3870
S'RUNX2'
p3871
S'increases'
p3872
tp3873
(lp3874
s(S'EBF2'
p3875
S'FOXJ2'
p3876
S'increases'
p3877
tp3878
(lp3879
s(S'Estradiol'
p3880
S'KRAS MRNA'
p3881
S'increases'
p3882
tp3883
(lp3884
s(S'RXRB'
p3885
S'CYP26A1'
p3886
S'increases'
p3887
tp3888
(lp3889
s(S'bisphenol A'
p3890
S'KRAS MRNA'
p3891
S'decreases'
p3892
tp3893
(lp3894
s(S'COMPLEX (GRB2/SOS)'
p3895
S'FGFR1-4'
p3896
S'binds'
p3897
tp3898
(lp3899
s(S'POU2F1'
p3900
S'RUNX1'
p3901
S'increases'
p3902
tp3903
(lp3904
s(S'TCF3'
p3905
S'TLX2'
p3906
S'increases'
p3907
tp3908
(lp3909
s(S'SPZ1'
p3910
S'POU2F1'
p3911
S'increases'
p3912
tp3913
(lp3914
s(S'TFAP4'
p3915
S'FOXO4'
p3916
S'increases'
p3917
tp3918
(lp3919
s(S'OR5I1'
p3920
S'MECOM'
p3921
S'increases'
p3922
tp3923
(lp3924
s(S'Rho Family GTPase-active'
p3925
S'JNK1'
p3926
S'adds_modification'
p3927
tp3928
(lp3929
s(S'TFDP1'
p3930
S'POU2F1'
p3931
S'increases'
p3932
tp3933
(lp3934
s(S'AHR'
p3935
S'MAX'
p3936
S'increases'
p3937
tp3938
(lp3939
s(S'BACH1'
p3940
S'CYP26A1'
p3941
S'increases'
p3942
tp3943
(lp3944
s(S'ZBTB14'
p3945
S'MAZ'
p3946
S'increases'
p3947
tp3948
(lp3949
s(S'TCF3'
p3950
S'FOXO4'
p3951
S'increases'
p3952
tp3953
(lp3954
s(S'MASTERMIND'
p3955
S'NICS'
p3956
S'binds'
p3957
tp3958
(lp3959
s(S'BPTF'
p3960
S'FOXO4'
p3961
S'increases'
p3962
tp3963
(lp3964
s(S'MYOD1'
p3965
S'RUNX1'
p3966
S'increases'
p3967
tp3968
(lp3969
s(S'JUN'
p3970
S'CYP26A1'
p3971
S'increases'
p3972
tp3973
(lp3974
s(S'BPTF'
p3975
S'CYP26A1'
p3976
S'increases'
p3977
tp3978
(lp3979
s(S'POU3F1'
p3980
S'CYP26A1'
p3981
S'increases'
p3982
tp3983
(lp3984
s(S'NRF1'
p3985
S'CYP26A1'
p3986
S'increases'
p3987
tp3988
(lp3989
s(S'TFAP2C'
p3990
S'POU3F2'
p3991
S'increases'
p3992
tp3993
(lp3994
s(S'NFAT1-C-4-INACTIVE2'
p3995
S'YWHAQ'
p3996
S'binds'
p3997
tp3998
(lp3999
s(S'STAT6'
p4000
S'ONECUT1'
p4001
S'increases'
p4002
tp4003
(lp4004
s(S'RUNX1'
p4005
S'RUNX2'
p4006
S'increases'
p4007
tp4008
(lp4009
g913
ag914
ag915
as(S'ZIC3'
p4010
S'MYCN'
p4011
S'increases'
p4012
tp4013
(lp4014
s(S'CYP26A1'
p4015
S'MAX'
p4016
S'increases'
p4017
tp4018
(lp4019
s(S'ETS2'
p4020
S'FOXO4'
p4021
S'increases'
p4022
tp4023
(lp4024
s(S'GATA6'
p4025
S'FOXA1'
p4026
S'increases'
p4027
tp4028
(lp4029
s(S'Doxorubicin'
p4030
S'HRAS MRNA'
p4031
S'increases'
p4032
tp4033
(lp4034
s(S'PPARA'
p4035
S'HOXA9'
p4036
S'increases'
p4037
tp4038
(lp4039
s(S'REPIN1'
p4040
S'GABPB2'
p4041
S'increases'
p4042
tp4043
(lp4044
s(S'FOXN1'
p4045
S'FOXA1'
p4046
S'increases'
p4047
tp4048
(lp4049
s(S'Dronabinol'
p4050
S'KRAS MRNA'
p4051
S'increases'
p4052
tp4053
(lp4054
s(S'FOXO1'
p4055
S'RUNX1'
p4056
S'increases'
p4057
tp4058
(lp4059
s(S'SMAD4'
p4060
S'HOXA9'
p4061
S'increases'
p4062
tp4063
(lp4064
s(S'PAX4'
p4065
S'JUN'
p4066
S'increases'
p4067
tp4068
(lp4069
s(S'Raf-1'
p4070
S'MEK'
p4071
S'adds_modification'
p4072
tp4073
(lp4074
g702
ag707
ag732
ag744
as(S'PIM1'
p4075
S'MYC/MAX'
p4076
S'binds'
p4077
tp4078
(lp4079
s(S'YY1'
p4080
S'MECOM'
p4081
S'increases'
p4082
tp4083
(lp4084
s(S'NRF1'
p4085
S'MAZ'
p4086
S'increases'
p4087
tp4088
(lp4089
s(S'GATA1'
p4090
S'MECOM'
p4091
S'increases'
p4092
tp4093
(lp4094
s(S'PDGF/PDGFRA'
p4095
S'SHC/GRB2/SOS1'
p4096
S'increases_activity'
p4097
tp4098
(lp4099
s(S'GRB2/SOS1'
p4100
S'FAK'
p4101
S'binds'
p4102
tp4103
(lp4104
s(S'HNF4A'
p4105
S'HOXA9'
p4106
S'increases'
p4107
tp4108
(lp4109
s(S'FOXA2'
p4110
S'CYP26A1'
p4111
S'increases'
p4112
tp4113
(lp4114
s(S'FOXI1'
p4115
S'CYP26A1'
p4116
S'increases'
p4117
tp4118
(lp4119
s(S'GRB2 BOUND TO TIE2'
p4120
S'SOS1'
p4121
S'binds'
p4122
tp4123
(lp4124
s(S'PHOSPHORYLATED BRF1 (SER54, SER92, SER203):MRNA COMPLEX'
p4125
S'YWHAB'
p4126
S'binds'
p4127
tp4128
(lp4129
s(S'COMPLEX (GRB2/SOS)'
p4130
S'GAB'
p4131
S'binds'
p4132
tp4133
(lp4134
s(S'NFE2'
p4135
S'TLX2'
p4136
S'increases'
p4137
tp4138
(lp4139
s(S'MAX'
p4140
S'FOXF2'
p4141
S'increases'
p4142
tp4143
(lp4144
s(S'GRB2:SOS1'
p4145
S'ACTIVATED FGFR:P-FRS2'
p4146
S'binds'
p4147
tp4148
(lp4149
s(S'FOXO4'
p4150
S'MECOM'
p4151
S'increases'
p4152
tp4153
(lp4154
s(S'TCF3'
p4155
S'LEF1'
p4156
S'increases'
p4157
tp4158
(lp4159
s(S'ZIC1'
p4160
S'LEF1'
p4161
S'increases'
p4162
tp4163
(lp4164
s(S'NFIL3'
p4165
S'CYP26A1'
p4166
S'increases'
p4167
tp4168
(lp4169
s(S'RAF1'
p4170
S'MEK1'
p4171
S'increases_activity'
p4172
tp4173
(lp4174
s(S'AR'
p4175
S'FOXA1'
p4176
S'increases'
p4177
tp4178
(lp4179
S'FOXA1 is essential for androgen-stimulated binding of AR to the target genes\n['
p4180
aS'The pioneer factor FOXA1 also plays an important role in androgen receptor (AR) signaling of molecular apocrine tumors, which have been recently identified as an additional subgroup of ER-negative and AR-positive breast tumors (Ni et al. '
p4181
as(S'POU2F1'
p4182
S'POU3F2'
p4183
S'increases'
p4184
tp4185
(lp4186
s(S'PCBP1'
p4187
S'MAZ'
p4188
S'increases'
p4189
tp4190
(lp4191
s(S'LEF1'
p4192
S'HOXA9'
p4193
S'increases'
p4194
tp4195
(lp4196
s(S'NR6A1'
p4197
S'CYP26A1'
p4198
S'increases'
p4199
tp4200
(lp4201
s(S'PI3K'
p4202
S'BTK'
p4203
S'translocates'
p4204
tp4205
(lp4206
S'While AKT is the PI3K effector that is most widely implicated in cancer, there are several AKT-independent pathways activated by PI3K, which notably include BTK ('
p4207
aS'In addition, small-molecule inhibitors of PI3K and BTK, including GS-101 and ibrutinib, respectively, have demonstrated remarkable results in relapsed/refractory CLL and MCL, and are anticipated to gain FDA approval within the next year.'
p4208
aS'Targeting the PI3K and BTK pathways in NHL.'
p4209
aS'First studies using the BTK inhibitor Ibrutinib or the PI3K/mTOR inhibitor Bez235 showed promising effects.'
p4210
aS'On activation of BCR signaling, subsequent BTK and PI3K activations occur which consequently manifest in upregulation of CLL-specific chemokines, such as CCL3 and CCL4, which activate T cells, generating survival signals via CD40/CD40L interactions.'
p4211
as(S'AHR'
p4212
S'RUNX1'
p4213
S'increases'
p4214
tp4215
(lp4216
s(S'NR1H4'
p4217
S'CYP26A1'
p4218
S'increases'
p4219
tp4220
(lp4221
s(S'NR2F2'
p4222
S'CYP26A1'
p4223
S'increases'
p4224
tp4225
(lp4226
s(S'GNB1/GNG2'
p4227
S'PI3K'
p4228
S'binds'
p4229
tp4230
(lp4231
s(S'RHOA/GTP'
p4232
S'PKN2'
p4233
S'increases_activity'
p4234
tp4235
(lp4236
s(S'MAZ'
p4237
S'LEF1'
p4238
S'increases'
p4239
tp4240
(lp4241
s(S'RFX1'
p4242
S'MECOM'
p4243
S'increases'
p4244
tp4245
(lp4246
s(S'RUNX1'
p4247
S'HOXA9'
p4248
S'increases'
p4249
tp4250
(lp4251
s(S'FOXL1'
p4252
S'POU2F1'
p4253
S'increases'
p4254
tp4255
(lp4256
s(S'GRB2:SOS1'
p4257
S'PHOSPHORYLATED ERBB2:EGFR HETERODIMERS'
p4258
S'binds'
p4259
tp4260
(lp4261
s(S'TFAP4'
p4262
S'MYCN'
p4263
S'increases'
p4264
tp4265
(lp4266
s(S'E2F1'
p4267
S'GATA1'
p4268
S'increases'
p4269
tp4270
(lp4271
s(S'PTF1A'
p4272
S'GATA6'
p4273
S'increases'
p4274
tp4275
(lp4276
s(S'REL'
p4277
S'CYP26A1'
p4278
S'increases'
p4279
tp4280
(lp4281
s(S'MTF1'
p4282
S'JUN'
p4283
S'increases'
p4284
tp4285
(lp4286
s(S'ZEB1'
p4287
S'REPIN1'
p4288
S'increases'
p4289
tp4290
(lp4291
s(S'IRF8'
p4292
S'GATA6'
p4293
S'increases'
p4294
tp4295
(lp4296
s(S'P-Y349,350-SHC1:PHOSPHORYLATED ERBB2 HETERODIMERS'
p4297
S'GRB2:SOS1'
p4298
S'binds'
p4299
tp4300
(lp4301
s(S'BACH2'
p4302
S'EN1'
p4303
S'increases'
p4304
tp4305
(lp4306
s(S'GFI1'
p4307
S'MEIS1'
p4308
S'increases'
p4309
tp4310
(lp4311
s(S'FOXN1'
p4312
S'LEF1'
p4313
S'increases'
p4314
tp4315
(lp4316
s(S'CYP26A1'
p4317
S'JUN'
p4318
S'increases'
p4319
tp4320
(lp4321
s(S'TCF3'
p4322
S'ONECUT1'
p4323
S'increases'
p4324
tp4325
(lp4326
s(S'FOXF2'
p4327
S'POU2F1'
p4328
S'increases'
p4329
tp4330
(lp4331
s(S'MAZ'
p4332
S'MAX'
p4333
S'increases'
p4334
tp4335
(lp4336
s(S'FOXN1'
p4337
S'CYP26A1'
p4338
S'increases'
p4339
tp4340
(lp4341
s(S'HNF1A'
p4342
S'FOXD3'
p4343
S'increases'
p4344
tp4345
(lp4346
s(S'EGR2'
p4347
S'RUNX1'
p4348
S'increases'
p4349
tp4350
(lp4351
s(S'MYC'
p4352
S'RUNX2'
p4353
S'increases'
p4354
tp4355
(lp4356
s(S'TFAP2A'
p4357
S'IRF1'
p4358
S'increases'
p4359
tp4360
(lp4361
s(S'FOXO4'
p4362
S'YY1'
p4363
S'increases'
p4364
tp4365
(lp4366
s(S'VEGFR2 (dimer)/VEGFA (dimer)'
p4367
S'SRC'
p4368
S'adds_modification'
p4369
tp4370
(lp4371
s(S'resveratrol'
p4372
S'KRAS MRNA'
p4373
S'decreases'
p4374
tp4375
(lp4376
s(S'FOXO4'
p4377
S'CYP26A1'
p4378
S'increases'
p4379
tp4380
(lp4381
s(S'STAT3'
p4382
S'FOXO4'
p4383
S'increases'
p4384
tp4385
(lp4386
s(S'GRB2/SOS1'
p4387
S'FRS2 FAMILY/SHP2'
p4388
S'binds'
p4389
tp4390
(lp4391
s(S'LEF1'
p4392
S'CYP26A1'
p4393
S'increases'
p4394
tp4395
(lp4396
s(S'GTF2A2'
p4397
S'SRF'
p4398
S'increases'
p4399
tp4400
(lp4401
s(S'PPARA'
p4402
S'STAT5A'
p4403
S'increases'
p4404
tp4405
(lp4406
s(S'hsa-miR-143-3p'
p4407
S'KRAS'
p4408
S'decreases'
p4409
tp4410
(lp4411
s(S'GFI1'
p4412
S'CYP26A1'
p4413
S'increases'
p4414
tp4415
(lp4416
s(S'RAC1/GTP'
p4417
S'MKK4-MKK7'
p4418
S'increases_activity'
p4419
tp4420
(lp4421
s(S'REPIN1'
p4422
S'ETS1'
p4423
S'increases'
p4424
tp4425
(lp4426
s(S'ZIC1'
p4427
S'GATA6'
p4428
S'increases'
p4429
tp4430
(lp4431
s(S'INTERLEUKIN RECEPTOR COMPLEXES WITH ACTIVATED SHC1'
p4432
S'GRB2:SOS1'
p4433
S'binds'
p4434
tp4435
(lp4436
s(S'Selenium'
p4437
S'HRAS MRNA'
p4438
S'increases'
p4439
tp4440
(lp4441
s(S'HOXA4'
p4442
S'CYP26A1'
p4443
S'increases'
p4444
tp4445
(lp4446
s(S'NKX2-1'
p4447
S'POU2F1'
p4448
S'increases'
p4449
tp4450
(lp4451
s(S'VSX1'
p4452
S'MAX'
p4453
S'increases'
p4454
tp4455
(lp4456
s(S'FOXD1'
p4457
S'FOXD3'
p4458
S'increases'
p4459
tp4460
(lp4461
s(S'MAX'
p4462
S'NRAS'
p4463
S'increases'
p4464
tp4465
(lp4466
s(S'HOXA9'
p4467
S'TCF3'
p4468
S'increases'
p4469
tp4470
(lp4471
s(S'IRF1'
p4472
S'CYP26A1'
p4473
S'increases'
p4474
tp4475
(lp4476
s(S'HRAS'
p4477
S'RAF1'
p4478
S'adds_modification'
p4479
tp4480
(lp4481
s(S'CUX1'
p4482
S'HOXA9'
p4483
S'increases'
p4484
tp4485
(lp4486
s(S'ZHX2'
p4487
S'FOXA1'
p4488
S'increases'
p4489
tp4490
(lp4491
s(S'TFDP1'
p4492
S'MYC'
p4493
S'increases'
p4494
tp4495
(lp4496
s(S'RAC1/GTP'
p4497
S'PAK1'
p4498
S'increases_activity'
p4499
tp4500
(lp4501
s(S'AHR'
p4502
S'MAZ'
p4503
S'increases'
p4504
tp4505
(lp4506
s(S'BRAF/14-3-3'
p4507
S'KSR/14-3-3 /MEK1-2'
p4508
S'increases_activity'
p4509
tp4510
(lp4511
s(S'PPARA'
p4512
S'CYP26A1'
p4513
S'increases'
p4514
tp4515
(lp4516
s(S'REPIN1'
p4517
S'SRF'
p4518
S'increases'
p4519
tp4520
(lp4521
s(S'PAX5'
p4522
S'SRF'
p4523
S'increases'
p4524
tp4525
(lp4526
s(S'PAX4'
p4527
S'FOXJ2'
p4528
S'increases'
p4529
tp4530
(lp4531
s(S'REPIN1'
p4532
S'MYCN'
p4533
S'increases'
p4534
tp4535
(lp4536
s(S'RALA/GTP'
p4537
S'SRC'
p4538
S'adds_modification'
p4539
tp4540
(lp4541
s(S'FOXO4'
p4542
S'ETS1'
p4543
S'increases'
p4544
tp4545
(lp4546
s(S'TFDP1'
p4547
S'CDC5L'
p4548
S'increases'
p4549
tp4550
(lp4551
s(S'TFDP1'
p4552
S'CYP26A1'
p4553
S'increases'
p4554
tp4555
(lp4556
s(S'GATA6'
p4557
S'RUNX2'
p4558
S'increases'
p4559
tp4560
(lp4561
s(S'FOXM1'
p4562
S'CYP26A1'
p4563
S'increases'
p4564
tp4565
(lp4566
s(S'sodium arsenite'
p4567
S'HRAS PROTEIN'
p4568
S'increases'
p4569
tp4570
(lp4571
s(S'STAT5A'
p4572
S'RUNX1'
p4573
S'increases'
p4574
tp4575
(lp4576
s(S'CEBPA'
p4577
S'EN1'
p4578
S'increases'
p4579
tp4580
(lp4581
s(S'MSX1'
p4582
S'POU2F1'
p4583
S'increases'
p4584
tp4585
(lp4586
s(S'NHLH1'
p4587
S'CBFA2T3'
p4588
S'increases'
p4589
tp4590
(lp4591
s(S'Parathion'
p4592
S'HRAS PROTEIN'
p4593
S'increases'
p4594
tp4595
(lp4596
s(S'SMAD4'
p4597
S'CYP26A1'
p4598
S'increases'
p4599
tp4600
(lp4601
s(S'E2F1'
p4602
S'MYC'
p4603
S'increases'
p4604
tp4605
(lp4606
S'Overall and globally, the patients are divided into two major groups: the MYC group\nthat also includes the RUNX1, E2F1 transcription factors, and the second group, which\nincludes Suz12 and P53 as key enriched transcription factors.'
p4607
aS'In addition to E2F1 and EF4 proteins, a higher level of MYC and MAX response protein was found HPV-positive OPC.'
p4608
aS'In fact they have been conducted on a limited number of samples and the predictive power of changes of factors such as MYC/MAX or E2F1, an alteration of this transcript profile, has not yet been established.'
p4609
aS'Interestingly, similar to PDCD4-mediated pathways, miR-184 mimics suppressed the expression of pRB, C-MYC, CCND1 and E2F1 ('
p4610
aS'We found that PDCD4-mediated growth suppression attributed to cell cycle transition obstacle by repressing the expression of cell cycle factors, including C-MYC, CCND1, pRb and E2F1, and transcription factor C-Jun, and the elevation of cell apoptosis level by inducing the cleavage of CASP9, 3, 6, 7 and PARP.'
p4611
aS'Four transcription factors (HIC1, p53, E2F1, and cMYC) have been identified to modulate SIRT1 expression under oxidative stress/DNA-damage conditions and/or nutrient deprivation.'
p4612
aS'As a demonstration of the possibility and the effectiveness of miRNA based fuzzy mechanism, a fuzzy cognitive map -a mathematical formalism combining neural network and fuzzy logic- has been developed to study the apoptosis/proliferation control performed by the miRNA-17-92 cluster/E2F1/cMYC circuitry.'
p4613
aS'As a demonstrative case of application of FCM to miRNA regulation, we selected the well studied miRNA-17-92 (miR-17-92)/E2F1/cMYC circuitry (Fig. '
p4614
aS'Independently of the initial values chosen for the 6 nodes of the map, the cellular behaviour node indicated a normal cell cycle condition, with mild over-expression of cMYC and miR-17-92 (cell behaviour=0.41, cMYC=0.65, miR-17-92=0.72, E2F1=0.52, E2F2=0.52, E2F3=0.52).'
p4615
aS'Independently from the initial values chosen for the 6 FCM nodes, the cell behaviour node indicated a normal cell cycle condition (0.41) and\na mild over expression of cMYC (0.65), miR-17-92 (0.72), E2F1 (0.52), E2F2 (0.52) and E2F3 (0.52).'
p4616
as(S'CYP26A1'
p4617
S'FOXO3'
p4618
S'increases'
p4619
tp4620
(lp4621
s(S'TCF3'
p4622
S'CBFA2T3'
p4623
S'increases'
p4624
tp4625
(lp4626
s(S'ZHX2'
p4627
S'FOXF2'
p4628
S'increases'
p4629
tp4630
(lp4631
s(S'POU2F1'
p4632
S'MECOM'
p4633
S'increases'
p4634
tp4635
(lp4636
s(S'CYP26A1'
p4637
S'POU2F1'
p4638
S'increases'
p4639
tp4640
(lp4641
s(S'MYOD1'
p4642
S'CYP26A1'
p4643
S'increases'
p4644
tp4645
(lp4646
s(S'RAF'
p4647
S'COMPLEX (RAS/GTP)'
p4648
S'binds'
p4649
tp4650
(lp4651
s(S'RET51/GFRalpha1/GDNF/DOK1'
p4652
S'HRAS/GDP'
p4653
S'increases_activity'
p4654
tp4655
(lp4656
s(S'MAFG'
p4657
S'CYP26A1'
p4658
S'increases'
p4659
tp4660
(lp4661
s(S'CRX'
p4662
S'CYP26A1'
p4663
S'increases'
p4664
tp4665
(lp4666
s(S'hsa-miR-126-3p'
p4667
S'KRAS'
p4668
S'decreases'
p4669
tp4670
(lp4671
s(S'EBF2'
p4672
S'CYP26A1'
p4673
S'increases'
p4674
tp4675
(lp4676
s(S'RUNX1'
p4677
S'CYP26A1'
p4678
S'increases'
p4679
tp4680
(lp4681
s(S'HOXA5'
p4682
S'FOXA1'
p4683
S'increases'
p4684
tp4685
(lp4686
s(S'benzo(a)pyrene-3,6-quinone'
p4687
S'HRAS MRNA'
p4688
S'increases'
p4689
tp4690
(lp4691
s(S'K 7174'
p4692
S'HRAS MRNA'
p4693
S'decreases'
p4694
tp4695
(lp4696
s(S'LEF1'
p4697
S'NRAS'
p4698
S'increases'
p4699
tp4700
(lp4701
s(S'SPI1'
p4702
S'FOXA1'
p4703
S'increases'
p4704
tp4705
(lp4706
s(S'hsa-let-7b-5p'
p4707
S'NRAS'
p4708
S'decreases'
p4709
tp4710
(lp4711
s(S'CEBPA'
p4712
S'JUN'
p4713
S'increases'
p4714
tp4715
(lp4716
s(S'GABPB2'
p4717
S'CYP26A1'
p4718
S'increases'
p4719
tp4720
(lp4721
s(S'PI-3-4-5-P3'
p4722
S'MTOR'
p4723
S'increases_activity'
p4724
tp4725
(lp4726
s(S'GRB2:SOS1'
p4727
S'EGF:P-6Y-EGFR'
p4728
S'binds'
p4729
tp4730
(lp4731
s(S'HNF1A'
p4732
S'CYP26A1'
p4733
S'increases'
p4734
tp4735
(lp4736
s(S'HIF1A'
p4737
S'FOXO4'
p4738
S'increases'
p4739
tp4740
(lp4741
s(S'FOXJ1'
p4742
S'HOXA9'
p4743
S'increases'
p4744
tp4745
(lp4746
s(S'hsa-miR-96-5p'
p4747
S'KRAS'
p4748
S'decreases'
p4749
tp4750
(lp4751
s(S'SRC'
p4752
S'SYNDECAN-2/RASGAP'
p4753
S'binds'
p4754
tp4755
(lp4756
s(S'FOXA1'
p4757
S'MEIS1'
p4758
S'increases'
p4759
tp4760
(lp4761
s(S'LEF1'
p4762
S'MEIS1'
p4763
S'increases'
p4764
tp4765
(lp4766
s(S'PAX3'
p4767
S'CYP26A1'
p4768
S'increases'
p4769
tp4770
(lp4771
s(S'PAX4'
p4772
S'HOXA9'
p4773
S'increases'
p4774
tp4775
(lp4776
s(S'hsa-miR-18a-3p'
p4777
S'KRAS'
p4778
S'decreases'
p4779
tp4780
(lp4781
s(S'FOXF2'
p4782
S'EN1'
p4783
S'increases'
p4784
tp4785
(lp4786
s(S'Pyk2'
p4787
S'SRC FAMILY KINASES'
p4788
S'increases_activity'
p4789
tp4790
(lp4791
s(S'TP53'
p4792
S'HOXA9'
p4793
S'increases'
p4794
tp4795
(lp4796
s(S'Genistein'
p4797
S'KRAS MRNA'
p4798
S'decreases'
p4799
tp4800
(lp4801
s(S'POU1F1'
p4802
S'CYP26A1'
p4803
S'increases'
p4804
tp4805
(lp4806
s(S'manumycin'
p4807
S'KRAS PROTEIN'
p4808
S'decreases_activity'
p4809
tp4810
(lp4811
s(S'Ginkgo biloba extract 761'
p4812
S'GCLC PROTEIN'
p4813
S'increases'
p4814
tp4815
(lp4816
s(S'GATA1'
p4817
S'NRAS'
p4818
S'increases'
p4819
tp4820
(lp4821
s(S'CBFA2T3'
p4822
S'FOXF2'
p4823
S'increases'
p4824
tp4825
(lp4826
s(S'PCBP1'
p4827
S'ELK1'
p4828
S'increases'
p4829
tp4830
(lp4831
s(S'MYC'
p4832
S'FOXF2'
p4833
S'increases'
p4834
tp4835
(lp4836
s(S'hsa-mir-622'
p4837
S'KRAS'
p4838
S'decreases'
p4839
tp4840
(lp4841
s(S'TCF3'
p4842
S'MAZ'
p4843
S'increases'
p4844
tp4845
(lp4846
s(S'STAT2'
p4847
S'MEIS1'
p4848
S'increases'
p4849
tp4850
(lp4851
s(S'CYP26A1'
p4852
S'YY1'
p4853
S'increases'
p4854
tp4855
(lp4856
s(S'CYP26A1'
p4857
S'EN1'
p4858
S'increases'
p4859
tp4860
(lp4861
s(S'GRB2/SOS1'
p4862
S'SHC'
p4863
S'binds'
p4864
tp4865
(lp4866
s(S'BAD'
p4867
S'YWHAZ'
p4868
S'binds'
p4869
tp4870
(lp4871
s(S'SPI1'
p4872
S'MAX'
p4873
S'increases'
p4874
tp4875
(lp4876
s(S'PI-3-4-5-P3'
p4877
S'CENTA1'
p4878
S'translocates'
p4879
tp4880
(lp4881
s(S'XBP1'
p4882
S'CYP26A1'
p4883
S'increases'
p4884
tp4885
(lp4886
s(S'PAX4'
p4887
S'NRAS'
p4888
S'increases'
p4889
tp4890
(lp4891
s(S'PI3K'
p4892
S'EPHRIN A1/EPHA2'
p4893
S'binds'
p4894
tp4895
(lp4896
s(S'POU1F1'
p4897
S'MEIS1'
p4898
S'increases'
p4899
tp4900
(lp4901
s(S'NR3C1'
p4902
S'ETS1'
p4903
S'increases'
p4904
tp4905
(lp4906
s(S'MAZ'
p4907
S'POU3F2'
p4908
S'increases'
p4909
tp4910
(lp4911
s(S'Estradiol'
p4912
S'HRAS MRNA'
p4913
S'increases'
p4914
tp4915
(lp4916
s(S'Aflatoxin B1'
p4917
S'HRAS PROTEIN'
p4918
S'increases'
p4919
tp4920
(lp4921
s(S'ETV7'
p4922
S'STAT4'
p4923
S'increases'
p4924
tp4925
(lp4926
s(S'PBX1'
p4927
S'LEF1'
p4928
S'increases'
p4929
tp4930
(lp4931
s(S'CEBPB'
p4932
S'CYP26A1'
p4933
S'increases'
p4934
tp4935
(lp4936
s(S'MAZ'
p4937
S'JUN'
p4938
S'increases'
p4939
tp4940
(lp4941
s(S'FOXF2'
p4942
S'MYC'
p4943
S'increases'
p4944
tp4945
(lp4946
s(S'FOXJ2'
p4947
S'HOXA9'
p4948
S'increases'
p4949
tp4950
(lp4951
s(S'Capsaicin'
p4952
S'HRAS MRNA'
p4953
S'increases'
p4954
tp4955
(lp4956
s(S'POU3F1'
p4957
S'GATA6'
p4958
S'increases'
p4959
tp4960
(lp4961
s(S'EIF2A'
p4962
S'14-3-3 E'
p4963
S'binds'
p4964
tp4965
(lp4966
s(S'RAS family/GTP'
p4967
S'RAF1-BRAF'
p4968
S'increases_activity'
p4969
tp4970
(lp4971
s(S'GATA6'
p4972
S'GATA1'
p4973
S'increases'
p4974
tp4975
(lp4976
g827
as(S'RASA1'
p4977
S'PHOSPHO PDGF BETA RECEPTOR: PDGF CHAIN B HOMODIMER'
p4978
S'binds'
p4979
tp4980
(lp4981
s(S'CART1'
p4982
S'POU2F1'
p4983
S'increases'
p4984
tp4985
(lp4986
s(S'ZIC3'
p4987
S'POU2F1'
p4988
S'increases'
p4989
tp4990
(lp4991
s(S'TCF4'
p4992
S'FOXA1'
p4993
S'increases'
p4994
tp4995
(lp4996
s(S'PKC theta'
p4997
S'RASGRP1'
p4998
S'adds_modification'
p4999
tp5000
(lp5001
s(S'PTF1A'
p5002
S'STAT5A'
p5003
S'increases'
p5004
tp5005
(lp5006
s(S'SPI1'
p5007
S'FOXO4'
p5008
S'increases'
p5009
tp5010
(lp5011
s(S'HNF1A'
p5012
S'GATA6'
p5013
S'increases'
p5014
tp5015
(lp5016
s(S'FOXJ1'
p5017
S'RUNX1'
p5018
S'increases'
p5019
tp5020
(lp5021
s(S'STAT2'
p5022
S'GATA6'
p5023
S'increases'
p5024
tp5025
(lp5026
s(S'RAS FAMILY/GTP'
p5027
S'PI3K'
p5028
S'binds'
p5029
tp5030
(lp5031
s(S'PAX4'
p5032
S'IRF1'
p5033
S'increases'
p5034
tp5035
(lp5036
s(S'PAX3'
p5037
S'HOXA9'
p5038
S'increases'
p5039
tp5040
(lp5041
s(S'MYB'
p5042
S'MAZ'
p5043
S'increases'
p5044
tp5045
(lp5046
s(S"Guanosine-5'-Triphosphate"
p5047
S'HRAS'
p5048
S'increases_activity'
p5049
tp5050
(lp5051
s(S'alpha9/beta1 Integrin/Tenascin C'
p5052
S'SRC'
p5053
S'adds_modification'
p5054
tp5055
(lp5056
s(S'RAF1'
p5057
S'MEK1'
p5058
S'adds_modification'
p5059
tp5060
(lp5061
s(S'JUN'
p5062
S'FOXA1'
p5063
S'increases'
p5064
tp5065
(lp5066
s(S'NFE2L2'
p5067
S'BACH1'
p5068
S'increases'
p5069
tp5070
(lp5071
s(S'CUX1'
p5072
S'FOXD3'
p5073
S'increases'
p5074
tp5075
(lp5076
s(S'JUN'
p5077
S'EN1'
p5078
S'increases'
p5079
tp5080
(lp5081
s(S'ESR1'
p5082
S'CYP26A1'
p5083
S'increases'
p5084
tp5085
(lp5086
s(S'ESRRA'
p5087
S'FOXA1'
p5088
S'increases'
p5089
tp5090
(lp5091
s(S'POU2F1'
p5092
S'MEIS1'
p5093
S'increases'
p5094
tp5095
(lp5096
s(S'TFCP2'
p5097
S'FOXA1'
p5098
S'increases'
p5099
tp5100
(lp5101
s(S'PI-3-4-5-P3'
p5102
S'PDK1'
p5103
S'increases_activity'
p5104
tp5105
(lp5106
s(S'TCF3'
p5107
S'FOXA1'
p5108
S'increases'
p5109
tp5110
(lp5111
s(S'STAT3'
p5112
S'CYP26A1'
p5113
S'increases'
p5114
tp5115
(lp5116
s(S'CYP26A1'
p5117
S'POU3F2'
p5118
S'increases'
p5119
tp5120
(lp5121
s(S'Curcumin'
p5122
S'KRAS MRNA'
p5123
S'decreases'
p5124
tp5125
(lp5126
s(S'STAT1'
p5127
S'CYP26A1'
p5128
S'increases'
p5129
tp5130
(lp5131
s(S'GFI1'
p5132
S'POU2F1'
p5133
S'increases'
p5134
tp5135
(lp5136
s(S'ZIC1'
p5137
S'POU2F1'
p5138
S'increases'
p5139
tp5140
(lp5141
s(S'PI-3-4-5-P3'
p5142
S'AKT3'
p5143
S'adds_modification'
p5144
tp5145
(lp5146
s(S'BACH1'
p5147
S'NRAS'
p5148
S'increases'
p5149
tp5150
(lp5151
s(S'SCF/KIT'
p5152
S'SHC/GRB2/SOS1'
p5153
S'increases_activity'
p5154
tp5155
(lp5156
s(S'CDX2'
p5157
S'CYP26A1'
p5158
S'increases'
p5159
tp5160
(lp5161
s(S'RET51/GFRalpha1/GDNF/DOK/RasGAP/NCK'
p5162
S'HRAS/GDP'
p5163
S'decreases_activity'
p5164
tp5165
(lp5166
s(S'BETAPIX'
p5167
S'RAC1/GTP'
p5168
S'binds'
p5169
tp5170
(lp5171
s(S'RHOA/GTP'
p5172
S'CITRON'
p5173
S'increases_activity'
p5174
tp5175
(lp5176
s(S'P-SHC1:GRB2:SOS'
p5177
S'P-5Y-LAT-2'
p5178
S'binds'
p5179
tp5180
(lp5181
s(S'PAX4'
p5182
S'CYP26A1'
p5183
S'increases'
p5184
tp5185
(lp5186
s(S'TCF3'
p5187
S'KRAS'
p5188
S'increases'
p5189
tp5190
(lp5191
s(S'GRB2:SOS1'
p5192
S'PHOSPHORYLATED ERBB2:ERBB4 HETERODIMERS'
p5193
S'binds'
p5194
tp5195
(lp5196
s(S'CDX2'
p5197
S'MEIS1'
p5198
S'increases'
p5199
tp5200
(lp5201
s(S'SP3'
p5202
S'RUNX1'
p5203
S'increases'
p5204
tp5205
(lp5206
s(S'REST'
p5207
S'CYP26A1'
p5208
S'increases'
p5209
tp5210
(lp5211
s(S'PTF1A'
p5212
S'CYP26A1'
p5213
S'increases'
p5214
tp5215
(lp5216
s(S'PI-3-4-5-P3'
p5217
S'PI3K/GAB1'
p5218
S'translocates'
p5219
tp5220
(lp5221
s(S'LMO2'
p5222
S'FOXO4'
p5223
S'increases'
p5224
tp5225
(lp5226
s(S'STAT4'
p5227
S'ETS1'
p5228
S'increases'
p5229
tp5230
(lp5231
s(S'GTF2A2'
p5232
S'HOXA9'
p5233
S'increases'
p5234
tp5235
(lp5236
s(S'FOXF2'
p5237
S'POU3F2'
p5238
S'increases'
p5239
tp5240
(lp5241
s(S'GATA1'
p5242
S'GABPB2'
p5243
S'increases'
p5244
tp5245
(lp5246
s(S'Polychlorinated Biphenyls'
p5247
S'KRAS MRNA'
p5248
S'decreases'
p5249
tp5250
(lp5251
s(S'GRB2/SOS1'
p5252
S'EGF/EGFR DIMER/SHC'
p5253
S'binds'
p5254
tp5255
(lp5256
s(S'CYP26A1'
p5257
S'FOXF2'
p5258
S'increases'
p5259
tp5260
(lp5261
s(S'EGR1'
p5262
S'CYP26A1'
p5263
S'increases'
p5264
tp5265
(lp5266
s(S'MAX'
p5267
S'FOXO3'
p5268
S'increases'
p5269
tp5270
(lp5271
s(S'T-DHT/AR/PELP1'
p5272
S'SRC'
p5273
S'binds'
p5274
tp5275
(lp5276
s(S'CUX1'
p5277
S'FOXF2'
p5278
S'increases'
p5279
tp5280
(lp5281
s(S'CEBPD'
p5282
S'CYP26A1'
p5283
S'increases'
p5284
tp5285
(lp5286
s(S'CBFA2T3'
p5287
S'NRAS'
p5288
S'increases'
p5289
tp5290
(lp5291
s(S'Cisplatin'
p5292
S'HRAS MRNA'
p5293
S'translocates'
p5294
tp5295
(lp5296
s(S'BAD/BCL-X(L)'
p5297
S'YWHAZ'
p5298
S'binds'
p5299
tp5300
(lp5301
s(S'GATA1'
p5302
S'FOXA1'
p5303
S'increases'
p5304
tp5305
(lp5306
s(S'RREB1'
p5307
S'CYP26A1'
p5308
S'increases'
p5309
tp5310
(lp5311
s(S'STAT4'
p5312
S'RUNX2'
p5313
S'increases'
p5314
tp5315
(lp5316
s(S'FOXD3'
p5317
S'NRAS'
p5318
S'increases'
p5319
tp5320
(lp5321
s(S'NDEL1'
p5322
S'14-3-3 E'
p5323
S'binds'
p5324
tp5325
(lp5326
s(S'CYP26A1'
p5327
S'REPIN1'
p5328
S'increases'
p5329
tp5330
(lp5331
s(S'MAF'
p5332
S'CDC5L'
p5333
S'increases'
p5334
tp5335
(lp5336
s(S'CYP26A1'
p5337
S'ELK1'
p5338
S'increases'
p5339
tp5340
(lp5341
s(S'MYC'
p5342
S'FOXD3'
p5343
S'increases'
p5344
tp5345
(lp5346
s(S'MAX'
p5347
S'FOXD3'
p5348
S'increases'
p5349
tp5350
(lp5351
s(S'POU1F1'
p5352
S'GATA6'
p5353
S'increases'
p5354
tp5355
(lp5356
s(S'POU2F1'
p5357
S'STAT4'
p5358
S'increases'
p5359
tp5360
(lp5361
s(S'GTF3A'
p5362
S'FOXO3'
p5363
S'increases'
p5364
tp5365
(lp5366
s(S'MYB'
p5367
S'FOXF2'
p5368
S'increases'
p5369
tp5370
(lp5371
s(S'ZIC3'
p5372
S'CYP26A1'
p5373
S'increases'
p5374
tp5375
(lp5376
s(S'POU2F1'
p5377
S'EN1'
p5378
S'increases'
p5379
tp5380
(lp5381
s(S'JUN'
p5382
S'STAT1'
p5383
S'increases'
p5384
tp5385
(lp5386
s(S'TEF'
p5387
S'CYP26A1'
p5388
S'increases'
p5389
tp5390
(lp5391
s(S'MAF'
p5392
S'CYP26A1'
p5393
S'increases'
p5394
tp5395
(lp5396
s(S'PAX4'
p5397
S'GATA6'
p5398
S'increases'
p5399
tp5400
(lp5401
s(S'ZIC2'
p5402
S'GATA6'
p5403
S'increases'
p5404
tp5405
(lp5406
s(S'hsa-miR-181d-5p'
p5407
S'HRAS'
p5408
S'decreases'
p5409
tp5410
(lp5411
s(S'BACH2'
p5412
S'CYP26A1'
p5413
S'increases'
p5414
tp5415
(lp5416
s(S'TCF12'
p5417
S'CYP26A1'
p5418
S'increases'
p5419
tp5420
(lp5421
s(S'GATA1'
p5422
S'FOXO4'
p5423
S'increases'
p5424
tp5425
(lp5426
s(S'RFX1'
p5427
S'FOXD3'
p5428
S'increases'
p5429
tp5430
(lp5431
s(S'FOXJ1'
p5432
S'CYP26A1'
p5433
S'increases'
p5434
tp5435
(lp5436
s(S'GTF2A2'
p5437
S'POU2F1'
p5438
S'increases'
p5439
tp5440
(lp5441
s(S'YY1'
p5442
S'SRF'
p5443
S'increases'
p5444
tp5445
(lp5446
S'The C-terminal Zinc-Finger domain of GATA-4 is known to interact with various transcriptional activators such as GATA-6, MEF-2, NFAT, Nkx-2.5, SRF, dHAND and YY1 ['
p5447
as(S'AHR'
p5448
S'REPIN1'
p5449
S'increases'
p5450
tp5451
(lp5452
s(S'MAZ'
p5453
S'CYP26A1'
p5454
S'increases'
p5455
tp5456
(lp5457
s(S'Quercetin'
p5458
S'HRAS MRNA'
p5459
S'increases'
p5460
tp5461
(lp5462
s(S'ELK1'
p5463
S'NRAS'
p5464
S'increases'
p5465
tp5466
(lp5467
s(S'HIF1A'
p5468
S'ONECUT1'
p5469
S'increases'
p5470
tp5471
(lp5472
s(S'FOXF2'
p5473
S'CYP26A1'
p5474
S'increases'
p5475
tp5476
(lp5477
s(S'SOX9'
p5478
S'ETS1'
p5479
S'increases'
p5480
tp5481
(lp5482
s(S'HSF1'
p5483
S'JUN'
p5484
S'increases'
p5485
tp5486
(lp5487
s(S'CEBPA'
p5488
S'CYP26A1'
p5489
S'increases'
p5490
tp5491
(lp5492
s(S'NR1H4'
p5493
S'MEIS1'
p5494
S'increases'
p5495
tp5496
(lp5497
s(S'SMAD1'
p5498
S'GATA1'
p5499
S'increases'
p5500
tp5501
(lp5502
s(S'Quercetin'
p5503
S'HRAS MRNA'
p5504
S'decreases'
p5505
tp5506
(lp5507
s(S'Glycyrrhetinic Acid'
p5508
S'HRAS PROTEIN'
p5509
S'decreases'
p5510
tp5511
(lp5512
s(S'HOXA4'
p5513
S'POU2F1'
p5514
S'increases'
p5515
tp5516
(lp5517
s(S'FOXQ1'
p5518
S'CYP26A1'
p5519
S'increases'
p5520
tp5521
(lp5522
s(S'FOXI1'
p5523
S'CEBPA'
p5524
S'increases'
p5525
tp5526
(lp5527
s(S'GTF3A'
p5528
S'MYCN'
p5529
S'increases'
p5530
tp5531
(lp5532
s(S'LMO2'
p5533
S'IRF1'
p5534
S'increases'
p5535
tp5536
(lp5537
s(S'FOXO1'
p5538
S'CYP26A1'
p5539
S'increases'
p5540
tp5541
(lp5542
s(S'Copper Sulfate'
p5543
S'NRAS MRNA'
p5544
S'increases'
p5545
tp5546
(lp5547
s(S'TFAP2A'
p5548
S'CYP26A1'
p5549
S'increases'
p5550
tp5551
(lp5552
s(S'FOXJ1'
p5553
S'EN1'
p5554
S'increases'
p5555
tp5556
(lp5557
s(S'MEIS1'
p5558
S'RUNX1'
p5559
S'increases'
p5560
tp5561
(lp5562
s(S'MAZ'
p5563
S'FOXA1'
p5564
S'increases'
p5565
tp5566
(lp5567
s(S'ETS1'
p5568
S'FOXO4'
p5569
S'increases'
p5570
tp5571
(lp5572
s(S'ZBTB14'
p5573
S'FOXD3'
p5574
S'increases'
p5575
tp5576
(lp5577
s(S'FOXC1'
p5578
S'LEF1'
p5579
S'increases'
p5580
tp5581
(lp5582
s(S'IRF1'
p5583
S'EN1'
p5584
S'increases'
p5585
tp5586
(lp5587
s(S'NR3C1'
p5588
S'CYP26A1'
p5589
S'increases'
p5590
tp5591
(lp5592
s(S'VSX1'
p5593
S'BACH1'
p5594
S'increases'
p5595
tp5596
(lp5597
s(S'CYP26A1'
p5598
S'ETS1'
p5599
S'increases'
p5600
tp5601
(lp5602
s(S'CEBPA'
p5603
S'MEIS1'
p5604
S'increases'
p5605
tp5606
(lp5607
s(S'ELF1'
p5608
S'FOXO4'
p5609
S'increases'
p5610
tp5611
(lp5612
s(S'RXRA'
p5613
S'CYP26A1'
p5614
S'increases'
p5615
tp5616
(lp5617
s(S'CREB1'
p5618
S'CYP26A1'
p5619
S'increases'
p5620
tp5621
(lp5622
s(S'IRF7'
p5623
S'GATA6'
p5624
S'increases'
p5625
tp5626
(lp5627
s(S'ZEB1'
p5628
S'CYP26A1'
p5629
S'increases'
p5630
tp5631
(lp5632
s(S'AR'
p5633
S'CYP26A1'
p5634
S'increases'
p5635
tp5636
(lp5637
s(S'TFDP2'
p5638
S'MYC'
p5639
S'increases'
p5640
tp5641
(lp5642
s(S'hsa-mir-217'
p5643
S'KRAS'
p5644
S'decreases'
p5645
tp5646
(lp5647
s(S'MEK'
p5648
S'ERK'
p5649
S'adds_modification'
p5650
tp5651
(lp5652
g653
ag654
aS'Disturbances in the RAS/RAF/MEK/ERK signaling pathway are the most frequent and perhaps the most important observed defects, with activating mutations in the '
p5653
aS'However, under these treatment conditions MEK1/2 phosphorylation declined while ERK1/2 activity was rising arguing that camptothecin effects on the ERK1/2 pathway are more complicated than just altered MKP-1 expression.'
p5654
aS'It is historically well known that signaling by the PI3K-AKT and MEK1/2-ERK1/2 pathways in a cell type-dependent fashion can collaborate to maintain cell viability.'
p5655
aS'Inhibition of MEK1/2 or knockdown of ERK2 blocked sustained AKT activity in cells treated with a PI3K/mTOR inhibitor.'
p5656
aS'Another likely advantage of direct RAS effector interaction site targeted drugs would be that they would also be expected to inhibit other RAS effector pathways such as RAF/MEK/ERK, which are activated from the same region of RAS.'
p5657
aS'Aberrant activation of Wnt, MEK/ERK, and Notch signaling pathways is known to contribute to the pathogenesis of myeloid leukemias and acute T-cell lymphoblastic leukemias and lymphomas ['
p5658
aS'Our E2-enhanced cell expansion model was characterized by the early activation of genes belonging to the MEK/ERK survival pathway and a remarkable regulation of multiple cancer-associated genes.'
p5659
aS"MPNST: malignant peripheral nerve sheath tumor; NF1: neurofibromatosis type 1; FAP: familial adenomatous polyposis; NSAID: nonsteroidal anti-inflammatory drug; COX: cyclooxigenase; PDE: phosphodiesterase; PKG: proteinkinase G; JNK: C-jun N-terminal protein kinase; MEKK: mitogen activated protein kinase kinase kinase; PARP: poly (ADP-ribose) polymerase; phospho-ERK1/2: phosphorylated extracellular signal-regulated kinase 1 and 2; NIH: national institute of health; DMEM: Dulbecco's modified eagle medium; FBS: fetal bovine serum; DMSO: dimethyl sulfoxide; BrdU: 5-Bromo-2'deoxyuridine; bFGF: basic fibroblastic growth factor; PBS: phosphate buffered saline; XTT: sodium 3'-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro)benzene sulfonic acid hydrate); TUNEL: terminal deoxynucleotidyltransferase dUTP nick end labelling; PI: propidium iodide; TBS: Tris-buffered normal saline; EGF: epidermal growth factor; DTT: dithiothreitol; PMSF: phenylmethylsulfonyl fluoride; DHA; docosahexaenoic acid; SAPK: stress-activated protein kinase; h: hours."
p5660
aS"p27: p27Kip1; p21: p21Cip1/Waf1; AMPK: 5'-AMP-activated protein kinase; TSC: tuberous sclerosis complex; mTOR: mammalian target of rapamycin; RTK: receptor tyrosine kinase; PTEN: phosphatase and tensin homolog; PI3K: phosphoinositide 3-kinase; PKB: protein kinase B; MAPK: mitogen-activated protein kinase; MEK: mitogen-activated protein (MAP) kinase kinase; ERK: ERK MAP kinase; MNK: MAP kinase interacting kinase; m"
p5661
aS'uPAR-induced resistance to anoikis in the nontransformed retinal epithelial cells resulted from uPA binding and activation of MEK/ERK and PI3K/Akt pathways.'
p5662
aS"Nonstandard abbreviations: p27, p27Kip1; p21, p21Cip1/Waf1; AMPK, 5'-AMP-activated protein kinase; TSC, tuberous sclerosis complex; mTOR, mammalian target of rapamycin; RPTK, receptor protein tyrosine kinase; PI3K, phosphoinositide 3-kinase; PDK, phosphoinositide-dependent kinase; PKB, protein kinase B; MAPK, mitogen-activated protein kinase; MEK, mitogen-activated protein (MAP) kinase kinase; ERK, ERK MAP kinase; MNK, MAP kinase interacting kinase; m"
p5663
aS'RAS is a small GTP-binding protein tethered to the inner cell membrane that couples growth factor receptor activation to the downstream RAF-MEK-ERK MAPK cascade (Figure '
p5664
aS'APC: adenomatous polyposis coli; BADJ: bronchio-alveolar duct junction; BASC: bronchio-alveolar stem cell; CC: Clara cell; c-Myc: cellular Myelocytomatosis; EGFR: epidermal growth factor receptor; ERK: extracellular signal-regulated kinase; HGF: hepatocyte growth factor; LEF: lymphoid enhancer factor; MAPK: mitogen-activated protein kinase; MEK: MAP kinase extracellular signal-regulated kinase; NSCLC: non-small-cell lung cancer; PCR: polymerase chain reaction; PI3K: phosphoinositide-3-kinase; RT-PCR: reverse transcription- polymerase chain reaction; rtTA: reverse transcriptional transactivator; SCID: severe combined immune deficiency; SP-C: surfactant protein-C; Sca1: stem cell antigen 1; TCF: T-cell factor; VEGF: vascular endothelial growth factor; Wnt: wingless/int.'
p5665
aS'To confirm the conclusion that in PC-3 cells the MEK/ERK 1/2 pathway is down-regulated, levels of ERK 1/2 phosphorylation in DU-145 and PC-3 cells were measured using a cell-based ELISA assay.'
p5666
aS'EGF increased the mRNA expression of RAF1, MEK, ERK and MAPK14 significantly in HepG2 cells (Figure '
p5667
aS'MEK inhibitors U0126 and AZD6244 deactivated phosphorylated ERK, decreased endogenous MRP1 expression, reversed gemcitabine or doxorubicin induced MRP1 and MRP3 upregulation, and increased the intracellular doxorubicin accumulation.'
p5668
aS'Western blot analysis revealed that MEK inhibitors U0126 and AZD6244 modulated the MAPK pathway by increasing the p-MEK levels and decreasing the p-ERK levels.'
p5669
ag661
ag662
ag663
aS'As well as Mirk/Dyrk1B regulating cell cycle-related proteins cyclin D1 and p27kip1, it has been demonstrated that blocking mitogenic-activated protein kinase kinae (MEK) - extracellular signal-regulated kinase (ERK) signaling pathway increases Mirk abundance by up-regulating Mirk/Dyrk1B transcription in either myoblast or colon cancer cells ['
p5670
aS'The data suggested that CCN1 is a tumor promoter in AML that acts through the MEK/ERK pathway to up-regulate c-Myc and Bcl-xL and to down-regulate Bax.'
p5671
aS'We demonstrated that CCN1 influences the MEK/ERK pathway in AML cells, potentially regulating c-Myc, Bcl-xL and Bax.'
p5672
aS'These findings suggest that CCN1 is elevated in AML and promotes survival through the MEK/ERK pathway by up-regulating c-Myc and Bcl-xL and by down-regulating Bax.'
p5673
ag664
aS'Total and phosphorylated ERK1/2 and MEK were assessed.'
p5674
aS'To down-regulate the ERK1/2 signaling pathway, cells were treated with the kinase inhibitor U0126, which is specific for MEK1/2, an upstream kinase in the ERK cascade ('
p5675
aS'Abbreviations: EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; IGF1R, insulin-like growth factor 1 receptor; MEK, MAPK/extracellular signal-regulated kinase kinase; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol 3-kinase; PKB, protein kinase B; VEGF(R), vascular endothelial growth factor (receptor).'
p5676
aS'BRAF is an integral part of the RAS-RAF-MEK-ERK (mitogen-activated protein kinase) signal transduction pathway, a protein kinase cascade which regulates cellular growth, proliferation, differentiation, and survival in response to extracellular signals, including growth factors, cytokines, and hormones.'
p5677
aS'Regorafenib is an oral multi kinase inhibitor targeting both tumor cell proliferation/survival pathways (RAF/MEK/ERK) and selected RTKs such as VEGFR-2/3, TIE-2, PDGFR, RET, and c-KIT ('
p5678
aS'Furthermore, the level of activated pERK1/2, detected by immunohistochemistry, was strongly reduced in treated mice, indicating that, in vivo, regorafenib effectively inhibited the RAF/MEK/ERK signaling cascade.'
p5679
aS'Regorafenib also inhibits oncogenesis, in part, by selectively targeting the intracellular kinases BRAF and RAF1, an activator of downstream mitogen-activated protein kinases (MEK and ERK) that promote cell proliferation.'
p5680
aS'Brain metastases are the most common cause of death in patients with metastatic melanoma, and the RAF-MEK-ERK and PI3K-AKT signaling pathways are key players in melanoma progression and drug resistance.'
p5681
aS'As the RAF-MEK-ERK and PI3K-AKT signaling pathways are thought to be key players in melanoma progression and drug resistance, we performed immunohistochemical analyses of cerebral metastases and of matched extracerebral metastases from the same patients.'
p5682
ag666
ag667
ag1866
ag668
ag669
ag670
ag671
ag672
aS'Further experiments demonstrated that overexpression of ANO1 in T24 and UM-SCC1 cancer cells induced RAS-RAF-MEK-ERK pathway activation '
p5683
aS'Pharmacologic inhibition of MEK/ERK (using specific inhibitors for MAPK/ERK signaling pathway, UO126 and AZD6244) and genetic inactivation of ERK1/2 (using siRNA and dominant-negative constructs) abrogated the growth effect of ANO1, indicating a role for MAPK activation to enhance the ANO1-mediated proliferation.'
p5684
ag673
ag674
ag675
aS'An inhibitor to MEK or curcumin significantly suppressed the phosphorylation of ERK1/2 and expression of VEGF.'
p5685
aS'An inhibitor to MEK1/2 inhibitor (U0126) and antibodies to phospho-ERK and ERK were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA).'
p5686
ag676
aS'The RAS-RAF-MEK-ERK-MAP kinase pathway is an important cellular signal transduction pathway which mediates cellular responses to growth signals.'
p5687
aS'Mutations in both KRAS and BRAF stimulate the MEK-ERK-MAP kinase cascade pathway ['
p5688
ag677
aS'HB-EGF transactivates epidermal growth factor receptors (EGFR) resulting in intracellular signaling via both the MEK/ERK and PI3K/AKT signaling pathways.'
p5689
ag688
ag689
aS'The prototype member of the MEK kinase family, designated MAP kinase kinase (MKK-1)/or MEK-1, specifically phosphorylates the MAP kinase regulatory threonine and tyrosine residues present in the Thr-Glu-Tyr motif of ERK 1/2 ['
p5690
aS'It promotes proliferation and cell survival through activation of MEK/ERK and P13-k/Akt signaling cascades in the cell ['
p5691
aS'Several signal pathways related to survival of cancer cells are frequently deregulated in melanoma (RAS-RAF-MEK-ERK pathway, p16INK4A-CDK4-RB pathway, ARF-p53 pathway, PI3K-AKT pathway and the canonical Wnt signaling pathway).'
p5692
aS'One such pathway is the MAPK/ ERK pathway: Treatment of cells with the MEK1 inhibitor PD98059, or expression of mutants of RAS, which is upstream of MAPK/ ERK, can prevent EMT ['
p5693
aS'Oxidative stress can activate the ERK/MEK and the PI3K/AKT pathways.'
p5694
aS'HspB1 and HspB5 have been reported to stimulate constitutive cell division by interacting with different cytoplasmic receptors, such as VEGF, FGF-2 and Her2, leading to an enhanced activity of the MAPK kinase/MEK/ERK pathway.'
p5695
ag690
aS'For example, they can promote constitutive cell division by interacting with cytoplasmic receptors (VEGF, FGF-2, Her2) leading to enhanced activity of MAPK kinase/MEK/ERK pathway.'
p5696
ag691
aS'Cleaved caspase 3, cleaved caspase 8, cleaved caspase 9 (Asp330), caspase 8, caspase 9,\nphospho-p44/42 MEK (Thr202/Tyr204) (phospho-ERK1/2), total AKT, phospho-p90RSK (rabbit\npolyclonals; Cell Signaling), anti-Akt/PKB[pS'
p5697
aS'The inhibition of ERK1/2 phosphorylation and function by EGFR and MEK\nantagonists.'
p5698
aS'This is not surprising as EGFR has been reported to enhance ERK phosphorylation\ndownstream of MEK through dual-specificity phosphatases ('
p5699
aS'Both PI3K-Akt and MEK/ERK signalling pathways are important for cytokine induction by palmitate.'
p5700
aS'MEK/ERK signalling is necessary for synergistic induction of IL-6 by palmitate and insulin.'
p5701
aS'Insulin binding to the insulin receptor engages two primary signal transduction pathways, the mitogen activated protein kinase (MAPK)/extracellular regulated kinase (ERK) kinase (MEK) - ERK pathway and phosphatidylinositide 3-kinase (PI3K) - Akt pathway, in insulin responsive cells ['
p5702
aS'These changes were reversed by tiron (ROS scavenger), PD98059 (MEK/ERK inhibitor), or siRNA of GATA-4.'
p5703
aS'Hyperglycemia can cause systolic dysfunction and a higher expression of cTnI in cardiomyocytes through ROS, enhancing MEK/ERK-induced GATA-4 phosphorylation and accumulation in the cell nucleus.'
p5704
aS'The transcriptional activity of GATA-4 could be enhanced via a p38 and MEK/ERK MAPK-dependent pathway to phosphorylate GATA-4 activation domains and GATA binding sites for the activation of target cardiac promoters ['
p5705
aS'It has been well-established that hypertension and stimulation with isoproterenol, phenylephrine, endothelin or other hypertrophic signals can activate GATA-4 through the MEK/ERK pathway to promote GATA-4 serine105 p38 phosphorylation for higher binding of GATA-4 on the specific promoter region to increase the transcriptional activity ['
p5706
aS'We have demonstrated that hyperglycemia-induced ROS activate the MEK/ERK pathway to increase GATA-4 phosphorylation for higher transcription.'
p5707
aS'Given that RSK4, a p53-related gene, participates in Ras-MEK-ERK pathway and could regulate senescence, we postulate that RSK4 might be a mediator in EPCs senescence in DM.'
p5708
aS'Mutant BRAF led to deregulated activation of downstream MEK/ERK effectors in melanoma patients.'
p5709
aS'BRAF serine/threonine kinase is a member of the RAF kinase family involved in the RAS/RAF/MEK/ERK kinase cascade, which regulates cellular differentiation and proliferation ['
p5710
aS'When the IGF-I receptor is stimulated, the downstream signaling pathways, including PI3K-AKT-TOR and RAF-MEK-ERK, are activated ['
p5711
aS'One of these is a pathway dependent on phosphoinositide-3 kinase and MEK-extracellular signal-regulated kinase (ERK) signaling.'
p5712
aS'Three kinase enzymes are part of this pathway: mitogen-activated protein kinase (MAPK), MEK, and extracellular signal-regulated kinase (ERK) ['
p5713
aS'Our data establish that inhibition of BRAF in the presence of oncogenic RAS hyperactivates CRAF, MEK, and ERK.'
p5714
aS'In this study, we show that inhibition of BRAF by chemical or genetic means in the presence of oncogenic or growth-factor activated RAS induces BRAF binding to CRAF, leading to CRAF hyperactivation and consequently elevated MEK and ERK signaling.'
p5715
ag1308
aS'BRAF Inhibitors Activate CRAF, MEK, and ERK in RAS Mutant Cell Lines'
p5716
aS'Cell lysates were western blotted for NRAS, CRAF, phospho-MEK (ppMEK), phospho-ERK (ppERK) and tubulin (loading control).'
p5717
aS'The lysates were also western blotted for BRAF, CRAF, phospho-MEK (ppMEK), phospho-ERK (ppERK) and total ERK2.'
p5718
aS'BRAF, CRAF, phospho-MEK (ppMEK), phospho-ERK (ppERK) and total ERK2 levels in the cell lysates are also shown.'
p5719
ag694
ag695
ag696
ag697
ag698
ag699
aS'The result of focal adhesion signaling is activation of signaling pathways that are emerging as mechanically responsive and include focal adhesion kinase (FAK), the MEK/ERK pathway and activation of Rho itself.'
p5720
ag700
aS'Addition of the MEK inhibitor U0126 into the transfected L02 cells described above inhibited ERK phosphorylation and hTERT expression.'
p5721
ag701
aS'ASK1 was first identified as a member of the MAPKKK family and was found to activate the MAPKK 4 (MKK4)-JNK and MKK3/6-p38 pathways but not the MAP/ERK kinase (MEK)-extracellular signal-regulated kinase (ERK) pathway (Figure '
p5722
aS'The ERK1/2 inhibitor PD98059, which blocks the upstream kinase (MEK1) of ERK1/2, the p38 inhibitor SB203580, and the PKC inhibitor Calphostin C were obtained from Sigma (St. Louis, MO).'
p5723
aS'The interactions between MAP kinase and its immediate upstream kinase (MAPKK) are highly specific: for instance, p42/p44 MAP kinases are phosphorylated solely by MAP/ERK kinase (MEK) 1 and 2; p38 MAP kinase is selectively activated by MAP kinase kinases (MKK) 3 and 6, while JNK is activated by MKK7 and MKK4 in most conditions, however MKK4 can sometimes activate p38 MAP kinase when over expressed.'
p5724
aS'MEK MAP/ERK kinase'
p5725
ag702
aS'Activation by the fibroblast growth factors (FGFs) leads to activation of the RAS-RAF-MEK-ERK (MAPK) pathway kinases, ultimately directing the cellular action, including proliferation, apoptosis, differentiation or senescence ['
p5726
ag703
ag704
ag705
ag707
aS'We previously found that the ERK scaffold MEK Partner 1 (MP1) is required for focal adhesion disassembly in fibroblasts.'
p5727
aS'MEK Partner 1 (MP1) is a putative scaffolding protein that binds MEK1 and ERK ['
p5728
ag708
ag709
ag710
ag711
aS'This activation was not accompanied by enhanced ERK1/2 or MEK1/2 phosphorylation ['
p5729
aS'MEK Partner 1 (MP1 or MAPKSP1) is a scaffold protein that has been reported to function in multiple signaling pathways, including the ERK, PAK and mTORC pathways.'
p5730
aS'The small protein MEK Partner 1 (MP1, also known as Map Kinase Scaffold Protein 1 and LAMTOR3) was originally identified as a scaffold protein that potentiates MAPK signaling by binding to MEK1 and ERK1 ['
p5731
aS'Phosphoimmunoblotting of PCMOs indicated that both EGF and HB-EGF activated MEK-1/2 and ERK1/2 in a concentration-dependent fashion with the effect of EGF being more prominent.'
p5732
aS'The results suggested that the addition of EGF or HB-EGF to PCMO differentiation medium superactivates MEK/ERK signaling which then increases both PCMO proliferation, number, and functional differentiation of PCMO-derived NeoHepatocytes.'
p5733
aS'ERK and MEK activation is involved in M-CSF and EGF-induced proliferation of PCMOs.'
p5734
aS'To test whether this is associated with activation of MEK/ERK signaling, we performed immunoblot analysis of ERK activation (Figure '
p5735
aS'Since both EGF and HB-EGF are known to stimulate ERK activation, we reasoned that these agents may enhance proliferation by superactivating the MEK/ERK pathway.'
p5736
aS'To test this prediction, PCMOs were generated in standard PCMO differentiation medium in the absence or presence of either EGF or HB-EGF and subjected to immunoblot analysis of phospho-MEK and phospho-ERK.'
p5737
aS'The results indicated that both EGF and HB-EGF activated MEK and ERK and that the effect was concentration-dependent and more prominent in EGF-treated than in HB-EGF-treated PCMOs (Figure '
p5738
aS'M-CSF and IL-3 present in the PCMO generation medium induce a proliferative response in a subset of monocytes through activation of MEK/ERK1/2 signaling (see Figure '
p5739
aS'The present data reveal that EGF and HB-EGF improve the proliferation of PCMOs by superactivating MEK/ERK signaling.'
p5740
ag712
aS'DUB: De-ubiquitinating enzyme; EGF: Epidermal growth factor; EGFR: Epidermal growth factor receptor; ERK: Extracellular signal-regulated kinase; Cbl: Casitas b-lineage lymphoma; RTK: Receptor tyrosine kinase; EPS15: Epidermal growth factor receptor substrate 15; MVB: Multivesicular body; UIM: Ubiquitin-interacting motif; HRS: Hepatocyte growth factor-regulated tyrosine kinase substrate; HECT: Homologous to the E6-AP carboxyl terminus; STAMP: Signal transducing adaptor molecule; STAMBP: STAM binding protein; USP8: Ubiquitin specific peptidase 8; Rab5: Ras-related protein Rab5; GEF: Guanine nucleotide exchange factor; GA: Benzoquinone ansamycin Geldanamycin; JNK: c-Jun N-terminal kinase; MEKK1: MEK kinase 1; ITCH Itchy: E3 ubiquitin protein ligase; NEDD4: Neural precursor cell expressed developmentally down-regulated protein 4; Rpn4: Regulatory particle non-ATPase; RING1B: Really interesting new gene 1 protein.'
p5741
ag713
ag714
ag715
ag716
ag717
ag718
aS'We show that MDA-MB-231 breast tumour cells negatively regulate CCN2 and type I collagen gene expression in CCD-1068SK fibroblasts in a Smad7-dependent manner through decreased activation of the MEK/ERK signalling pathway.'
p5742
aS'Previous studies have shown that the MEK/ERK signalling pathway is a positive regulator of CCN2 gene expression ['
p5743
aS'To determine whether decreased activation of the MEK/ERK signalling pathway could be associated with decreased expression of CCN2 and type I collagen, CCD-1068SK fibroblasts were cultured in the presence of the MEK pathway inhibitor U0126.'
p5744
aS'Investigating the intracellular signalling events leading to CCN2 and type I collagen down-regulation, we found that tumour cell-mediated up-regulation of Smad7 negatively affected the MEK/ERK pathway.'
p5745
aS'Previous studies have suggested that Ras/MEK/ERK signalling positively regulates CCN2 promoter activity and is required for basal CCN2 promoter activity ['
p5746
aS'BDNF: Brain-derived neutrophic factor; CAV: Caveolin; CN: Clinostat; CTGF: Connective tissue growth factor; EGF: Epidermal growth factor; ERK: Extracellular signal-regulated kinase; FCS: Fetal calf serum; FTC: Follicular thyroid cancer; GBF: Ground-based facilities; GM-CSF: Granulocyte-macrophage colony-stimulating factor; IFN: Interferon; IL: Interleukin; ITBG1: Integrin beta 1; LDD: Least detectable dose; MAP: Multi-Analyte Profiling; MCP: Monocyte chemotactic protein; MCTS: Multicellular tumor spheroids; MEK: Mitogen-activated protein kinases; MIP: Macrophage inflammatory protein; MMP: Matrix metalloproteinase; MRNA: Messenger ribonucleic acid; PCR: Polymerase chain reaction; PDGFR: Platelet-derived growth factor receptor; PRKCA: Protein kinase C alpha; RBM: Rules-based medicine; RPM: Random positioning machine; RWV: Rotating Wall Vessel; SCF: Stem cell factor; SD: Standard deviation.'
p5747
aS'It is not surprising that co-incubation of MEKi with FGF2 was expected to show uniform inhibition of pERK.'
p5748
aS'One of the sets gave almost no response to MEKi while two others incorrectly predicted pERK response to stimulation by FGF2.'
p5749
aS'As expected previously, matching model prediction with the more stringent experimental test of fitting pERK response to FGF2 and MEKi scheduled with a time lag helps identify physiologically relevant parameter sets for the FGFR pathway.'
p5750
aS'where m is equal to the number of FGF concentrations used, n is equal to the number of intracellular molecules considered (ERK, MEK, FRS2 and FGFR) and m(i,j) is equal to the peak level of phosphorylated molecules of species j for FGF concentration '
p5751
aS'Western blotting showed ILK expression and phosphorylation of MEK1/2 and ERK1/2 in MKN45 cells treated with MG132.'
p5752
ag719
aS'In addition to the MEK/ERK pathway, PI3K-Akt pathway also plays a critical role in cell survival.'
p5753
aS'(B) PDGF maintained increased phosphorylation of ERK for at least 1 h, and this effect was abolished by PDGF receptor antagonist STI-571, MEK inhibitor U0126 but not by PI3-K inhibitor LY294002; STI: STI-571: LY: LY294002.'
p5754
aS'ERK5 is a non-redundant mitogen-activated protein kinase (MAPK) stimulated in response to growth factors and cellular stresses via the MAPK kinase 5 (MEK5) ('
p5755
ag720
ag721
ag722
aS'We also detected the activation of extracellular signal-regulated kinase (ERK) and the knockdown of ERK regulator mitogen-activated protein kinase kinase (MEK)1/2 or overexpression of a dominant-negative (DN) ERK inhibited CB-induced glioma cell death upstream of the mitochondria.'
p5756
aS'Furthermore, MEK inhibitors or overexpression of a DN ERK failed to significantly inhibit X-ray-induced T98G and U251 cell death.'
p5757
aS'Bim is known to be critical in killing of melanoma cells by inhibition of the RAF/MEK/ERK pathway.'
p5758
aS'It is well established that blockade of the RAF/MEK/ERK pathway inhibits melanoma cell growth.'
p5759
aS'Several mechanisms have been reported to contribute to apoptosis induced by inhibition of the RAF/MEK/ERK pathway.'
p5760
aS'Immunoblotting was performed with the following antibodies: p-AKTser473 (Cell Signaling 9271), AKT (Cell Signaling 9272), p-mTOR (Cell Signaling 2971), p-ERK (Cell Signaling 4377), ERK (Cell Signaling 4695), p-MEK (Cell Signaling 2338) and MEK (Cell Signaling 4694).'
p5761
aS'Other reports suggest involvement of the MAP/ERK kinase (MEK)-1/-2 pathway in vacuolation.'
p5762
ag723
ag724
ag725
ag726
ag727
ag728
ag729
aS'The primary antibodies used in this study pSrc (Y416), Src, MEK1, phospho-ERK1/2 (Thr202/Tyr204), ERK1/2 PTEN, cleaved caspase-3, cleaved caspase-7, cleaved-PARP, phosphor-AKT (Ser473), AKT, pBAD (Ser112), BAD, ATG-5, Mcl-1, LC3 I/II, Bcl-2, PDGFR'
p5763
aS'In this study, we show that Bmf is regulated at the post-translational level by mutant B-RAF-MEK-ERK2 signaling.'
p5764
aS'The basal MEK/ERK pathway activity is low in 293FT cells and no apparent electrophoretic mobility shift was detected when Bmf was expressed alone or together with ERK2 WT ('
p5765
aS'Our studies relate to cell survival mechanisms in mutant B-RAF melanomas with elevated MEK-ERK1/2 pathway activity.'
p5766
aS'Inhibiting the upstream MAPK/ERK1/2 kinase (MEK) by adding U0126 with each dose of MPP'
p5767
aS'Specifically, Myc-mediated transcription (downstream of MEK-ERK signaling) both enhances glucose uptake and diverts glucose carbon into the nonoxidative pentose phosphate pathway to facilitate nucleotide biosynthesis.'
p5768
aS'As MEK/ERK activity can phosphorylate Bim'
p5769
aS'Although the role of MEK/ERK signaling in phosphorylation of Bim'
p5770
aS'Activation of the MEK/ERK pathway has been well documented to protect cells from ER stress-induced apoptosis.'
p5771
aS'The siRNA constructs used are: MEK1 siGENOME SMARTpool (M-003571-01-0010), ERK1 siGENOME SMARTpool (M-003592-03-0005), ERK2 siGENOME SMARTpool (M-003555-04-0005), CHOP siGENOME SMARTpool (M-004819-03-0005), and non-targeting siRNA pool (D-001206-13-20) as control.'
p5772
aS'Whereas our results show that Bak apoptotic function is not directly regulated by phosphorylation, multiple targets upstream of Bak may be regulated by phosphorylation, and thus account for the ability of MEK/ERK signaling and PTPN5 to regulate Bak-mediated apoptosis.'
p5773
ag730
aS'To further examine whether the promoting effect of mutant p53 on EGF-induced sustained ERK1/2 activation is due to enhanced phosphorylation of ERK1/2 or decreased dephosphorylation of phosphorylated-ERK1/2 (p-ERK1/2), p53-273H-expressing or control H1299 cells were pre-treated with EGF before the addition of MEK-1 (MAP ERK kinase) inhibitor U0126 at the different time points.'
p5774
aS'To clarify the signaling pathways in ESA-mediated apoptosis, we investigated the functions of RIP1, MEK, ERK, as well as AIF.'
p5775
aS'Necrostatin (Nec)-1 blocked MEK/ERK phosphorylation and ESA-mediated apoptosis.'
p5776
aS'Nec1 blocked the interaction of MEK with ERK upon ESA stimulation.'
p5777
aS'Here, we show that a novel RIP1-dependent apoptotic cell death induced by ESA is mediated through MEK/ERK pathway.'
p5778
aS'MEK/ERK pathway appears to be involved in ESA-mediated apoptosis.'
p5779
aS'RIP1 constitutively associates with ERK1/2, and transiently associates with MEK2.'
p5780
aS'RIP1 can mediate MEK/ERK signaling cascades in a manner different from that previously published, such as dephosphorylation.'
p5781
aS'We conclude that ESA activates phosphatases such as calcineurin followed by dephosphorylation of RIP1 as well as AIF, which results in the activation of ERK signaling pathway through MEK1/2 activation.'
p5782
aS'Antibodies against MEK (61B12), ERK, phospho-ERK, caspase-3 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH, clone 14C10) were purchased from Cell Signaling Technology (Danvers, MA, USA).'
p5783
aS'ERK1/2 is activated through MEK1/2 phosphorylation and association with RIP1 complex.'
p5784
aS'(2) Phosphorylated MEK1/2/ activates ERK1/2 associated with RIP1.'
p5785
aS'Induction of melanoma cell death by HDAC inhibitors or blockade of the RAF/MEK/ERK pathway is associated with the up-regulation of Bim and the downregulation of Mcl-1.'
p5786
aS'Although we and others have previously found that upregulation of Bim is important for killing of sensitive melanoma cells by inhibition of the MEK/ERK pathway,'
p5787
aS'The effect of ROS on the mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK)-extracellular signal-regulated kinase (ERK) 1/2 pathway may be another possible mechanism underlying MK commitment.'
p5788
aS'This analysis identified activation of known DNA damage response pathways (e.g., phosphorylation of MKK3/6, p38, MK2, Hsp27, p53 and Chk1) as well as of prosurvival (e.g., MEK-ERK, cAMP response element-binding protein (CREB), protein kinase C (PKC)) and antiapoptotic markers (e.g., Bad, Bcl-2).'
p5789
aS'To elucidate whether PKC or other main signaling cascades regulate cell viability in NHFs upon IR treatment, a radiosensitivity screen with inhibitors specific for key components of the MEK-ERK, p38, JNK or PKC pathways was performed ('
p5790
aS'Previously, RAF/MEK/ERK-mediated signaling was implicated in the sorafenib-induced anticancer effect.'
p5791
ag733
aS'These data together suggest that inhibition of the MEK/ERK and PI3K/AKT pathways is closely related to the antitumor activity of statins in various tumors.'
p5792
ag734
aS'Several solid tumors have a hyper-activated MEK/ERK pathway and ERK was already proposed to be a regulator of MT dynamics and mitosis.'
p5793
aS'Obserivng the relationship among P-FAKSer732, MEK/ERK activation and polymerized tubulin ('
p5794
aS'MEK/ERK pathway is one of the downstream effector of EGFR'
p5795
aS'These data strongly indicate that EGFR/MEK/ERK/CDK5 pathway induces the phosphorylation of FAK at Ser732 independently from the FAK autophosphorylation, thus contributing to spindle formation and mitosis of tumor cells.'
p5796
aS'Hence, FAK can exert in tumor cells a dual role: one, fully described elsewhere, integrin-dependent associated to phosphorylation of Tyr397 and -576 with a role in migration, and the other, characterized here for the first time, integrin-independent associated to phosphorylation on Ser732 upon activation of the EGFR/MEK/ERK/CDK5 pathway, regulating MT dynamics.'
p5797
aS'We also showed that P-FAKSer732 was generated by the activation of the EGFR/MEK//ERK/CDK5 signaling.'
p5798
aS'The MEK/ERK pathway is involved in the phosphorylation at Ser732 associated with polymerized MTs.'
p5799
aS'EGF-dependent EGFR/MEK/ERK/CDK5 pathway induces P-FAKSer732, thus contributing to mitosis.'
p5800
ag735
aS'In this study, we showed that ERK MEKs and PI3K/Akt pathways are coregulated in NPCs cotransduced and transfected with miR-9 lentivirus/MCPIP1-overexpressing constructs ('
p5801
ag736
ag737
aS'There is substantial cross-talk between PI3K/AKT and MEK/ERK pathways, and the inhibition of either pathway leads to activation of the other one.'
p5802
ag738
aS'However, in our study, the MEK inhibitor U0126 did not block DC120-induced phosphorylation of P70S6K and 4E-BP1, and the mTORC1 inhibitor RAD001 did not alleviate the phosphorylation of ERK1/2 ('
p5803
aS'To further elucidate the role of p38 and ERK1/2 signaling in BMP-2-induced Runx2 activity in an inflammatory environment, we ectopically induced p38 and ERK1/2 signaling activation before exposure to BMP-2 by transfection with CA-MKK3 or CA-MEK1, respectively.'
p5804
aS'Transfection with CA-MKK3 or CA-MEK1 induced strong expression and phosphorylation of p38 and ERK1/2 signaling, respectively, in C2C12 cells without BMP-2 or TNF-'
p5805
aS'PI3K/AKT and MEK/ERK pathways have pivotal role in fundamental cellular functions such as cell proliferation, cell growth, and survival by phosphorylating a variety of substrates.'
p5806
aS'Anti-Gli1 (3538), anti-Phospho-MEK1/2 (9154), anti-MEK1/2 (9126), anti-Phospho-ERK1/2 (4344), anti-ERK1/2 (4695), and anti-'
p5807
aS'We reported earlier that MM activated MEK1/2 (assessed by ERK1/2) and downstream JNK pathways, and thereby affected cultured astrocytes.'
p5808
aS'TrkA can activate PI3K/Akt, MEK/ERK1/2 and phospholipase C (PLC) signalling pathways.'
p5809
ag740
aS'Silencing ADCY5 stimulated EGFR translocation to mitochondria, resulting in upregulation of ERK and MEK.'
p5810
ag741
aS'Our findings indicate that RAGE preferentially binds to mutant KRAS to activate the RAF-MEK-ERK and PI3K-AKT pathways, which contributes to HIF1'
p5811
ag742
ag743
ag744
ag745
aS'MEK1 and MEK2, two kinases upstream of ERK, have been shown to regulate cell cycle progression in two distinct ways ['
p5812
aS'Regardless of the nature of the upstream signal, MEK1 autoactivation represents an alternate means of ERK pathway activation.'
p5813
ag746
aS'The experiments above indicate that MEK, ERK, MLCK, and Myosin II each contribute partially to SCV-associated F-actin.'
p5814
aS'To study whether MEK, ERK, and Myosin are in the same SteC-induced pathway, we examined SCV-associated Myosin IIB in cells depleted of ERK1/2 or MEK1/2.'
p5815
ag747
aS'MEK and ERK Contribute to F-Actin Meshwork Formation'
p5816
aS'MEK1 phosphorylation leads to the activation of a signal transduction pathway involving ERK, MLCK, and Myosin IIB to induce cytoskeletal rearrangements in the vicinity of '
p5817
aS'Activation of the EGFR induces cell survival by stimulating the Ras-MEK-ERK and phosphoinositol 3-phosphate kinase (PI3K)-Akt pathways.'
p5818
aS'In particular, evidence obtained in HT-29 CRC cells revealed induction of autophagy through the extracellular signal-regulated kinases ERK1 and ERK2, when stimulated by the RAS-RAF-MEK pathway ['
p5819
aS'In this context, MAPK/ERK kinase kinase 3 (MEKK3) is activated by autophosphorylation of Ser526.'
p5820
aS'The ERK pathway represents the prototypical example of a mitogen-activated protein kinase (MAPK) cascade where ERK (a MAPK) is activated by MEK, a MAPK kinase (MAPKK), which in turn is activated by RAF, a MAPKK kinase (MAPKKK).'
p5821
aS'Subsequently, different signaling molecules are recruited to the activated receptors, which leads to activation of kinases such as the Ser/Thr kinase RAF (rapidly accelerating fibrosarcoma) which in turn phosphorylates and activates MEK (MAP kinase kinase, a dual specificity Tyr/Thr kinase) which is responsible for activating the MAP kinases such as extracellular signal regulated kinases 1 and 2 (ERK1/2).'
p5822
aS'Knockdown of flotillin-2 in HeLa cells was accompanied by an increase in the basal phosphorylation of the cRAF kinase, MEK1/2 and ERK1/2, indicating that the ERK1/2 pathway is overactive in the absence of flotillin-2 ['
p5823
aS'Under non-pathological conditions, MAPK/ERK signaling components are expressed in most regions of the brain, and show a largely overlapping expression pattern (with the exception of MEK2, which is almost completely absent) ['
p5824
ag750
ag751
aS'We have explored the possible role of dual specificity phosphatases (DUSPs) on acute EGF-mediated ERK signalling using high content imaging and a delayed MEK inhibition protocol to distinguish direct and indirect effects of the phosphatases on ERK activity.'
p5825
aS'They are activated by MAPK/ERK kinases (MEKs) 1 and 2 which catalyse the phosphorylation of Thr and Tyr residues in the ERK TEY activation loops '
p5826
aS'The effect of the MEK inhibitor demonstrates the importance of continuous MEK activity for the observed ppERK1/2 responses and provides a method for monitoring the kinetics of ERK inactivation in isolation.'
p5827
aS'That is, in normal cells ppERK1/2 responses are shaped by feed-forward activation of MEK and by negative feedback and cross-talk from other MAPK pathways upstream of MEK, as well as by direct dephosphorylation of ERK1/2, but if MEK could be completely and instantly inhibited (MEK inhibition after stimulation) ERK1/2 inactivation kinetics would reflect solely the direct dephosphorylation of ppERK1/2.'
p5828
aS'Together, the mathematical and experimental approaches described above demonstrate the potential for modulation of basal and stimulated ppERK1/2 levels by direct alteration of dephosphorylation or by alteration of feedback, and the utility of delayed MEK inhibitor protocol for delineating these direct and indirect effects.'
p5829
aS'The data above suggest that the JNK/p38 MKPs have no direct effect on ERK activity in cells acutely stimulated with EGF (because they have no effect on inactivation kinetics in the presence of the MEK inhibitor) but instead have an indirect positive regulatory effect that is overcome by siRNA-mediated knock-down.'
p5830
aS'We have explored the possible role of DUSPs on acute EGF-mediated ERK signalling using high content imaging and a delayed MEK inhibition protocol to distinguish direct and indirect effects on ERK activity.'
p5831
aS'Rates of ERK inactivation after MEK inhibition were estimated (assuming exponential decay after MEK addition).'
p5832
aS'Finally, oncogenic Ras is able to provide resistance to pro-apoptotic cisplatin-based chemotherapy in part via modulating MEK-ERK signaling '
p5833
ag752
aS'EGFR signals through the RAS/RAF/MEK/ERK and PI3K/AKT pathways to promote cellular proliferation and survival.'
p5834
aS' drugs inhibiting RAS-RAF-MEK-ERK pathway,'
p5835
aS'The RAS-RAF-MEK-ERK which is involved in regulation of cell cycle is activated in many cancers due to mutations in BRAF or RAS genes ['
p5836
aS'MEK: MAPK (mitogen-activated protein kinase) kinases/extracellular-signal-regulated kinases, ERK: extracellular-signal-related kinase; PTEN: phosphatase and tensin homolog, mTOR: mammalian target of rapamycin. '
p5837
aS'The RAF/MEK/ERK pathway was the first RAS effector pathway identified and the best characterized.'
p5838
aS'Arsenic trioxide is a potent inducer of autophagy in acute leukemia cells, and such induction is dependent on activation of the MEK/ERK pathway but uncoupled from JNK.'
p5839
ag753
ag756
aS'B-RAF and MEK are both involved in the RAS-RAF-MEK-ERK cascade signaling pathway, regulating several important cellular functions, such as cell survival, proliferation, and apoptosis resistance'
p5840
aS'MEK/ERK-dependent B7-H1 expression in HSCs.'
p5841
ag757
ag758
aS'Genetic aberrations in the MAPK pathway are present in over 80% of cutaneous melanomas, involving abnormalities in RAS, RAF, MEK and ERK.'
p5842
aS'RAS in turn activates RAF (proto-oncogene RAF protein), MEK, and ERK through phosphorylation ('
p5843
aS'Selumetinib (AZD6244/ARRY-142886, AstraZeneca) is an orally active new inhibitor that binds to MEK to block the RAF/MEK/ERK pathway, which appears to be the most significant signaling pathway in HCC development ('
p5844
ag1878
aS'To further characterize global ERK1/2-induced changes in membrane protein phosphorylation within human RBCs, a label-free quantitative phosphoproteomic analysis was applied to sickle and normal RBC membrane ghosts pre-treated with U0126, a specific inhibitor of MEK1/2, the upstream kinase of ERK1/2, in the presence or absence of recombinant active ERK2.'
p5845
aS'The abundance of twelve of the thirty-six phosphopeptides were subsequently increased in normal RBCs co-incubated with recombinant ERK2 and therefore represent specific MEK1/2 phospho-inhibitory targets mediated via ERK2.'
p5846
aS'These findings also identify additional protein targets of this pathway other than the RBC adhesion molecule ICAM-4 and enhance the understanding of the mechanism of small molecule inhibitors of MEK/1/2/ERK1/2, which could be effective in ameliorating RBC hemorheology and adhesion, the hallmarks of SCD.'
p5847
aS'Recently, we have shown that extracellular signal-regulated kinase (ERK1/2) is hyperactive and can be inducible in SS but not in AA RBCs, and can act downstream of the cAMP/PKA/MEK1/2 pathway\n['
p5848
aS'To further characterize global MEK1/2/ERK1/2-induced changes in protein phosphorylation within human RBCs, we employed a previously established label-free quantitative phosphoproteomics strategy to the plasma membrane ghosts of human RBCs\n['
p5849
aS'To further characterize global MEK1/2/ERK1/2-induced changes in protein phosphorylation within human SS RBCs, a global label-free quantitative phosphoproteomic discovery analysis of SS and AA RBC plasma membrane ghosts was performed\n['
p5850
aS'Putative downstream targets specific to MEK1/2-dependent activation of ERK1/2 were initially identified in SS RBCs, in which 36 unique phosphopeptides (from 21 unique phosphoproteins) decreased in abundance upon treatment with U0126.'
p5851
aS'Here we applied a label-free quantitative phosphoproteomic strategy to characterize signaling pathways from healthy and sickle RBC membrane fractions in the presence or absence of a specific MEK1/2 inhibitor with and without subsequent ERK2 activation.'
p5852
aS'Interestingly, these data revealed that glycophorin A phosphorylation was highly differentiated between healthy and sickle RBCs, and its levels of phosphorylation were modulated by the presence of the MEK1/2 inhibitor U0126 and the presence of exogenously spiked ERK2.'
p5853
aS'PKA, protein kinase A; DARPP-32, dopamine-and cAMP-regulated phosphoprotein with molecular weight 32; CREB, cAMP response element-binding; GSK-3, glycogen synthase kinase-3; Dvl, dishevelled; ERK1/2, extralcellular signal-regulated kinases 1/2; MEK, mitogen-activated protein kinase kinase; p90RSK, p90 ribosomal S6 kinase; PP2A, protein phosphatase 2A; EGF, epidermal growth factor; MKP1, mitogen-activated protein kinase phosphatases 1.'
p5854
aS'4EBP1: eukaryotic translation initiation factor E4-binding protein 1; BAC: bacterial artificial chromosome; CNA: copy number alterations; CSF1R: colony-stimulating factor 1 receptor; DAPI: 4.6-diamidino-2-phenylindole; EGFR: epidermal growth factor receptor; ERK1/2: extracellular signal-regulated kinase; fdr: false discovery rate; HER2: v-ERBB2 Avian erythroblastic leukemia viral oncogene homolog 2; IHC: immunohistochemistry; IS: intimal sarcoma; MEK: mitogen-activated kinase kinase kinase 1; mTOR: mammalian target of rapamycin; NCBI: National Center for Biotechnology Information; PCR: polymerase chain reaction; PDGFR: platelet derived growth factor receptor; PI3K: phosphatidyl inositol 3 kinase; PKB or AKT: protein kinase B; RTK: receptor tyrosine kinase; S6K: ribosomal protein S6 kinase; SG: spectrum green; SO: spectrum orange; TK: tyrosine kinase; TKI: tyrosine kinase inhibitors; TMA: tissue microarrays.'
p5855
ag759
aS'MEK, MAPK/ERK kinase.'
p5856
aS'Further experiments revealed that the MEK (mitogen-activated protein kinase/ERK kinase) inhibitor PD98059 potently inhibited ERK phosphorylation, as expected, and increased primary hepatocyte apoA-I production by 3-fold.'
p5857
aS'PD98059 is a potent inhibitor of MEK, the kinase that activates ERK.'
p5858
aS'Sorafenib induces growth inhibition and apoptosis in human HCC cells by inhibiting the RAF/MEK/ERK signaling pathway.'
p5859
aS'In this study, the activity of the RAF/MEK/ERK signaling pathway was determined by measuring the levels of ERK phosphorylation by Western blot analysis of HepG2 cells treated with sorafenib and VK2, either alone or in combination.'
p5860
aS'Previous studies have revealed that VK2 itself can inhibit the RAF/MEK/ERK signaling pathway by inhibiting RAS/RAF activation, thus causing a decrease in the levels of phosphorylated ERK in several cancer cell lines, including HCC HuH7 cells ('
p5861
ag760
ag761
aS'In addition, inactivated or absent menin promotes RAS expression; activating mutations of RAF, MEK, or ERK may accelerate cell proliferation ('
p5862
aS'The MEK-ERK pathway was early suggested as being involved in the activation of SOCE in human platelets, probably as a downstream effector of Ras proteins,'
p5863
aS'PP-induced suppression of hepatocyte apoptosis was shown to rely upon the activation of the MEK/ERK signalling pathway ['
p5864
aS'Phosphorylation of MEK1/2, upstream signal of ERK1/2, also happened.'
p5865
aS'We clarified that HSC proliferation in response to galectin-1 and galectin-3 could be mediated by a MEK1/2-ERK1/2 pathway.'
p5866
aS'It was found that some of these mutations could activate the RAF/MEK/ERK kinase pathway.'
p5867
aS'One of numerous postulated treatment strategies involves the application of the mitogen extracellular kinase (MEK) inhibitor which should block extracellular signal-regulated kinase (ERK).'
p5868
aS'Research on two MEK inhibitors showed that they protected against the abnormal activation of the RAF/MEK/ERK signal pathway.'
p5869
ag762
aS'K-RAS mutations yield a defective GTPase activity and then an increased population of active K-RAS protein, activating signaling in two pathways, PI3K/PTEN/AKT and RAF/MEK/ERK which are involved in cell proliferation, survival and angiogenesis.'
p5870
ag2309
aS'PE-induced IL-8 expression is also abolished in the presence of the MEK inhibitor U0126, indicating the involvement of ERK1/2 in this process.'
p5871
aS'The treatment of cells with PD98059, a selective inhibitor of ERK kinase (MEK), blocked both the protective effect of DADLE and the ERK phosphorylation induced by DADLE.'
p5872
aS'This activation induces mitogen ERK kinase kinase 2 (MEKK2) and c-jun N-terminal kinase (JNK) activation and phagocytosis of proatherogenic ox-LDL ['
p5873
aS'One of the most highly studied MAPK pathways is the extracellular signal-regulated kinase (ERK1/2) pathway, which transmits its signals through a series of activation steps involving receptor tyrosine kinases (RTKs), Ras, RAF (MAP3K), MEK (MAP2K), and ERK (MAPK).'
p5874
aS'We will highlight the development of direct and cascade assays for the RAF-MEK-ERK pathway using C-RAF, B-RAF, and B-RAF V599E.'
p5875
aS'The following kinases were all full-length: B-RAF, unactive MEK1, active MEK1, unactive-fluorescein-labeled MEK1, active ERK2, and unactive ERK2.'
p5876
aS'For double (MEK-ERK) and triple (RAF-MEK-ERK) cascade assays, it was necessary to first optimize the concentration of the unactivated kinase(s) prior to optimizing the concentration of the active kinase; this procedure is explained in the Results section.'
p5877
aS'Using this FRET-based method, cascade and direct assays were configured in order to recapitulate the RAF-MEK-ERK signaling pathway '
p5878
aS'After defining the optimal concentration of unactivated ERK2 to use in the assay, we then optimized the concentration of MEK1.'
p5879
aS'In the case of the double cascade, active MEK1 was titrated with 140 nM unactivated ERK2 and ~50% phosphorylation of the substrate was seen with ~8 nM active MEK1 (Fig. '
p5880
aS'The third step in the assay optimization process was to titrate each RAF isoform against unactivated MEK1 and ERK2 at the optimal concentration of each, as determined above (Fig. '
p5881
aS'The RAF/MEK/ERK signaling pathway is ubiquitious in eukaryotic cells and regulates numerous physiologic processes such as cellular proliferation, differentiation, and survival ['
p5882
aS'Traditional radiometric RAF/MEK/ERK cascade assays have been reported ['
p5883
aS'The RAF/MEK/ERK signaling pathway forms a critical link between extra-cellular stimuli and intra-cellular responses that ultimately regulate cellular proliferation, differentiation, mobility, and survival.'
p5884
aS'Schematic of fluorescent assay formats used to characterize kinase inhibitors within the RAF-MEK-ERK pathway.'
p5885
aS'(D) Linear plots of the percent phosphorylation achieved for each of the triple cascades with increasing concentrations of active RAF isoform, using the optimized concentrations for unactive MEK1 (20 nM) and unactive ERK2 (140 nM), with R'
p5886
aS'ERK1/2 are activated via dual phosphorylation on specific tyrosine (Tyr204) and threonine (Thr202) residues by mitogen-activated or extracellular signal-regulated protein kinase kinase (MEK).'
p5887
aS'Radiation activates the MEK/ERK signaling pathway by increasing ROS generation.'
p5888
aS'For example, the somatic mutation V599E in BRAF, commonly observed in melanoma, is known to activate the MEK-ERK cascade constitutively ['
p5889
aS'BRD7 inhibits NPC cell cycle progression, preventing passage through G0/G1 by suppressing ras/MEK/ERK, Rb/E2F and Wnt signaling pathways.'
p5890
aS'Extra-cellular signals can be transmitted into the nucleus cell cycle machinery through diverse signaling pathways, among which MEK/ERK/MAPK is one intensively studied pathways ['
p5891
ag766
aS'Therefore, inhibition of MEK-mediated ERK activation is very appealing in cancer therapy.'
p5892
aS'Although complex reasons may have contributed to this outcome, an alternative possibility is that the MEK-ERK pathway may not solely provide proliferation signals to malignancies, the central scientific rationale in developing MEK inhibitors for cancer therapy.'
p5893
aS'Accumulating evidence now demonstrated that the MEK-ERK pathway contributes to the proper execution of cellular DNA damage response (DDR), a major pathway of tumor suppression.'
p5894
aS'During DDR, the MEK-ERK pathway is commonly activated, which facilitates the proper activation of DDR checkpoints to prevent cell division.'
p5895
aS'Inhibition of MEK-mediated ERK activation, therefore, compromises checkpoint activation.'
p5896
aS'ERK1 and ERK2 (ERK1/2) kinases belong to the mitogen-activated protein kinase (MAPK) family and are activated by two highly conserved upstream kinases, MEK1/2 (MAPK kinase).'
p5897
aS'Inhibition of ERK activation with the commonly used MEK inhibitors (PD98059 and U0126) and a dominant negative MEK1K97M attenuates ETOP and HU-induced G2/M and S phase arrest in several cell lines, including NIH3T3, MCF7, MEF, and HCT116 ['
p5898
aS'While the underlying mechanisms responsible for DNA damage-induced ERK activation remain elusive, the accumulating evidence indicates that MEK mediates ERK activation in DDR.'
p5899
aS'The inhibition of MEK activation with MEK inhibitors (PD98059, U0126), a dominant negative MEK1K97M, and MEK siRNA inhibited ERK activation that is induced by a variety of genotoxic agents ['
p5900
aS'Research carried out in the last decade gradually consolidated the contributions of the MEK-ERK kinases to DDR.'
p5901
aS'ERK activity is widely regarded to provide proliferation signals to cancerous cells, the main underlying reason to target ERK activation by using MEK inhibitors.'
p5902
aS'This is consistent with the observation that activation of the RAF-MEK-ERK pathway is commonly associated with chemotherapy and radiotherapy ['
p5903
aS'The contribution of ERK to DDR outlines a scientific background for a combinational therapy involving genotoxic drugs and MEK inhibitors.'
p5904
ag768
ag769
aS'For example, AM-induced proliferation and migration of lymphatic endothelial cells is mediated in part by cAMP and downstream MEK/ERK pathways ['
p5905
ag770
ag771
aS'The most commonly used strategy to prevent ERK activation is by blocking the activation of ERK by its upstream kinase MEK (Fig. '
p5906
aS'The most commonly used approach to avert ERK phosphorylation consists in blocking the interaction between phosphorylated MEK and inactive ERK.'
p5907
ag773
ag774
aS'Subsequently either 200 ml isotonic medium or 200 ml de-ionized water was added to each well, without any drug, together with 10 nM AVP; together with 1 mM AG1478 (inhibitor of EGF receptor); together with AVP and AG1478; or together with AVP and 10 mM U0126 (inhibitor of MAP kinase/ERK kinase (MEK) and thus of ERK1/2 phosphorylation), and the incubation was continued for another 22.5 min.'
p5908
aS'Another example where a pseudokinase forms complexes with active kinases are members of the kinase suppressor of Ras 1 and 2 (KSR1/2), that are essential for Ras induced activation of the RAF-MEK-ERK module in MAP kinase signalling.'
p5909
aS'When considering the cross-talk between Notch signaling and the RAS/MEK/ERK and PI-3K/Akt pathways downstream of EGFR and their roles in experimental gliomas, it is tempting to speculate that simultaneous inhibition of several of these pathways could lead to improved treatment of glioma patients.'
p5910
ag776
as(S'ZBTB18'
p5911
S'ONECUT1'
p5912
S'increases'
p5913
tp5914
(lp5915
s(S'TGIF'
p5916
S'MAX'
p5917
S'increases'
p5918
tp5919
(lp5920
s(S'ETS1'
p5921
S'NRAS'
p5922
S'increases'
p5923
tp5924
(lp5925
s(S'KLF12'
p5926
S'GATA1'
p5927
S'increases'
p5928
tp5929
(lp5930
s(S'HRAS/GTP'
p5931
S'PAK2'
p5932
S'increases_activity'
p5933
tp5934
(lp5935
s(S'CYP26A1'
p5936
S'FOXD3'
p5937
S'increases'
p5938
tp5939
(lp5940
s(S'LMO2'
p5941
S'RUNX1'
p5942
S'increases'
p5943
tp5944
(lp5945
s(S'MLK3'
p5946
S'MKK3/6'
p5947
S'adds_modification'
p5948
tp5949
(lp5950
S'MLK3 stimulates the MAPKKs MKK3/6 and MKK4, which finally activate p38 and JNK MAPKs in the last steps of initiating HSC proliferation ['
p5951
as(S'TAK'
p5952
S'MKK3/6'
p5953
S'adds_modification'
p5954
tp5955
(lp5956
s(S'GRB2:SOS1'
p5957
S'HB-EGF:P-6Y-EGFR DIMER'
p5958
S'binds'
p5959
tp5960
(lp5961
s(S'FOXO4'
p5962
S'NRAS'
p5963
S'increases'
p5964
tp5965
(lp5966
s(S'MECOM'
p5967
S'NRAS'
p5968
S'increases'
p5969
tp5970
(lp5971
s(S'KLF12'
p5972
S'CYP26A1'
p5973
S'increases'
p5974
tp5975
(lp5976
s(S'RAS family/GTP/PI3K'
p5977
S'TRPV1'
p5978
S'adds_modification'
p5979
tp5980
(lp5981
s(S'hsa-let-7a-5p'
p5982
S'NRAS'
p5983
S'decreases'
p5984
tp5985
(lp5986
s(S'NF1'
p5987
S'HOXA9'
p5988
S'increases'
p5989
tp5990
(lp5991
s(S'REPIN1'
p5992
S'FOXD3'
p5993
S'increases'
p5994
tp5995
(lp5996
s(S'CYP26A1'
p5997
S'FOXJ2'
p5998
S'increases'
p5999
tp6000
(lp6001
s(S'FOXO4'
p6002
S'MEIS1'
p6003
S'increases'
p6004
tp6005
(lp6006
s(S'EBF2'
p6007
S'MECOM'
p6008
S'increases'
p6009
tp6010
(lp6011
s(S'ETS1'
p6012
S'FOXO3'
p6013
S'increases'
p6014
tp6015
(lp6016
s(S'SP3'
p6017
S'CYP26A1'
p6018
S'increases'
p6019
tp6020
(lp6021
s(S'LNXp80'
p6022
S'NUMB'
p6023
S'decreases'
p6024
tp6025
(lp6026
s(S'RUNX2'
p6027
S'CYP26A1'
p6028
S'increases'
p6029
tp6030
(lp6031
s(S'AHR'
p6032
S'FOXO3'
p6033
S'increases'
p6034
tp6035
(lp6036
s(S'VSX1'
p6037
S'FOXF2'
p6038
S'increases'
p6039
tp6040
(lp6041
s(S'BPTF'
p6042
S'RUNX1'
p6043
S'increases'
p6044
tp6045
(lp6046
s(S'7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide'
p6047
S'HRAS PROTEIN'
p6048
S'increases'
p6049
tp6050
(lp6051
s(S'TCF3'
p6052
S'POU3F2'
p6053
S'increases'
p6054
tp6055
(lp6056
s(S'TCF3'
p6057
S'IRF1'
p6058
S'increases'
p6059
tp6060
(lp6061
s(S'SREBF1'
p6062
S'EN1'
p6063
S'increases'
p6064
tp6065
(lp6066
s(S'FOXO4'
p6067
S'RUNX2'
p6068
S'increases'
p6069
tp6070
(lp6071
s(S'hsa-miR-181a-5p'
p6072
S'HRAS'
p6073
S'decreases'
p6074
tp6075
(lp6076
s(S'Myb'
p6077
S'NRAS'
p6078
S'decreases'
p6079
tp6080
(lp6081
s(S'HSPA8'
p6082
S'ADP'
p6083
S'binds'
p6084
tp6085
(lp6086
s(S'SOCS3'
p6087
S'RASGAP'
p6088
S'binds'
p6089
tp6090
(lp6091
s(S'ONECUT1'
p6092
S'NRAS'
p6093
S'increases'
p6094
tp6095
(lp6096
s(S'PITX2'
p6097
S'EN1'
p6098
S'increases'
p6099
tp6100
(lp6101
s(S'HGF(dimer)/MET(dimer)'
p6102
S'SRC'
p6103
S'adds_modification'
p6104
tp6105
(lp6106
s(S'2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine'
p6107
S'HRAS PROTEIN'
p6108
S'increases'
p6109
tp6110
(lp6111
s(S'GFI1'
p6112
S'POU3F2'
p6113
S'increases'
p6114
tp6115
(lp6116
s(S'FARNESYL DIPHOSPHATE'
p6117
S'KRAS'
p6118
S'increases_activity'
p6119
tp6120
(lp6121
s(S'IL2/IL2R BETA/GAMMA/JAK1/LCK/JAK3'
p6122
S'PI3K'
p6123
S'binds'
p6124
tp6125
(lp6126
s(S'GTF3A'
p6127
S'MECOM'
p6128
S'increases'
p6129
tp6130
(lp6131
s(S'EGR2'
p6132
S'CYP26A1'
p6133
S'increases'
p6134
tp6135
(lp6136
s(S'RUNX1'
p6137
S'FOXF2'
p6138
S'increases'
p6139
tp6140
(lp6141
s(S'IL3/IL3RA/CSF2RB (DODECAMER)'
p6142
S'YWHAZ'
p6143
S'binds'
p6144
tp6145
(lp6146
s(S'RAF1'
p6147
S'BRAF'
p6148
S'binds'
p6149
tp6150
(lp6151
g5680
as(S'MYC'
p6152
S'CYP26A1'
p6153
S'increases'
p6154
tp6155
(lp6156
s(S'UBP1'
p6157
S'CYP26A1'
p6158
S'increases'
p6159
tp6160
(lp6161
s(S'MTF1'
p6162
S'REPIN1'
p6163
S'increases'
p6164
tp6165
(lp6166
s(S'HNF1A'
p6167
S'RUNX1'
p6168
S'increases'
p6169
tp6170
(lp6171
s(S'NHLH1'
p6172
S'FOXA1'
p6173
S'increases'
p6174
tp6175
(lp6176
s(S'HLF'
p6177
S'FOXA1'
p6178
S'increases'
p6179
tp6180
(lp6181
s(S'MEIS1'
p6182
S'GATA6'
p6183
S'increases'
p6184
tp6185
(lp6186
s(S'PDGF-BB/PDGFRB (DIMER)/SHP2'
p6187
S'GRB2/SOS1'
p6188
S'binds'
p6189
tp6190
(lp6191
s(S'ZBTB14'
p6192
S'EN1'
p6193
S'increases'
p6194
tp6195
(lp6196
s(S'alpha6/beta4 Integrin'
p6197
S'HRAS/GDP'
p6198
S'increases_activity'
p6199
tp6200
(lp6201
s(S'ErbB2'
p6202
S'HRAS/GDP'
p6203
S'increases_activity'
p6204
tp6205
(lp6206
s(S'MEIS1'
p6207
S'FOXO3'
p6208
S'increases'
p6209
tp6210
(lp6211
s(S'RELA'
p6212
S'IRF1'
p6213
S'increases'
p6214
tp6215
(lp6216
s(S'MYCN'
p6217
S'FOXO3'
p6218
S'increases'
p6219
tp6220
(lp6221
s(S'RHOA/GTP'
p6222
S'DIA'
p6223
S'increases_activity'
p6224
tp6225
(lp6226
s(S'Fluorouracil'
p6227
S'KRAS PROTEIN'
p6228
S'decreases'
p6229
tp6230
(lp6231
s(S'ATF2'
p6232
S'CYP26A1'
p6233
S'increases'
p6234
tp6235
(lp6236
s(S'GNAI2/GTP'
p6237
S'SRC FAMILY KINASES'
p6238
S'increases_activity'
p6239
tp6240
(lp6241
s(S'HAND1'
p6242
S'POU2F1'
p6243
S'increases'
p6244
tp6245
(lp6246
s(S'PI5K Type 1 family'
p6247
S'PI-4-P'
p6248
S'translocates'
p6249
tp6250
(lp6251
s(S'HSF1'
p6252
S'CBFA2T3'
p6253
S'increases'
p6254
tp6255
(lp6256
s(S'BACH1'
p6257
S'FOXA1'
p6258
S'increases'
p6259
tp6260
(lp6261
s(S'PI-3-4-5-P3'
p6262
S'SGK1'
p6263
S'adds_modification'
p6264
tp6265
(lp6266
s(S'hsa-miR-20a-5p'
p6267
S'NRAS'
p6268
S'decreases'
p6269
tp6270
(lp6271
s(S'CYP26A1'
p6272
S'MECOM'
p6273
S'increases'
p6274
tp6275
(lp6276
s(S'FOXF2'
p6277
S'RUNX1'
p6278
S'increases'
p6279
tp6280
(lp6281
s(S'EGR2'
p6282
S'SRF'
p6283
S'increases'
p6284
tp6285
(lp6286
s(S'LEF1'
p6287
S'FOXD3'
p6288
S'increases'
p6289
tp6290
(lp6291
s(S'TFAP2C'
p6292
S'MECOM'
p6293
S'increases'
p6294
tp6295
(lp6296
s(S'SHC'
p6297
S'GRB2/SOS1'
p6298
S'binds'
p6299
tp6300
(lp6301
s(S'CA2+'
p6302
S'CAM'
p6303
S'binds'
p6304
tp6305
(lp6306
s(S'MYC'
p6307
S'POU3F2'
p6308
S'increases'
p6309
tp6310
(lp6311
s(S'PAX8'
p6312
S'HOXA9'
p6313
S'increases'
p6314
tp6315
(lp6316
s(S'TFDP2'
p6317
S'CDC5L'
p6318
S'increases'
p6319
tp6320
(lp6321
s(S'RAF1/14-3-3'
p6322
S'KSR/14-3-3 /MEK1-2'
p6323
S'increases_activity'
p6324
tp6325
(lp6326
s(S'DDIT3'
p6327
S'MEIS1'
p6328
S'increases'
p6329
tp6330
(lp6331
s(S'GNB1/GNG2'
p6332
S'HRAS/GDP'
p6333
S'increases_activity'
p6334
tp6335
(lp6336
s(S'ACTIVATED FGFR MUTANTS:P-FRS2ALPHA'
p6337
S'GRB2:SOS1'
p6338
S'binds'
p6339
tp6340
(lp6341
s(S'HIF1A'
p6342
S'CYP26A1'
p6343
S'increases'
p6344
tp6345
(lp6346
s(S'RAF1-BRAF'
p6347
S'ERK1-2'
p6348
S'increases_activity'
p6349
tp6350
(lp6351
s(S'SMAD4'
p6352
S'CBFA2T3'
p6353
S'increases'
p6354
tp6355
(lp6356
s(S'resveratrol'
p6357
S'HRAS PROTEIN'
p6358
S'increases'
p6359
tp6360
(lp6361
s(S'Malathion'
p6362
S'HRAS MRNA'
p6363
S'increases'
p6364
tp6365
(lp6366
s(S'NRF1'
p6367
S'FOXO4'
p6368
S'increases'
p6369
tp6370
(lp6371
s(S'CREB1'
p6372
S'JUN'
p6373
S'increases'
p6374
tp6375
(lp6376
s(S'CDC5L'
p6377
S'HOXA9'
p6378
S'increases'
p6379
tp6380
(lp6381
s(S'CDX2'
p6382
S'HOXA9'
p6383
S'increases'
p6384
tp6385
(lp6386
s(S'HMGA1'
p6387
S'POU2F1'
p6388
S'increases'
p6389
tp6390
(lp6391
s(S'Coumestrol'
p6392
S'KRAS MRNA'
p6393
S'decreases'
p6394
tp6395
(lp6396
s(S'LEF1'
p6397
S'FOXO3'
p6398
S'increases'
p6399
tp6400
(lp6401
s(S'CYP26A1'
p6402
S'MEIS1'
p6403
S'increases'
p6404
tp6405
(lp6406
s(S'GTF2A2'
p6407
S'MEIS1'
p6408
S'increases'
p6409
tp6410
(lp6411
s(S'REPIN1'
p6412
S'CBFA2T3'
p6413
S'increases'
p6414
tp6415
(lp6416
s(S'hsa-miR-143-3p'
p6417
S'HRAS'
p6418
S'decreases'
p6419
tp6420
(lp6421
s(S'[(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-METHYL]-PHOSPHONIC ACID'
p6422
S'KRAS'
p6423
S'increases_activity'
p6424
tp6425
(lp6426
s(S'TFDP1'
p6427
S'ONECUT1'
p6428
S'increases'
p6429
tp6430
(lp6431
s(S'YY1'
p6432
S'CYP26A1'
p6433
S'increases'
p6434
tp6435
(lp6436
s(S'PITX2'
p6437
S'RUNX1'
p6438
S'increases'
p6439
tp6440
(lp6441
s(S'STAT5A'
p6442
S'NRAS'
p6443
S'increases'
p6444
tp6445
(lp6446
s(S'Valproic Acid'
p6447
S'HRAS MRNA'
p6448
S'increases'
p6449
tp6450
(lp6451
s(S'Malathion'
p6452
S'HRAS PROTEIN'
p6453
S'increases'
p6454
tp6455
(lp6456
s(S'TFAP4'
p6457
S'CBFA2T3'
p6458
S'increases'
p6459
tp6460
(lp6461
s(S'TFAP4'
p6462
S'EN1'
p6463
S'increases'
p6464
tp6465
(lp6466
s(S'POU3F2'
p6467
S'CYP26A1'
p6468
S'increases'
p6469
tp6470
(lp6471
s(S'PAX3'
p6472
S'FOXD3'
p6473
S'increases'
p6474
tp6475
(lp6476
s(S'FOXA2'
p6477
S'RUNX2'
p6478
S'increases'
p6479
tp6480
(lp6481
s(S'MAX'
p6482
S'BACH1'
p6483
S'increases'
p6484
tp6485
(lp6486
s(S'PDX1'
p6487
S'CYP26A1'
p6488
S'increases'
p6489
tp6490
(lp6491
s(S'EPO/EPOR (dimer)/JAK2'
p6492
S'SHC/GRB2/SOS1'
p6493
S'increases_activity'
p6494
tp6495
(lp6496
s(S'E2F1'
p6497
S'MEIS1'
p6498
S'increases'
p6499
tp6500
(lp6501
s(S'FOXF2'
p6502
S'MEIS1'
p6503
S'increases'
p6504
tp6505
(lp6506
s(S'SPZ1'
p6507
S'FOXJ2'
p6508
S'increases'
p6509
tp6510
(lp6511
s(S'SRY'
p6512
S'NRAS'
p6513
S'increases'
p6514
tp6515
(lp6516
s(S'REPIN1'
p6517
S'CYP26A1'
p6518
S'increases'
p6519
tp6520
(lp6521
s(S'VEGFR3/VEGFC-D'
p6522
S'PKC'
p6523
S'increases_activity'
p6524
tp6525
(lp6526
s(S'MEIS1'
p6527
S'EN1'
p6528
S'increases'
p6529
tp6530
(lp6531
s(S'FOXJ1'
p6532
S'FOXD3'
p6533
S'increases'
p6534
tp6535
(lp6536
s(S'SPZ1'
p6537
S'FOXO4'
p6538
S'increases'
p6539
tp6540
(lp6541
s(S'RHOA/GTP'
p6542
S'ROCK1-ROCK2'
p6543
S'increases_activity'
p6544
tp6545
(lp6546
s(S'HMGA1'
p6547
S'ONECUT1'
p6548
S'increases'
p6549
tp6550
(lp6551
s(S'uPA/uPAR/alphav/beta3 Integrin/Vitronectin'
p6552
S'SRC'
p6553
S'adds_modification'
p6554
tp6555
(lp6556
s(S'ETS1'
p6557
S'CYP26A1'
p6558
S'increases'
p6559
tp6560
(lp6561
s(S'ESRRA'
p6562
S'TLX2'
p6563
S'increases'
p6564
tp6565
(lp6566
s(S'ROCK2'
p6567
S'RHO FAMILY GTPASE-ACTIVE'
p6568
S'binds'
p6569
tp6570
(lp6571
s(S'ATF4'
p6572
S'CYP26A1'
p6573
S'increases'
p6574
tp6575
(lp6576
s(S'OR5I1'
p6577
S'CYP26A1'
p6578
S'increases'
p6579
tp6580
(lp6581
s(S'PITX2'
p6582
S'GATA1'
p6583
S'increases'
p6584
tp6585
(lp6586
s(S'AHR'
p6587
S'ONECUT1'
p6588
S'increases'
p6589
tp6590
(lp6591
s(S'PTF1A'
p6592
S'MECOM'
p6593
S'increases'
p6594
tp6595
(lp6596
s(S'arsenic trioxide'
p6597
S'HRAS MRNA'
p6598
S'increases'
p6599
tp6600
(lp6601
s(S'TCF3'
p6602
S'REPIN1'
p6603
S'increases'
p6604
tp6605
(lp6606
s(S'STAT6'
p6607
S'FOXO3'
p6608
S'increases'
p6609
tp6610
(lp6611
s(S'POU1F1'
p6612
S'POU2F1'
p6613
S'increases'
p6614
tp6615
(lp6616
s(S'RHOA/GTP'
p6617
S'ROCK'
p6618
S'increases_activity'
p6619
tp6620
(lp6621
s(S'PITPNA'
p6622
S'PI-4-5-P2'
p6623
S'translocates'
p6624
tp6625
(lp6626
s(S'MDM-2'
p6627
S'P14/19 ARF'
p6628
S'binds'
p6629
tp6630
(lp6631
s(S'TEAD1'
p6632
S'FOXO3'
p6633
S'increases'
p6634
tp6635
(lp6636
s(S'MYC'
p6637
S'MAX'
p6638
S'increases'
p6639
tp6640
(lp6641
S'Pharmacological inhibition of MYC/MAX heterodimer formation and MYC function in BL cell lines (using 10058-F4; Sigma-Aldrich, St Louis, MO, USA)'
p6642
ag4608
aS'MAX is a bHLH-LZ protein required for MYC activity and through their association, the MYC/MAX complexes are able to activate the transcription of MYC target genes.'
p6643
ag4609
as(S'GRB2:SOS1'
p6644
S'EGF:PHOSPHO-EGFR:PHOSPHO-SHC'
p6645
S'binds'
p6646
tp6647
(lp6648
s(S'NF1'
p6649
S'RUNX1'
p6650
S'increases'
p6651
tp6652
(lp6653
s(S'ZEB1'
p6654
S'GATA6'
p6655
S'increases'
p6656
tp6657
(lp6658
s(S'TBP'
p6659
S'EN1'
p6660
S'increases'
p6661
tp6662
(lp6663
s(S'FOXA1'
p6664
S'FOXD3'
p6665
S'increases'
p6666
tp6667
(lp6668
s(S'CART1'
p6669
S'EN1'
p6670
S'increases'
p6671
tp6672
(lp6673
s(S'MAX'
p6674
S'CEBPA'
p6675
S'increases'
p6676
tp6677
(lp6678
s(S'GATA6'
p6679
S'NRAS'
p6680
S'increases'
p6681
tp6682
(lp6683
s(S'PTF1A'
p6684
S'FOXO3'
p6685
S'increases'
p6686
tp6687
(lp6688
s(S'LEF1'
p6689
S'FOXA1'
p6690
S'increases'
p6691
tp6692
(lp6693
s(S'hsa-let-7g-5p'
p6694
S'KRAS'
p6695
S'decreases'
p6696
tp6697
(lp6698
s(S'ZBTB14'
p6699
S'CYP26A1'
p6700
S'increases'
p6701
tp6702
(lp6703
s(S'POU1F1'
p6704
S'FOXO4'
p6705
S'increases'
p6706
tp6707
(lp6708
s(S'PI3K'
p6709
S'PI-4-5-P2'
p6710
S'translocates'
p6711
tp6712
(lp6713
s(S'GABPB2'
p6714
S'NRAS'
p6715
S'increases'
p6716
tp6717
(lp6718
s(S'ELK1'
p6719
S'LEF1'
p6720
S'increases'
p6721
tp6722
(lp6723
s(S'Estrogens'
p6724
S'HRAS MRNA'
p6725
S'increases'
p6726
tp6727
(lp6728
s(S'CYP26A1'
p6729
S'CEBPA'
p6730
S'increases'
p6731
tp6732
(lp6733
s(S'SPI1'
p6734
S'POU2F1'
p6735
S'increases'
p6736
tp6737
(lp6738
s(S'PPARG'
p6739
S'CYP26A1'
p6740
S'increases'
p6741
tp6742
(lp6743
s(S'Asbestos, Serpentine'
p6744
S'HRAS PROTEIN'
p6745
S'increases'
p6746
tp6747
(lp6748
s(S'RET51/GFRALPHA1/GDNF/DOK1'
p6749
S'RASGAP'
p6750
S'binds'
p6751
tp6752
(lp6753
s(S'FOXO1'
p6754
S'GATA6'
p6755
S'increases'
p6756
tp6757
(lp6758
s(S'Cadmium'
p6759
S'KRAS PROTEIN'
p6760
S'increases'
p6761
tp6762
(lp6763
s(S'MAX'
p6764
S'EN1'
p6765
S'increases'
p6766
tp6767
(lp6768
s(S'TLX2'
p6769
S'NRAS'
p6770
S'increases'
p6771
tp6772
(lp6773
s(S'SREBF1'
p6774
S'CYP26A1'
p6775
S'increases'
p6776
tp6777
(lp6778
s(S'SMAD3'
p6779
S'MEIS1'
p6780
S'increases'
p6781
tp6782
(lp6783
s(S'Acetaminophen'
p6784
S'NRAS MRNA'
p6785
S'decreases'
p6786
tp6787
(lp6788
s(S'LEF1'
p6789
S'ETS1'
p6790
S'increases'
p6791
tp6792
(lp6793
s(S'SRF'
p6794
S'MEIS1'
p6795
S'increases'
p6796
tp6797
(lp6798
s(S'BRAF'
p6799
S'MKK3-MKK6'
p6800
S'increases_activity'
p6801
tp6802
(lp6803
s(S'HRAS/GTP'
p6804
S'RAF1'
p6805
S'adds_modification'
p6806
tp6807
(lp6808
s(S'MSX1'
p6809
S'CYP26A1'
p6810
S'increases'
p6811
tp6812
(lp6813
s(S'GATA4'
p6814
S'ETS1'
p6815
S'increases'
p6816
tp6817
(lp6818
s(S'E4F1'
p6819
S'FOXA1'
p6820
S'increases'
p6821
tp6822
(lp6823
s(S'FOXD1'
p6824
S'LEF1'
p6825
S'increases'
p6826
tp6827
(lp6828
s(S'CUX1'
p6829
S'MAX'
p6830
S'increases'
p6831
tp6832
(lp6833
s(S'CYP26A1'
p6834
S'CBFA2T3'
p6835
S'increases'
p6836
tp6837
(lp6838
s(S'CAM/CA2+'
p6839
S'KRAS ISOFORM 4B/GTP'
p6840
S'binds'
p6841
tp6842
(lp6843
s(S'MYOG'
p6844
S'STAT5A'
p6845
S'increases'
p6846
tp6847
(lp6848
s(S'MYOD1'
p6849
S'STAT5A'
p6850
S'increases'
p6851
tp6852
(lp6853
s(S'HNF1A'
p6854
S'POU3F2'
p6855
S'increases'
p6856
tp6857
(lp6858
s(S'EPH'
p6859
S'EPHR'
p6860
S'binds'
p6861
tp6862
(lp6863
S'As a result, cell sorting is triggered by the asymmetric location of E-cadherin and the affinity between EPHB-positive and EPHRIN-B-positive cells'
p6864
aS'EPHRIN-mediated reverse signaling also contributes to tumorigenicity by inhibiting apoptosis.'
p6865
aS'For example, stimulating EPHA with EPHRIN-A1 induces endothelial cell migration and vascular assembly through PI3K-mediated activation of the Rac1 GTPase'
p6866
aS'Since the discovery of their crucial role in tumor-associated angiogenesis, EPH receptors and EPHRIN ligands have become an exciting new area of anti-angiogenesis drug development'
p6867
aS'For example, inhibiting the Dll4/Notch as well as the EPHRIN-B2/EPHB4 signaling pathways was shown to result in a more efficient reduction of tumor size, vessel perfusion, and mural cell recruitment'
p6868
as(S'PDGF:PHOSPHO-PDGF RECEPTOR DIMER'
p6869
S'GRB2:SOS1'
p6870
S'binds'
p6871
tp6872
(lp6873
s(S'HRAS/GTP'
p6874
S'PI3K'
p6875
S'increases_activity'
p6876
tp6877
(lp6878
s(S'RUNX1'
p6879
S'TLX2'
p6880
S'increases'
p6881
tp6882
(lp6883
s(S'MYOG'
p6884
S'CYP26A1'
p6885
S'increases'
p6886
tp6887
(lp6888
s(S'PAX2'
p6889
S'EN1'
p6890
S'increases'
p6891
tp6892
(lp6893
s(S'TFCP2'
p6894
S'CYP26A1'
p6895
S'increases'
p6896
tp6897
(lp6898
s(S'hsa-miR-145-5p'
p6899
S'NRAS'
p6900
S'decreases'
p6901
tp6902
(lp6903
s(S'KAT2B'
p6904
S'GATA1'
p6905
S'increases'
p6906
tp6907
(lp6908
s(S'P-EGFR MUTANTS:P-Y349,350-SHC1'
p6909
S'GRB2:SOS1'
p6910
S'binds'
p6911
tp6912
(lp6913
s(S'E2F1'
p6914
S'MECOM'
p6915
S'increases'
p6916
tp6917
(lp6918
s(S'GNB1/GNG2'
p6919
S'SRC'
p6920
S'adds_modification'
p6921
tp6922
(lp6923
s(S'ZBTB14'
p6924
S'MAX'
p6925
S'increases'
p6926
tp6927
(lp6928
s(S'RALGDS'
p6929
S'P21 RAS:GTP'
p6930
S'binds'
p6931
tp6932
(lp6933
s(S'RHOA/GTP'
p6934
S'ROCK2'
p6935
S'increases_activity'
p6936
tp6937
(lp6938
s(S'NR1H3'
p6939
S'FOXD3'
p6940
S'increases'
p6941
tp6942
(lp6943
s(S'TFAP4'
p6944
S'GATA1'
p6945
S'increases'
p6946
tp6947
(lp6948
s(S'FOXA1'
p6949
S'GATA6'
p6950
S'increases'
p6951
tp6952
(lp6953
s(S'GRB2:SOS1'
p6954
S'P-SHC'
p6955
S'binds'
p6956
tp6957
(lp6958
s(S'E2F1'
p6959
S'FOXO3'
p6960
S'increases'
p6961
tp6962
(lp6963
S'Puma expression is normally kept very low, but can be induced by several transcription factors including p53, p73, E2F1 and FOXO3a, whereby it can induce an apoptotic response.'
p6964
as.